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There are several biophysical methods developed to rapidly identify weakly binding fragments to a 
target protein. X-ray crystallography provides structural information that is crucial for fragment 
optimization, however there are several criteria that must be met for a successful fragment screening 
including the production of soakable and well-diffracting crystals.  Therefore, having a reliable cascade 
of screening methods to be used as pre-screens prior to labor-intensive X-ray crystallography would 
be extremely beneficial. This would allow the filtering of compounds as the screening progresses so 
that only the most promising hits remain. But which method should be the one to start the screening 
cascade? In this work, various sets of fragment libraries were screened against three different proteins; 
namely tRNA guanine transglycosylase (TGT) an important protein in Shigella, membrane associated 
protein peroxin 14 (PEX14) of T. Brucei, and endothiapepsin (EP), to investigate whether different 
screening methods will reveal similar collections of putative binders. The detailed comparative analysis 
of the findings obtained by the different methods is discussed in this thesis.  
Shigellosis, an acute bacterial infection of the intestine, is caused by the gram-negative Shigella 
bacterium whose pathogenicity is reliant on virulence factors (VirF) required to invade epithelial cells. 
The expression of these VirF is modulated by TGT. Strategies developed to inhibit TGT include potent 
active-site inhibitors to block the binding of tRNA, thereby preventing the transcription of the virulence 
factors. Our 96-fragment library was screened against TGT using SPR, NMR, and X-ray crystallography, 
as described in Chapter 2. A total of 81 fragments were screened in SPR using a direct binding assay 
approach, revealing a hit rate of 12%. A total of 77 fragments were screened in NMR revealing a hit 
rate of 29%. High-resolution crystal structures were also collected for the entire fragment library by 
soaking, revealing a hit rate of 8%. Upon comparison of all discovered fragment hits no overlaps from 
all three methods were found. Several factors are responsible for this finding such as exclusion of 
fragments from individual screens due to technical reasons. In detail, four X-ray hits were excluded 
from the SPR and NMR screens, two SPR hits were discarded from the NMR screen, and five NMR hits 
were never subjected to the SPR screen. SPR and NMR are currently the most commonly applied 
primary fragment screening techniques, however, our results suggest that if they would have been 
applied as incipient methods of a screening cascade, they would have missed three binders discovered 
by a subsequently applied, more elaborate crystallographic screen. X-ray crystallography allows the 
detection of specific binders that may be too weak binders to be detected by SPR and even by NMR 
but can still provide valid structural information to support the search for appropriate starting points 
in lead discovery. Additionally, MD simulations of the apo wild type TGT have predicted the opening 
of a transient sub-pocket located above the guanine/preQ1 pocket, which suggested a strategy to 
target this new binding site for the design of new inhibitors against TGT following a structure- based 
drug design concept which is also discussed in section 2.3.  
The human African trypanosomiasis (HAT), also known as the sleeping sickness, is a vector-borne 
parasitic disease caused by T. brucei and transmitted to humans by bites of the tsetse fly. T. brucei 
lacks feedback allosteric regulation of early steps in glycolysis but compartmentalizes the relevant 
enzymes within organelles called glycosomes. PEX14, a peroxin protein essential for biogenesis of 
glycosomes, forms an important protein-protein interaction with PEX5, an import receptor that 
transports cytoplasmic glycosomal enzymes into the organelle. Disrupting the PEX14/PEX5 interaction 
leads to the accumulation of glycosomal enzymes in the cytosol, depletion of ATP, glucose toxicity, 
metabolic collapse and death of T. brucei. This disruption can be achieved through small molecules 
that bind to and block PEX14, preventing PEX5 binding. A previous NMR screening of a fragment library 




we attempted to validate these hits through X-ray crystallography by soaking, to allow visualization of 
the fragment interactions. The promising fragment hits would then be optimized into more potent 
lead compounds. Crystallization of the NTD PEX14 with a mutation in the first residue (E1W) revealed 
blocked binding pockets, as described in Chapter 3. The purpose of the added tryptophan was to 
render fluorescent properties to the short NTD construct which lacked fluorescent amino acids. 
However, this tryptophan was found to block the binding pockets of its neighboring crystal mates in 
the protein crystal, rendering a crystal form impossible to use for soaking. Attempts to find new crystal 
forms with free pockets were unsuccessful, as the small size of the protein and the hydrophobic nature 
of tryptophan rendered tightly packed protein crystals that block the binding pockets of neighboring 
crystal mates. Virtual Screening to discover novel ligands for co-crystallization revealed a ligand that 
aids the crystallization of the E1W PEX14 variant in the same space group but with a slightly different 
packing. This produced a crystal form that proved successful for fragment soaking as it enabled the 
binding of two additional fragment hits binding to further protein pockets. Additionally, the wild type 
form of PEX14 which lacks the tryptophan residue and thus has free binding pockets was crystallized. 
This enabled the soaking of a previously designed lead compound in different pockets of the PEX5 
binding site. By obtaining a crystal structure of this complex at a resolution of 1.8 Å, the feasibility of 
using wild type PEX14 crystals for further fragment screening has been demonstrated. 
Endothiapepsin is a member of the pepsin-like aspartic proteases responsible for the hydrolytic 
cleavage of peptide substrates. Owing to its high degree of similarity to other pharmacologically 
relevant aspartic proteases, it has served as the model enzyme for studying their mechanism and to 
discover first lead structures. In previous work done by other members from our group to identify and 
characterize endothiapepsin binders, X-ray crystallography was consulted as a primary fragment 
screening method and its hit identification potential was compared to several biochemical and 
biophysical screening methods. The fragment library screened was designed for general purposes and 
contained 361 entries. Comparison of the overlap in the hit rates of the different methods to that of 
X-ray crystallography revealed a low overlap, with the RDA having the highest overlap at 7% and MS 
having the lowest overlap at 1% followed by STD NMR at 3%. To understand the reason behind the low 
overlap, two of these screening techniques were prioritized for closer analysis as described in Chapter 
4. The 71 X-ray detected fragment hits were selected and rescreened again with STD NMR under 
slightly different buffer conditions, in addition to WaterLOGSY NMR experiments. The second STD NMR 
screen detected almost double the amount of hits as the initial one, and the Water LOGSY screen had 
the highest correlation from the NMR methods to the X-ray hits at 69%. This comparative analysis also 
revealed the phenomena of active site fragment displacement by use of so-called reporter ligands and 
that non-deuterated water in STD NMR may lead to false negatives. The entire 361 fragment library 
was also screened with SPR using an inhibition in solution assay, adding another biophysical method 
for our comparative analysis to give us further insight of which conditions are crucial to maintain while 
transferring across different techniques. The resulting hit rate from SPR was 34%, correlating to an 
overlap of 11% with the X-ray hits - the highest correlation between screening methods reported by 
us thus far. Finally, we also studied fragment detection and cocktailing in crystallography in comparison 
to fragment cocktailing in NMR. From this we concluded that cocktailing in crystallography can also 
lead to false negatives due to fragment competitive behavior and can reveal a different binding mode 
for a given fragment compared to the adopted geometry found when soaked individually. As for NMR, 
despite the ability to detect competitive binding of fragments due to the temporary binding and 
unbinding events, the parallel binding and thus detection of fragments is not always guaranteed as 
seen in 20% of the fragments we screened, in addition to our observation that the detection of 






Es gibt mehrere biophysikalische Methoden, um schwach bindende Fragmente an einem Zielprotein 
schnell zu identifizieren. Als eine Methode darunter liefert die Röntgenkristallographie strukturelle 
Informationen, die für die Optimierung von Fragmenten entscheidend sind. Dabei gibt es mehrere 
Kriterien, die für ein erfolgreiches Fragmentscreening erfüllt sein müssen, einschließlich der 
aufwändigen Herstellung von durchtränkbaren („soakable“) und gut streuenden Kristallen. Daher wäre 
es äußerst vorteilhaft, eine zuverlässige Kaskade von Screening-Methoden zu haben, die vor der 
arbeitsintensiven Röntgenkristallographie zur Vorselektion eingesetzt werden können. Diese würden 
das Aussortieren (oder Filtern) von Verbindungen im Laufe des Screenings ermöglichen, sodass nur die 
vielversprechendsten Treffer übrigblieben. Aber welche Methode sollte diejenige sein, mit der die 
Screening-Kaskade gestartet wird? In dieser Arbeit wurden verschiedene Varianten von 
Fragmentbibliotheken gegen drei verschiedene Proteine durchgemustert, und zwar tRNA-Guanin-
Transglykosylase (TGT), ein wichtiges Zielprotein bei Shigellose, das membranassoziiertes Protein 
Peroxin 14 (PEX14) von T. Brucei und Endothiapepsin (EP), eine repräsentative Aspartylprotease, um 
zu untersuchen, ob verschiedene Screening-Methoden ähnliche Gruppen von vermeintlich bindenden 
Substanzen aufdecken können. Die detaillierte vergleichende Analyse der Ergebnisse der 
verschiedenen Methoden wird in dieser Arbeit diskutiert. 
Die Shigellose, eine akute bakterielle Infektion des Darms, wird durch die Gram-negativen Shigella-
Bakterien verursacht. Ihre Pathogenität hängt von Virulenzfaktoren (VirF) ab, deren ungestörte 
Funktion für die Invasion von Epithelzellen erforderlich ist. Die Expression dieser VirFs wird durch das 
Enzym TGT moduliert. Zu den Strategien, die zur Hemmung von TGT entwickelt wurden, gehören 
potente Inhibitoren des aktiven Zentrums, welche die Bindung von tRNA blockieren und so die 
Transkription der Virulenzfaktoren verhindern. Unsere 96-Fragment-Bibliothek wurde, wie in Kapitel 2 
beschrieben, mittels SPR, NMR und Röntgenkristallographie auf TGT untersucht. Insgesamt 81 
Fragmente wurden mit der SPR-Methode in einem „Direct Binding Assay“-Ansatz untersucht, was eine 
Trefferquote von 12% ergab. Insgesamt 77 Fragmente wurden mittels NMR untersucht, was zu einer 
Trefferquote von 29% führte. Hochauflösende Kristallstrukturen wurden auch für die gesamte 
Fragmentbibliothek durch Tränken der Kristalle mit den entsprechenden Fragmentlösungen ermittelt, 
was eine Trefferquote von 8% ergab. Beim Vergleich aller gefundenen Fragment-Treffer wurden keine 
übereinstimmenden Treffer für alle drei Methoden gefunden. Dafür sind mehrere Faktoren 
verantwortlich, wie z.B. der Ausschluss mancher Fragmente von einzelnen Screens aus technischen 
Gründen. Im Einzelnen wurden vier Röntgentreffer aus dem SPR- und NMR-Screening ausgeschlossen, 
zwei SPR-Treffer aus dem NMR-Screening verworfen und fünf NMR-Treffer wurden nie mit in das SPR-
Screening einbezogen. SPR und NMR sind derzeit die am häufigsten angewandten primären Fragment-
Screening-Techniken, aber unsere Ergebnisse deuten darauf hin, dass sie, wenn sie als einleitende 
Methoden einer Screening-Kaskade angewandt worden wären, drei potentiell bindende Substanzen 
übersehen hätten, die von einem später angewandten, aufwändigeren kristallographischen Filter 
entdeckt wurden. Die Röntgenkristallographie ermöglicht die Detektion spezifisch bindender 
Substanzen, die allerdings zu schwach binden, um durch SPR und NMR detektiert zu werden. Sie liefern 
aber dennoch valide Strukturinformationen, um geeigneten Ansatzpunkten für eine Leitstruktur-
Entwicklung abzugeben. Darüber hinaus haben MD-Simulationen des apo-Wildtyp TGTs die Öffnung 
einer transienten Nebentasche oberhalb der Guanin/preQ1-Tasche vorhergesagt. Basierend darauf 
wurde eine Strategie zur Ausrichtung dieser neuen Bindungsstelle für das Design neuer Inhibitoren 






Die humane afrikanische Trypanosomiasis (HAT), auch bekannt als Schlafkrankheit, ist eine 
vektorübertragene parasitäre Krankheit, die durch T. brucei verursacht und durch Stiche der 
Tsetsefliege auf den Menschen übertragen wird. T. brucei fehlt es an einer rückgekoppelten 
allosterischen Regulation der frühen Schritte in der Glykolyse, sie verfügen aber über die relevanten 
Enzyme in abgetrennten Organellen, die Glykosome genannt werden. PEX14, ein Peroxinprotein, 
welches für die Biogenese der Glykosome essenziell ist, bildet eine wichtige Protein-Protein-
Interaktion mit PEX5, einem Importrezeptor, der zytoplasmatische glykosomale Enzyme in das 
Organell transportiert. Die Störung der PEX14/PEX5-Interaktion führt zur Anhäufung von glykosomalen 
Enzymen im Zytosol, damit zum Abbau von ATP, zur Glukosetoxizität, zum metabolischen 
Zusammenbruch und am Ende zum Tod von T. brucei. Diese Unterbrechung der Interaktion kann durch 
kleine Moleküle erreicht werden, die an PEX14 binden, und so die Bindung von PEX5 an PEX14 
verhindern. Ein initiales NMR-Screening einer Fragmentbibliothek führte zu Fragment-Treffern, die an 
die N-terminale Domäne (NTD) von T. brucei PEX14 binden. In der vorliegenden Arbeit wurde versucht, 
die NMR-Treffer durch Röntgenkristallographie durch Tränkexperimente zu validieren, um die 
räumlichen Wechselwirkungen der Fragmente sichtbar zu machen. Die vielversprechenden Fragment-
Treffer könnten dann zu potenteren Leitsubstanzen optimiert werden. Die Kristallisation des NTD 
PEX14 mit einer mutierten Variante im ersten Rest (E1W) zeigte blockierte Bindetaschen, wie in Kapitel 
3 beschrieben wird. Das hineinmutierte Tryptophans diente dem Zweck, das kurze NTD-Konstrukt mit 
fluoreszierende Eigenschaften zu versehen, denn dem nativen Protein fehlen fluoreszierende 
Aminosäuren. Es wurde jedoch festgestellt, dass dieses angefügte Tryptophan die Bindungstaschen 
seiner benachbarten Kristallpartner im Proteinkristall blockiert, was diese Kristallform für die 
Tränkungsversuche ungeeignet macht. Versuche, neue Kristallformen mit freien Taschen zu finden, 
blieben erfolglos, da die geringe Größe des Proteins und die hydrophobe Natur des Tryptophans dicht 
gepackte Proteinkristalle entstehen lässt, die wechselseitig die Bindungstaschen benachbarter 
Kristallpartner blockierten. Virtuelles Screening zur Entdeckung neuartiger Liganden für die Co-
Kristallisation ergab einen Liganden, der die Kristallisation der E1W PEX14-Variante in eine leicht 
geänderte Packung unter Erhalt der Raumgruppensymmetrie überführt. Dadurch entstand eine 
Kristallform, die sich für die Tränkungsexperimente in Fragment-Lösungen geeignet erwies. Sie 
erlaubte die Bindung von zwei weiteren Fragment-Treffern in anderen Bindetaschen. Weiterhin 
konnte die Wildtypform von PEX14 kristallisiert werden, welcher der Tryptophanrest fehlt und welche 
somit in der Packung unbesetzte Bindungstaschen aufweist. Dies ermöglichte das Eindiffundieren 
eines bereits zuvor synthetisch dargestellten Leitstrukturvorschlags. Es wurde eine Kristallstruktur des 
Komplexes bei einer Auflösung von 1,8 Å erhalten, in der der Ligand mehrere Taschen der PEX5-
Bindestelle besetzt. Dies unterstreicht die Machbarkeit von Wildtyp-PEX14-Kristallen und deren 
Eignung für ein weiteres Fragmentscreening. 
Endothiapepsin ist ein Mitglied der pepsinähnlichen Aspartylproteasen, die für die hydrolytische 
Spaltung von Peptidsubstraten verantwortlich sind. Aufgrund seiner hohen Ähnlichkeit mit anderen 
pharmakologisch relevanten Aspartylproteasen dient es als Modellenzym für die Untersuchung ihres 
Mechanismus und das Auffinden erster Leitstrukturen. In früheren Arbeiten anderer Mitglieder 
unserer Arbeitsgruppe zur Identifizierung und Charakterisierung von Endothiapepsin-bindenden 
Fragmenten wurde die Röntgenkristallographie als primäre Screening-Methode herangezogen und ihr 
Potenzial zu identifizieren von Treffern mit mehreren biochemischen und biophysikalischen Screening-
Methoden verglichen. Die untersuchte Fragmentbibliothek wurde für ein allgemeines Screening 
konzipiert und enthielt 361 Einträge. Der Vergleich der Trefferraten der verschiedenen Methoden mit 
denen der Röntgenkristallographie ergab eine nur geringe Überschneidung, wobei die RDA die höchste 
Überschneidung bei 7% und MS die niedrigste Überschneidung bei 1% aufweist, gefolgt von STD NMR 
mit 3%. Um die Gründe für die geringen Überschneidungen zu verstehen, wurden zwei dieser 




die 71 röntgenkristallographisch detektierten Fragment-Treffer selektiert und mit STD-NMR unter 
leicht unterschiedlichen Pufferbedingungen sowie mit WaterLOGSY NMR-Experimenten erneut 
durchmustert. Dieser zweite STD NMR Screen erkannte fast die doppelte Anzahl von Treffern als die 
erste, und der Water LOGSY Screen hatte mit 69% die höchste Korrelation zwischen den NMR 
Methoden und den Vorschlägen aus der Kristallographie. Diese vergleichende Analyse zeigte auch, 
dass Fragmente durch den Einsatz so genannter Reporterliganden nicht, wie gewünscht, räumlicher 
verdrängt sondern teilweise verschoben werden und dass nicht-deuteriertes Wasser in STD NMR zu 
falschen Negativen führen kann. Die gesamte 361 Fragment-Bibliothek wurde mittels SPR unter 
Invertieren des Messprinzips (so genannter „inhibition solution assay“) durchgemustert und als 
weitere biophysikalische Methode unserer vergleichenden Analyse hinzugefügt. Die erlaubt uns einen 
weiteren Einblick zu erkennen, welche Bedingungen beim Transfer zwischen verschiedenen Techniken 
unbedingt eingehalten werden müssen. Die resultierende Trefferrate aus SPR betrug 34%, was einer 
Überlappung von 11% mit den kristallographischen Treffern entspricht – somit der höchsten 
Korrelation zwischen den bisher von uns eingesetzten Screeningverfahren. Schließlich haben wir auch 
die Fragmenttreffer-Erkennung im Rahmen des so genannten „Cocktailing“ für Ergebnisse mit der 
Kristallographie im Vergleich zu der NMR-Methode untersucht. Dabei ergab sich, dass das 
„Cocktailing“ in der Kristallographie zu falschen negativen Treffern aufgrund der Kompetition von 
Fragmenten um den gleichen Bindeplatz führen kann oder abweichende Bindungsmodi für ein 
bestimmtes Fragment anzeigt werden als diese bei Einzelbestimmungen ermittelt wird. Was die NMR-
Methode betrifft, so ist trotz der Fähigkeit, konkurrierende Bindungen von Fragmenten im 
dynamischen Prozess als Bindupngsereignisse nebeneinander zu beobachten, nicht immer 
gewährleistet. In ca. 20% der von uns untersuchten Beispiele lieferte diese Parallelbindung keine 
korrekten Hinweise. Weiterhin kann die Erkennung von Fragmenten in der NMR-Methode aus einem 
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1 Introduction  
 
This thesis focuses on the analysis of tools and methods used in fragment screening. Fragment 
screening has persistently proven in the past decade to be an effective tool in identifying first starting 
points for lead development. It started as back as 1909, with Ehrlich’s notion that the chemical 
structure of a drug compound correlated with its activity 1, which was later formulated by Gund into 
what we now know as a pharmacophore.2 By the 1990s the concept of drug fragments was not a 
foreign one to medicinal chemists.3 Identifying small molecules by preparing and screening different 
analogues was the foundation of SAR (structure activity relationship)-driven medicinal chemistry but 
what was missing was the ability to screen weakly active fragment compounds. The Abbott SAR-by-
NMR screening method was one of the first methods to address this.4 At that time, Mattos and Ringe 
had probed the binding sites on protein surfaces to identify hot spots by using multiple solvent crystal 
structures (MSCS) 5, a method explored computationally by Goodford by his program GRID in 1985 6, 
and almost 2 decades after that by molecular dynamics by the group of Karplus using the multiple copy 
simultaneous search (MCSS).7 
Since then, there have been several biophysical methods developed to rapidly identify weakly binding 
fragments to a target protein including Surface Plasmon Resonance (SPR), Nuclear Magnetic 
Resonance (NMR), and X-ray crystallography. SPR has the advantage of utilizing small amounts of 
protein and fragment, as well as allowing us to observe how molecules interact in real time. 
Meanwhile, ligand-based NMR is sensitive enough to pick up molecules that interact with low-affinity 
and also allows us to follow the binding and unbinding events, not only the final binding. Crystal 
structures from X-ray crystallography have an advantage in providing a three-dimensional structure of 
the fragment binding pose, which is crucial in visualizing the available space for potential fragment 
growing. Because fragments are used at high concentrations (limited by their solubility), X-ray 
crystallography can cope with a large range of ligand binding affinity (sub-nanomolar to millimolar) as 
well as various sizes of the target macromolecule (even up to megadaltons, depending on the 
robustness of the crystal and achieved resolution).8  
Fragment screening is usually done in a cascade manner, but which method should be the one to start 
the screening cascade? Do these methods reveal similar collections of putative binders? 
The goal of this work is to elucidate the differences between these biophysical methods, namely SPR, 
NMR, and X-ray crystallography, that lead to deviating hit rates. Several proteins have been studied in 
this context, being tRNA-guanine transglycosylase (TGT) an important protein in Shigella flexneri, 
membrane associated protein peroxin 14 (PEX14) of Trypanosoma Brucei, and endothiapepsin (EP) a 
fungal aspartic protease frequently used as a model protein for therapeutically important proteases.  
The TGT project involves screening a 96-fragment library developed in collaboration with Jena 
Bioscience to validate its potential as a commercial product and suitability for an initial fragment-
screening campaign. TGT was one of several enzymes the library was screened against. The library was 
screened using SPR, NMR, and X-ray crystallography. The X-ray crystallography screen revealed a small 
fragment, chemically related to the amino acid arginine, which opens a transient sub-pocket when 
bound to the recognition pocket of the target protein.  This prompted us to target this transient sub-
pocket also discovered by MD simulations and the above-mentioned fragment screen through 
structure-based drug design (SBDD). This sub-pocket is found above the preQ1 recognition site and can 
provide a promising means of selectivity by developing covalent inhibitors that bind to the Cys158; the 
gatekeeper of this pocket.  





The PEX14 project was part of the AEGIS (Accelerated Early stage drug dIScovery) consortium funded 
by the Marie Skłodowska-Curie actions fellowship. A previous NMR screening of a fragment library 
resulted in fragment hits that bind to the N-terminal domain (NTD) of T. brucei E1W PEX14. In this 
project, we attempt to validate these hits through X-ray crystallography by soaking, to allow 
visualization of the fragment interactions. The promising fragment hits would then be optimized into 
more potent lead compounds. Additionally, as the objective of the consortium was finding novel 
inhibitors to treat neglected infectious diseases, virtual screening was also utilized to discover novel 
compounds that block the PEX14/PEX5 protein-protein interaction.  
Finally, the EP project entails an in-depth analysis of the deviating hit rates previously observed upon 
comparison of six different biophysical methods used to screen an inhouse 361- fragment library. The 
analysis was focused on two of these methods, X-ray crystallography and STD NMR, and explaining the 
low overlap between their discovered hits. Another goal of the project was screening of the 361- 
fragment library using SPR, a biophysical method that was not applied in the previous fragment 
screening due to complications in immobilizing the target protein. Instead the assay principal was 
inverted, and the protein was captured by an immobilized peptide decoy inhibitor. This additional 
biophysical method gives further insight of conditions crucial to maintain while transferring across 
different techniques. Finally, fragment detection and cocktailing in crystallography was compared to 























1.1 Fragment-Based Drug Design  
 
1.1.1 What are Fragments?  
 
The success of fragment screening is derived from deploying compounds of low molecular weights and 
simple structures – so called fragments - which enable a faster screening of libraries in comparison to 
more complex drug-like ligands. A typical fragment adheres to the ‘rule of three’ (Astex RO3) 9 which 
states that it should have a molecular weight of <300 Da, clogP ≤ 3, and up to 3 hydrogen bond donors 
and acceptors. There have been many exceptions to this rule where libraries assembled have 
fragments that do not strictly observe the Astex “RO3”, and were found to provide high hit rates.10 
Generally there are three steps in FBDD (fragment-based drug discovery), which include the design of 
the library, the screening of the library using several methods to detect binding to a target biomolecule, 
and finally the fragment hit-to-lead step which develops the fragment hit into a lead compound 
through synthetic chemistry guided by the structure information that could be provided by X-ray 
crystallography, in silico docking, and data on bioaffinity.11   
Fragments are also applied to overcome the problem of limited chemical diversity of currently 
available compound libraries. This is because a fragment library has around 103 fragments adhering to 
the RO3, whereas the estimated 1060-200 possible druglike compounds synthesized for HTS (high-
throughput screening) have 107 possible molecules that contain up to 11 atoms of C,N,O, and F that 
follow the “RO3”.11-12 Fragments are also “ligand efficient” (defined as −ΔG in kilocalories per mole 
divided by the number of heavy (nonhydrogen) atoms) 14 relative to the compounds that make up HTS 
libraries, because they are weakly binding and thus must make optimal interactions with their targets 
to bind with a sufficient affinity for detection (Figure 1.1).    
 
 
1.1.2 Fragment Libraries 
 
As mentioned above, the design and assembly of a fragment library is the first step taken in FBDD.  In 
our group, we designed a 361-fragment library from fragments that do not strictly adhere to the RO3 
criteria but are well suited for crystallographic screening and follow-up chemistry.10  Commercially 
available compounds from several chemical suppliers (ASINEX, ChemBridge, MayBridge, InterBio 
Screen, 
LifeChemicals, Enamine, Specs, Vitas M Laboratory) were selected and filtered based on the number 
of non-hydrogen atoms (between 8 and 20). This was done instead of filtering based on molecular 
weight simply because advantageous fragments with strong X-ray scatterers such as the electron-rich 
bromine tend to have large molecular weights. The fragments were then filtered based on undesirable 
moieties, log P values, number of rotatable bonds, number of hydrogen bond donors and acceptors, 
and the total polar surface area (TPSA). They were then clustered and selected by visual inspection to 
avoid accumulation of similar chemotypes to cover a range of chemical scaffolds. The physicochemical 
properties of the finally selected fragments in the library calculated using MOE (under the assumption 
of standard protonation states at physiological pH conditions) can be seen in Table 1.1. Considering 
the entire library, less than half of the selected compounds conform to the “RO3”. All 361 fragments 
were validated by screening against endothiapepsin in a fluorescence-based competition assay. This 
a) b) 
Figure 1.1: HTS hits (a) may bind through several suboptimal interactions. Fragment hits (b), on the other hand, are more 
ligand efficient as they involve fewer interactions, but they are more optimized. (Image taken from Scott et al., 2012.) 
 





library was the library screened in the EP project.  
 
Table 1.1: Physiochemical Parameters of the 361-Fragment Library.a 
Parameter Min Max Average 
No. of heavy atoms 8 20 15 
MW (g/mol) 122 359 224 
Lipinksi donor 0 4 1.3 
Lipinski acceptor 1 7 3.7 
Log P -1.3 5.4 1.6 
Free rotatable bonds 0 7 1.7 
TPSA (Å2) 15 126 52 
a) Copied from Koester et. al, 2011. 
 
The 96-fragment library (also known as the Frag Xtal Screen) was assembled in collaboration with Jena 
Bioscience. It was developed as a commercial screening plate that contains 96 wells spotted with the 
96 fragments, ready for solubilization and crystal soaking. Amongst the 96 fragments selected is a sub-
set of the original 361-fragment library (54%) which are the fragments that demonstrated suitability 
for fragment screening when validated on endothiapepsin. The remainder of the library was assembled 
by filtering compounds from the PDBeChemdatabase 15 according to the number of containing C, N, 
and O atoms. Other criteria of selection included price, compound stability, and availability. Exceptions 
to these filtering criteria were compounds found to be important for protein-function elucidation (e.g 
NAD) and thus were included in the library. At the end most of the compounds were purchased from 
Sigma–Aldrich Co. LLC, Taufkirchen, Germany Merck KGaA, Darmstadt, Germany, and Biomol GmbH, 
Hamburg, Germany.16 This library was the library screened in the TGT project. 
 
The fragment library used to screen PEX14 was an inhouse library assembled at the Helmholtz Zentrum 
in Munich. The fragments were selected from the Maybridge library with the criteria of maximize 


























1.2 Surface Plasmon Resonance 
 
1.2.1 Concept of SPR 
 
Surface plasmon resonance (SPR) spectroscopy is a label-free technique that allows monitoring 
noncovalent molecular interactions like protein−peptide and small molecule−macromolecule (e.g., 
receptor−inhibitor complex) in real time. It has gained popularity in the past few decades as a tool for 
fragment screening as well as determining compound binding affinities. The power of SPR is that it is 
noninvasive and does not require labelling the protein with tags, dyes, or specialized reagents.  SPR 
spectroscopy can provide answers regarding specificity of an interaction, the binding kinetics, and 
affinity of the compounds of interest.17   
The theory behind SPR revolves around TIR, total internal reflection. In SPR, a monochromatic 
polarized light beam moves from a medium of higher refractive index to a medium of lower refractive 
index, where it is reflected rather than refracted. The light beam rebounds with an angle of reflection 
equal to the angle of incidence. TIR occurs once most of the light beam is entirely reflected and less of 
it crosses the boundary (a gold-glass dielectric layer) between the two mediums. In TIR, the photons 
of the reflected light beam react with and excite the free electrons of the metal layer (gold), leaking 
some electrical field intensity known as the evanescent wave.  It is coined evanescent because the 
wave’s amplitude decays exponentially as it travels further from the interface surface. This evanescent 
wave yields surface plasmons which are electromagnetic surface waves that spread parallel to the 
interface. As they penetrate the medium with the lower refractive index, time-dependent shifts in the 
value of the reflected “angle” of polarized light are recorded. The value of this reflected light angle is 
calculated as a function of the angle of incident light.17–19  
  
A typical SPR instrument consists of three major components; an optical light source, a sensor chip 




The optical light source is usually a near-infrared light-emitting diode. The sensor chip is a glass surface 
covered with a thin layer of gold. This gold surface is often coated with an alkyl thiol monolayer which 
serves as a structural template for subsequent derivatizations and limits nonspecific interactions. After 
the alkyl thiol monolayer, a matrix of carboxymethylated dextran is often covalently attached. It has a 
thickness of about 25-100 nm and serves to promote a hydrophilic environment for biomolecular 
interaction. It is inert and does not interfere with SPR signals. To achieve TIR rather than dispersion, 
Figure 1. 2: A diagram showing the Kretschmann configuration which is the most common biosensor setup in SPR. The orange 
diamonds represent the ligand molecules immobilized on the gold surface while the green structures represent the analyte 
that binds to the ligand. The light source is a helium-neon (He -Ne) laser and the detector is usually a charge-coupled device 
(CCD). (Image adapted from Bakhtiar et al., 2013.) 





the gold-glass dielectric layer is coupled to a prism. The detection system is most commonly a charge-
coupled device (CCD).17 
The two interacting partners in SPR are referred to as analyte and ligand. The partner that is 
immobilized onto the gold layer surface is the ligand, whilst the second interaction partner which flows 
over the chip surface is the analyte. The ligand in the context of a direct-binding assay (section 1.2.2) 
is in fact the protein, whilst the analyte is in fact the ligand or compound of interest. This nomenclature 
differs from other biophysical methods, but in the coming text we will stick to the SPR nomenclature. 
This analyte is injected into a continuously flowing buffer solution referred to as running buffer. The 
flow of this running buffer occurs on the gold surface of the sensor. Analyte-ligand noncovalent 
interactions occurring at the sensor surface cause a change in the mass, which in turn causes a change 
in the refractive index of the sensor surface and changes the resonance angle. 17 If no binding occurs 
between the analyte molecule in the running buffer and the immobilized ligand, the mass at the sensor 
surface will not change, and the resonance angle change will be zero. 
The graphical output of an SPR experiment is a sensorgram, also known as a binding process curve 
(Figure 1.3). It plots the absolute response in resonance units (RU), which is the SPR angle change, 
against the time and 1000 RU is roughly a 0.1° change in SPR angle. A sensorgram shows the occurring 
interactions between the analyte and ligand in real time and can give information on the type of 
interaction occurring, whether it is a strong one or a weak one, and whether an interaction occurs at 
all. The positive response observed during injection of the analyte is known as the association phase 
when the analyte begins to interact with the ligand. Strong interactions will likely yield higher RUs at 
this phase than weaker ones, as more analyte molecules will bind to the ligand, leading to a greater 
change in the mass and thus the resonance angle. When the recorded response starts to decrease, this 
phase is known as the dissociation phase, when the analyte detaches from the ligand. After one cycle 
is complete, a regenerating solution is passed over the sensor chip to remove any bound analytes and 
prepare the chip for the next cycle.20 
 
For kinetic analysis experiments, the interaction is monitored as a function of time over a range of 
analyte concentrations. The sensorgrams are then fit (for the entire data set) using the software of the 
SPR instrument (e.g: BIAevaluation from Biacore®) to a mathematical model that describes the 
interaction. The phases of the interaction provide different information. The association phase during 
sample injection contains information on the association and dissociation processes, and the 
dissociation phase after sample injection once the running buffer has removed the dissociated analyte 






Figure 1.3: The output of an SPR experiment is a sensorgram which is a graphical representation of the interaction occurring 
between the analyte and the ligand. The bars below the curve show which solution is passed over the sensor surface at each 
given time.  (Image taken from www.gelifesciences.com.) 




A 1:1 interaction model can be described as the following ((Equation 1.1) 22:   
 
 
                                                                                                        
 
where:  
ka is the association rate constant (M-1s-1), or the rate of complex formation per second in M. 
and kd is the dissociation rate constant (s-1), or the rate of complex decay per second. 
 
The net rate of complex formation (association) during injection is given by (Equation 1.2) 22:  
 
                                                                                                                 
and the rate of dissociation after the end of the injection is (Equation 1.3) 22:  
   
                                                                                                                   
 
There are two options for running the kinetic analysis experiments depending on the kinetic properties 
of the analyte.  Multiple-cycle kinetics (MCK) is commonly used and it runs each analyte concentration 
in a separate cycle, where the surface is regenerated after each sample injection (Figure 1.4a).  Single-
cycle kinetics (SCK) is used when the analyte has a slow dissociation, and thus a series of analyte 
concentrations are run in one cycle with no regeneration between the sample injections (Figure 
1.4b).21  
 




Figure 1.4: Images of sensorgrams obtained from a MCK (a) where the cycles at each analyte concentration are seen here 










The affinity constant for a 1:1 binding event in kinetics is equal to the ratio of the equilibrium 
association constant (KA, where KA = ka/kd) to the equilibrium dissociation constant (KD, where KD = 
kd/ka). 
 
In steady-state affinity, the level of steady-state or equilibrium binding is analyzed as a function of 




1.2.2 Direct Binding Assays  
 
In a direct binding assay (DBA), the ligand (i.e.: target protein) is immobilized onto the gold surface of 
the sensor chip (Figure 1.6a). There are several immobilization strategies available by which this is 
achieved. They utilize free amines, thiols, maleimide, or aldehyde moieties of the ligand.23 The amine 
coupling for example is performed by utilizing the free primary amino groups in lysine amino acids, or 
even the N-terminus of the protein. It is important when immobilizing the target to allow sufficient 
density on the chip surface without overcrowding it and retain the native nature of the analyte 
molecule, in other words its biological and structural features. An excess of ligand immobilized onto 
the chip surface can lead to oligomerization or a phenomenon called “mass transport limitation” which 
is the rebinding of analyte molecules to the ligand after their dissociation. When this occurs, the 
measured kinetic constants will reflect the analyte transport process rather than the interaction 
between analyte and ligand. This can be avoided by reducing the amount of immobilized ligand to limit 
the amount of analyte binding or increasing the flow rate to remove the dissociated analyte and thus 
prevent it from rebinding.21 During immobilization it is important to consider the sample pH and 
isoelectric point (pI) of the protein to optimize the immobilization.  The pH of immobilization should 
be at least one order of magnitude below the pI of the protein (so it can adopt an overall positive 




1.2.3 Inhibition in Solution Assay 
 
In certain cases, immobilizing the ligand (i.e.: target protein) onto the surface of a sensor chip is not 
possible. A reason for this may be the difficulty in finding a pH suitable for immobilization, as will be 
discussed in Chapter 4. 
b a 
Figure 1.5: A sensorgram (a) and its corresponding plot of steady-state response against concentration (b) for binding affinity 
determination. The value of the calculated equilibrium dissociation constant KD (b) is indicated by a red vertical line. 




An inhibition in solution assay (ISA) works by a different concept to the direct binding assay. In ISA, 
rather than immobilizing the ligand to the sensor chip, a TDC (target definition compound) is 
immobilized instead (Figure 1.6b). A TDC is a known active-site binder of the target protein, for 
example a peptide. The target protein and the compounds being tested for putative protein binding 
are then incubated together in a 96-well plate and the mixture is injected over the TDC immobilized 
surface. There is a competition between the compound in the running buffer and the immobilized TDC 
for the active site of the protein. The initial binding rate is used to determine the percentage of free 
protein in solution, in other words the unbound protein available to bind to the TDC. When the 
compound and the free protein in the running buffer bind together, this is reflected in a decrease of 
the signal recorded, accordingly the percentage of free protein is reduced. This is then recorded as a 
reduction of the percentage of bound protein to the TDC (as less free protein is now available to bind) 
and hence corresponds to a higher percentage of active-site binding of the compound to the protein. 
This allows a qualitative affinity ranking of the compounds since the experiments are all conducted at 














Figure 1.6: a) Concept of DBA. The ligand (protein) is immobilized onto the sensor chip and the running buffer carries the 
analyte (compound) over the sensor chip surface. b) Concept of ISA derived from Geschwindner, S. et al. (2013). Instead 
of the protein, the ligand immobilized is a TDC and a solution of fragment and protein is passed over the surface being 
carried in the running buffer so that the fragment and TDC are in competition for the binding site of the protein. 





1.3 Nuclear Magnetic Resonance  
 
1.3.1 Concept of NMR 
 
1.3.1.1 Atomic Spins  
 
NMR is a widely applied spectroscopic technique in chemical analytics and is also used in fragment 
screening. It observes atomic nuclei with a spin in a magnetic field. These atomic nuclei are “magnetic”, 
which means that they have a “spin " and they perform, using a picture from classical physics, a 
precession movement in an externally applied magnetic field around the direction of the field. An 
example of such nuclei are the isotopes 1H, 13C, 15N, 19F that contain an odd number of protons and/or 
neutrons and possess a spin of 1/2. A spinning charge generates a magnetic field that has a magnetic 
moment (μ) proportional to the spin. Taking the hydrogen nuclei as an example, the hydrogen proton 
has a positive charge and can generate a magnetic moment. When placed in a magnetic field, the spin 
of the proton will either align “parallel” or “anti-parallel” relative to the direction of the applied 
magnetic field (Figure 1.7). 25  
 
The rate of precession of the magnetic moment of the spinning proton around the external magnetic 
field (change in orientation of its axis) is known as the Larmor frequency (Equation 1.4). 26  
Where ω is the precession frequency, βo is the strength of the applied external magnetic field, and γ is 
the gyromagnetic ratio which is a specific constant given to each nucleus or particle as seen in Table 
1.2.  
 
Table 1.2: Gyromagnetic ratios in MHz/Tesla of specific nucleus or particle. 










Figure 1.7: When a proton nucleus is exposed to an external magnetic field (B0), the proton dipole adopts one of two possible 
spin states; either aligning parallel to B0 to give +1/2, or anti-parallel to give -1/2. (Image taken from 
https://chem.libretexts.org.) 
(Equation 1.4) 




The “parallel” (low energy) and “anti-parallel” (high energy) spin states have a difference in energy 
(ΔE) proportional to the magnetic field strength (B0), gyromagnetic ratio (γ), and Planck constant (h)  
(Equation 1.5). 
If the atomic nuclei in the external magnetic field is subjected to radiofrequency (Rf) radiation (energy), 
it can absorb and re-emit electromagnetic radiation as energy.27 The choice of the specific Rf pulse 
(containing a range of frequencies) to use depends on the strength of the magnetic field and the atomic 
nuclei present. For example, a 15N in a magnetic field of 11.74 Tesla will need a pulse at a frequency of 
50MHz, as seen in Table 1.3.  
 







The summation of all the magnetic moments of the individual hydrogen nuclei (which are in precession 
in different phases) is known as the net magnetization vector (NMV), which is in the longitudinal 
direction or vertical in the direction of B0. If the applied Rf is equal to the Lamor frequency, we get 
what is known as resonance (practically induced by a 90° Rf pulse). A hallmark of resonance is the Rf 
inducing an in-phase precession of the protons, to give a transverse (NMV) and a transition of parallel 
to antiparallel spins known as spin flip. The amount of energy required to induce this flipping from one 
state to the other is equal to ΔE from (Equation 1.5).25  
 
When the Rf is removed, the NMV starts to recover, or relax, to its original vertical position in the 
direction of B0.   
 
The T1 relaxation time, also known as the spin-lattice relaxation time, is a measure of how quickly this 
occurs. This return of excited nuclei from the high energy state to the lower energy ground state is 
associated with loss of energy (thermal) to the surrounding nuclei. 
The T2 relaxation time, also known as spin-spin relaxation time, is a measure of how quickly protons 
return from their in-phase precession to out of phase precession. T2 is less than or equal to T1. 
T1 and T2 are different in large molecules and small molecules, which is a property exploited in NMR 
when studying protein-ligand interactions as will be discussed below. 
 
Isotopes NMR Frequency at Magnetic Field 11.74 T 
1
H 500 MHz 
13
C 125 MHz 
15
N 50 MHz 
19
F 470 MHz 
(Equation 1.5) 





1.3.1.2 NMR Spectra  
 
The energy absorbed by the nuclear spins after the Rf pulse induces a voltage in a recording coil (from 
the motion of the magnetic moments of the nuclei) that decays with time. This voltage is detected and 
amplified, and the signal is displayed as a free induction decay (FID), which is a time domain (Figure 
1.8a). The FID is converted by a Fourier Transformation (FT) into the NMR spectrum which is the 
frequency domain (Figure 1.8b) and discloses the resonance frequencies absorbed by individual nuclei 
in a molecule.28  
The structures of molecules can be studied according to the positions, intensities and the splitting of 
the resonance signals in an NMR spectrum. The location of the resonance, or NMR signals, on a 
spectrum is called the "chemical shift”. This location depends on the local chemical environment 
surrounding the nucleus under consideration, and once this environment changes due to chemical 
interactions (i.e: protein-ligand interactions) the chemical shift of the nuclei changes. The chemical 
shift is usually reported relative to a reference signal, mostly TMS (tetramethylsilane, C4H12Si). TMS is 
used as the internal standard as it contains twelve equivalent hydrogen atoms, and thus its 1H NMR 
spectrum consists of a single peak with a chemical shift assigned as δ=0, hence all chemical shifts are 
determined relative to it. 
Depending on the applied screening protocol NMR provides different amount of information, 
particularly with respect to the 3D structure. In all cases, the 3D structure insight is less detailed as in 
crystallography but NMR has the advantage of not only determining protein-ligand binding but also 







Figure 1.8: a) An FID is a time domain displaying the decay of the voltage induced by nuclei after a Rf pulse. b) Fourier 
Transformation is applied to the FID to convert it into the NMR spectrum in frequency domain. 




1.3.2 NMR Instrumentation 
 
A typical NMR spectrometer contains a super-conducting magnet that produces the external magnetic 
field and a spectrometer that transmits and receives the radio frequency waves used to make the NMR 
measurements. The magnet is cooled by a helium jacket followed by a nitrogen jacket. The sample 
probe is placed in between the poles of the magnet and the sample is immersed into this probe holder 
(Figure 1.9). 
 
1.3.3 Ligand-Observed NMR (CPMG, STD NMR, Water LOGSY)   
 
Also known as ligand-based NMR, ligand-observed NMR is a method of determining protein-ligand 
binding by observing a spectrum of the ligand signals. There are several different protocols that can be 
used to perform a ligand-observed NMR, each one using a different property to differentiate binding 
ligands from non-binding ligands. An example of an NMR protocol that is used is relaxation-based 
methods such as inversion-recovery (which measures T1) and the Carr-Purcell-Meiboom-Gill (CPMG) 
relaxation dispersion (which measures T2). Large molecules such as protein exhibit significantly 
different NMR properties than small ligands in terms of relaxation, resulting in different T1 and T2 
relaxation times. A protein has much shorter T2 relaxation times than small ligand molecules, and thus 
ligands that bind to the protein adopt the relaxation properties of the target macromolecule. This is 
due to the interaction of the ligand with the large macromolecule during the residence time of the 
bound ligand on the protein, as well as the chemical exchange that occurs when binding (Figure 1.10a). 
  
Another NMR protocol is STD NMR.  In STD experiments, the protein is irradiated with a selective Rf 
and a spectrum is recorded. Ligands that are binding to the saturated protein will receive the Rf 
irradiation via NOEs (the Nuclear Overhauser Effect). A NOE occurs when a specific nucleus and a 
neighboring nucleus (dipole-dipole coupled) at equilibrium is magnetically excited and relaxation 
occurs between the two nuclei. This relaxation causes the intensity of the nucleus that was at 
equilibrium to increase, whilst the intensity of the excited nucleus in the on-resonance spectrum 
decreases.  Another spectrum is recorded with an off-resonance irradiation. The two spectra are then 
subtracted (the difference spectrum is generated) and only signals from the binding ligands can be 
observed (Figure 1.10b). 30  
WaterLOGSY is also an NMR protocol that is widely applied.  In WaterLOGSY experiments, rather than 
Figure 1.9: The setup of an NMR spectrometer. The spectrometer transmits and receives radio frequency waves and a strong 
magnet produces the magnetic field. The magnet is cooled by two jackets; one with liquid helium and the second liquid 
nitrogen. The sample is placed in between the magnet. (Image is adapted from chembam.com.) 





irradiating the protein, water molecules are irradiated and transfer their magnetization to the small 
molecules also by NOE. The ligands that bind to the protein interact with water associated with the 
protein and receive irradiation from these waters, whereas the non-binding ligands are in the bulk 
solvent and receive irradiation from these “free” waters that are not associated with the protein. The 
NOE effect from associated water has an opposite sign to the one from free water. This results in two 
signals with opposite signs, one from the bound ligand, and one from the non-binding ligand (Figure 
1.10c). 31 1H 1D spectra of small ligand can be generated using the pulse sequence zggpw5.  
 
A benefit of using ligand-based NMR is that one does not need labelled protein, small amounts of 
protein are needed (10 µM) as well as small amounts of ligand (100-300 µM). However, it is a 1D NMR 
method meaning it only provides binding information in terms of “binding” or “not binding” but it 
cannot predict the binding site.    
 
1.3.4 Protein-Observed NMR (SOFAST HMQC)  
 
Protein-observed NMR is a method of determining protein-ligand binding by observing a spectrum of 
the protein signals. Unlike ligand-based NMR, protein-based NMR requires isotope labelled protein 
(13C or 15N). Additionally, larger amounts of both the protein (100 µM) and the ligand (1 mM) are 
required but the spectra produced are 2D spectra and thus provide information not only on the binding 
of a ligand but also about the binding site. Titration of different concentrations of the ligand can also 
provide binding affinities (apparent Kd), which is further elaborated in Chapter 3.  
An example of a protein-observed NMR experiment is SOFAST HMQC (selective optimized flip angle 
short transient heteronuclear multiple-quantum correlation) for which the technical details have been 
described elsewhere (Schanda et al., 2005). In SOFAST HMQC, not only 1H nuclei are observed but also 
15N or 13C nuclei (depending on the isotope used). This correlates the frequencies of both interacting 
nuclear spins which results in a 2D heteronuclear chemical shift correlation map with the 15N proton 
chemical shifts on the y-axis, and the 1H proton chemical shifts on the x-axis (Figure 1.11). This allows 
the heteronuclear NMR analysis of protein. Each peak in the 2D spectrum represents a bonded N-H 
pair in the protein, and the two coordinates of the peak correspond to the chemical shifts of each of 
the N and H atoms. A chemical shifting in the peaks indicates ligand binding. If the sequence of the 
a b c 
Figure 1.10: a) NMR spectra resulting from a relaxation-based method utilizes the difference in relaxation times between protein 
and ligand. Ligands that bind to protein adopt the slow relaxation properties of protein and their NMR signals are attenuated 
relative to non-binding ligands. b) STD NMR spectra is the difference between the on-resonance spectra and the off-resonance 
spectra. This results in a spectrum showing only the signals of the binding ligands. c) WaterLOGSY spectra display both the binding 
and non-binding ligands, but because their NOEs have opposite signals, it allows differentiating the binders from the non-binders. 
(All images are taken from www.theresonance.com.) 




protein is known, the assignment of the protein residues to each of the peaks allows determination of 
















Figure 1.11: A 2D NMR spectrum of a protein before ligand addition (blue) and after ligand addition (red). The residues 
exhibiting the largest chemical shifts are indicative of the ligand binding site (encircled in black) and protein backbone 
assignment can provide information on the residues involved in the interaction. 







1.4.1 Concept of X-ray Crystallography  
 
X-ray crystallography is a widely used technique for structure determination of macromolecules and is 
increasingly used for fragment screening.  In fragment screening it has the added benefit of not only 
determining whether a fragment binds to a protein or not, but also providing a three-dimensional (3D) 
molecular structure with the binding pose. This allows the visualization of the interacting protein 
residues and fragment moieties, which is crucial for molecular optimization and how to extend a 
molecular scaffold at the protein binding site.  
1.4.1.1 Crystals and Unit Cells 
 
A crystal can be described as a three-dimensional regular arrangement of molecules and the 
asymmetric unit of the unit cell is the smallest portion of the crystal lattice that can be used to generate 
the entire crystal packing, by applying translation and crystallographic symmetry (Figure 1.12a).  
Classification of the basic geometry of the unit cell in terms of axis, angles, and symmetry elements 
required to build up the unit cell from the asymmetric unit then leads to the space group.32 
The unit cell is defined by three repeating vectors 𝒂⃗ (that aligns with the direction of the x-axis of the 
crystal lattice), 𝒃⃗(that aligns with the direction of the y-axis of the crystal lattice), and 𝒄⃗ (that aligns 
with the direction of the z-axis of the crystal lattice) with the angles between them, α, β, and γ (Figure 
1.12b). Different planes are constructed from the intersections of the crystal lattice and depending on 
the orientation of the plane it intersects one, two, or all three lattice axes. Parallel lattice planes are 
determined by the Miller indices, h, k, and l, which label the corresponding reflections and describe 






Figure 1.12: An illustration of the relationship of a unit cell (b) to the entire crystal lattice (b). A unit cell can be defined as the 
smallest repeating part of a crystal lattice, where the angles aren’t necessarily 90° as depicted in the image. (Image taken 
from courses.lumenlearning.com.) 




1.4.1.2 Bragg’s Law 
 
When an incoming beam hits the crystal, the lattice planes containing regularly arranged atoms scatter 
an array of waves. Through destructive interference, the reflected beam waves often cancel one 
another. They only add up if the Bragg’s law is fulfilled, which occurs in a few specific directions (Figure 
1.13a).  
 
To obtain the diffraction pattern, a series of parallel crystal planes must intersect the Ewald sphere 
which results in reflection spots on the detector (Figure 1.13b). The Ewald sphere is a geometric 
construction that describes the relationship between the wavevector of the incident and diffracted X-
ray beams, the diffraction angle of a given reflection, and the reciprocal lattice of the crystal. 34 A single 
reflection spot is the result of a scattered wave from a set of reciprocal lattice planes occupied by an 














The workflow in X-ray crystallography consists of several steps that have been elegantly described by 
M.S. Smyth and J.H.J. Martin (2000) and are detailed below. 
1.4.2.1 Protein Crystallization 
 
Not all proteins readily crystallize, which makes this step rate limiting in many protein crystallographic 
studies. The principle of crystallization is to place the purified protein under supersaturated conditions 
that would lead it to nucleate and form crystals, rather than precipitate. This can be demonstrated by 
the phase diagram for crystal growth in Figure 1.14.35 To find the right conditions, this requires 
screening several different protein concentrations, precipitants, buffers, temperature, pH, salt and 
sometimes additives.36 A common crystallization method is vapor diffusion where water vapor leaves 
the protein drop and ends up in the reservoir to achieve equilibrium. This leads to supersaturation, 
nucleation, and crystallization.37 There are several commercially available crystallization screens which 
are 96-well or 384-well plates that contain solutions consisting of varying conditions. To find a new 
crystallization condition for a protein, the protein is added to such crystallization screens at varying 
a b 
Figure 1.13: a) Reflected beam waves often cancel each other out (destructive interference) except when they fulfill Bragg’s 
law, under which they add up (constructive interference). (Image adapted from Rhodes, G. 2006.) b) Parallel crystal planes 
must intersect the Ewald sphere for reflected beam waves to create a diffraction pattern. (Image taken from dissertation of 
Radeva, N. 2016.) 
(Equation 1.6) 





temperatures (most common are 4°C and 18°C) and the drops are monitored on a regular basis for 
crystal growth.  
Once the crystallization conditions are found and proven to be reproducible, crystallization plates with 
the protein are set up. There are two choices of crystallization plates; hanging drop or sitting drop 










Preparing crystals for X-ray measurements involves flash-freezing them in liquid nitrogen where they 
are also stored. This step is done to preserve the crystal structure for long-term storage. Additionally, 
X-ray measurements are done at cryogenic temperatures to avoid radiation damage to the crystals.  
To prevent the formation of ice rings in the crystal upon flash-freezing, a cryoprotecting step is added 
where the crystal is coated in a cryoprotectant such as PEG, MDP, or glycerol before it is immersed in 
liquid nitrogen.38 
a b 
Figure 1.14: The phase diagram of protein crystallization is divided into undersaturated and supersaturated regions. Crystals 
will only grow from a supersaturated protein solution. The line between the stable (white) and metastable phase (purple) 
represents the equilibrium between the solid and free-molecule phase. Nuclei will develop into crystals in the metastable 
and the labile (blue) region, and the region with very high supersaturation (green) is where the protein solution might 
precipitate. (Image taken from McPherson, A and Gavira, J. A., 2013.) 
Figure 1.15: The components of a hanging drop (a) and sitting drop (b) crystallization plate. Crystallization occurs through 
vapor diffusion where the pressure gradient across the vapor space between the drop and the reservoir leads to a net loss 
of water in the drop. (Image taken from M.S. Smyth and J.H.J. Martin, 2000.) 





1.4.2.2 Optical Setup 
 
Synchrotrons are extremely strong sources of X-rays. X-rays are generated from accelerating electrons 
in a synchrotron storage ring and a monochromator is used so that a single X-ray wavelength is 
selected. Slits are used to focus the beam and ensure that it is parallel and is adjusted to 0.1-0.3 mm 
diameter. The crystal is mounted into the beam using a device called a goniometer where it rotates 
through the Ewald sphere to allow 360° images of the crystal to be taken. A detector is placed after 
the crystal and a small lead pellet called the backstop is suspended in the path of the direct beam to 
prevent the intense X-rays from over-exposure and damaging the detector.36 The detector commonly 
used in X-ray experiments is a CCD (charge coupled device) detector. A CCD is an integrated circuit 
engraved onto a silicon surface that forms pixels (light sensitive elements). The electrical charge 
generated from incident photons on this surface is read by electronics and converted to a digital copy 
of the light patterns falling on the device.39 More advance detectors such as Pixel Array Detectors 
(using the photoelectric effect) are now found at many synchrotrons and allow the direct detection of 








Figure 1.16: The optical setup of an X-ray experiment. (Image taken from publish.illinois.edu.) 
 





1.4.2.3 Diffraction and Data Collection 
 
The photons from the X-ray beam interact with the electrons around an atom which creates a 
diffraction of the 3D lattice and the various lattice planes produce scattered waves that are recorded 
on the detector (Figure 1.17). The different lattices generate different diffraction patterns that reflect 
the symmetry and the distance of the atoms to one another.41 Based on the diffraction pattern, the 
arrangement of the atoms in the macromolecule can be determined.  
 
Before data collection, test images of the crystal are recorded and softwares are used to assign the 
space group and to suggest the appropriate strategy for data collection based on the resulting 
diffraction pattern. These softwares predict the space group of the crystal and calculate how many 
degrees the crystal should be rotated and the number of images to be collected to ensure a complete 
data set. An example of such a software is iMosflm.42 The resolution of the collected dataset is 
determined by the minimum spacing of lattice planes in the crystal giving rise to a reflection spot, and 
the distance from the crystal to the detector is adjusted to allow the maximum resolution for collecting 
diffracted spots. The resolution of spots collected is proportional to the diffraction angle, so the highest 
resolution will be at the edge of the detector.36  
 
1.4.2.4 Data Processing and Calculating an Electron Density Map  
 
After the diffraction images are collected, complex algorithms are used to process the diffraction data. 
The intensity of the individual reflection spots in the diffraction pattern holds information about the 
form of the molecule. Fourier transformation of this information translates the diffraction pattern to 
the generated electron density which represents the spatial distribution of the atoms in the crystal. 
The atoms of the crystallized molecules are then assigned to this electron density.  The diffractometers 
used in X-ray crystallography register the intensity of the light that hits them, but this measurement is 
incomplete. The reason for this is that diffracted waves have only amplitudes (square root of the 
intensity) but the structure factors also have phases, which are not accessible by the measurement.  
The phase information can be obtained by several methods, the simplest of which is molecular 
replacement (MR), which uses a previously solved structure of a homologous protein or the lower-
resolution protein NMR structure of the same protein to calculate the structure factor amplitudes Fcalc 
and the phases φcalc. The model used is translated and rotated in the unit cell by computer simulations, 
producing a calculated diffraction pattern (calculated structure factors 𝐹calculated) that is compared to 
Figure 1.17: A diffraction pattern recorded on a detector is the result of the scattering of atomic electrons after colliding with 
photons of the X-ray beam. 




the observed diffraction pattern of the unsolved protein (observed structure factors 𝐹observed) (Equation 




Other methods for solving the phase problem involve reconstructing the phases for individual 
reflections by atom through heaving atom soaking. Heavy atoms are electron rich and they dominate 
the diffraction pattern which allows their position in the crystal lattice to be determined. Additionally, 
if the protein contains methionine residues, selenomethionines can be incorporated into the protein 
during expression and the phases of the resulting crystal structure can be determined through 
anomalous scattering. 41 
The final electron density map combines the structural model (phases) and the experimentally 
collected data (amplitudes) and represents how well the selected model fits the experimental data. 
The two electron density maps that are most often used are the m|Fo|-|Fc| map and 2m|Fo|-|Fc| 
map. The m|Fo|-|Fc|  map, known also as a difference or omit map, shows what has been overfit or 
not accounted for by the model, while the 2m|Fo|-|Fc| map includes both the m|Fo|-|Fc|  map and 
the electron density around the model.43  
1.4.2.5 Data Refinement and Model Building 
 
This is the final step that renders a 3D model of the protein structure. In this step, the 2m|Fo|-|Fc| 
and m|Fo|-|Fc| maps are used to correct the model and explain any unclear electron density. The 
m|Fo|-|Fc| map can either show green blobs which are the map at positive sigma values, or red blobs 
which is the map at the negative sigma value. A green blob indicates regions of the experimental 
density where the model is missing. In fragment screening or co-crystallization, this can belong to the 
molecule of interest.  Red negative sigma density indicates regions where the model does not explain 
the experimental density, which could be a disordered region in the experimental data that was 
ordered in the model, such as a flexible loop. A common software used for display and model building 










Figure 1.18: An electron density map of a protein structure where the 2m|Fo|-|Fc| (blue) is contoured at a sigma level of 1σ 
and the m|Fo|-|Fc| map (green and red) is contoured at a sigma level of 3σ. The green blobs indicate areas that are not 
found in or explained by the model, while the red blobs indicate missing parts of the experimental data. In this dataset, the 
green blob indicates a fragment binding. 
(Equation 1.7) 





1.4.3 Fragment Screening Using X-ray Crystallography 
 
Fragment screening can be approached either by soaking or co-crystallization.    
In soaking, apo crystals of the protein are soaked into solutions containing the fragment of interest at 
concentrations reaching up to 100 mM. The soaking solution used can be the reservoir solution in 
addition to a cryoprotectant. In co-crystallization the ligand is added to the protein to form a complex 
with the protein as it crystallizes.45 When studying larger ligands, one should keep in mind that there 
may be differences between soaked and co-crystallized structures. This has been reported with TGT, 
where crystal structures obtained by soaking did not display the conformational adaption seen in co-
crystallized structures of the same complex. 46  
 
 









The first part of the following chapter (2.2 Fragment Screening) have been submitted to the ChemMedChem 
Journal.  
Another manuscript is in preparation for the second part of the chapter (2.3 Structure-based Drug Design). 
 
The expression and the purification of Z. mobilis TGT, the crystallization screen, and elucidation of the crystal 
structures was done by the author of this thesis.  
 
The SPR and NMR screens were done by the author of this thesis in collaboration with Dr. Stefan Geschwindner 
and Dr. Per-Olof Eriksson, respectively, during an academic scientific secondment at Astrazeneca R&D in 
Gothenburg, Sweden  
Design and synthesis of ligands 2.1- 2.6, 3.1, 3.2, 4.1, and 4.2 was done by Dr. Christoph Hohn, Dr. Levon 
Movsisyan, and Dr. F. Wieland Goetzke from the working group of Prof. Dr. François Diederich at ETH Zurich in 
Zurich, Switzerland. 
Co-crystallization, elucidation of the crystal structures, and determination of binding affinities for ligands 2.1- 2.6, 
3.1, and 3.2 was done by Dr. Frederik R. Ehrmann from the working group of Prof. Dr.  Gerhard Klebe at the 
Philipps University of Marburg in Marburg, Germany. Details can be found in his dissertation.  
 
Co-crystallization, elucidation of the crystal structures, and determination of binding affinities for ligands 4.1 and 
4.2 was done by the author of this thesis.   
 
MD simulations were previously done by Naomi Tidten and STTMap calculations were done by Tobias Wulsdorf , 
both from the working group of Prof. Dr.  Gerhard Klebe at the Philipps University of Marburg in Marburg, 
Germany 
 




























2.1.1.1 Epidemiology  
 
Shigellosis is a world-wide endemic with 165 million cases reported per year, including 1.1 million deaths globally, 
mostly in children under five years of age. It is an acute bacterial infection of the intestine caused by the gram-
negative Shigella. Symptoms of the disease include sudden abdominal cramping, nausea, fever, vomiting, and 
bloody stool. Sources of infection include contaminated food or water and therefore, it occurs in low income 
countries where poor sanitation and overcrowding can lead to the spread of the disease.47 Furthermore, after 
sudden natural disasters (earthquakes, floods, etc.) or chaos of war the disease can also rapidly spread in 
countries of higher life standards.  
 
2.1.1.2 Treatment  
 
The mode of treatment of shigellosis is antibiotics. These include; beta-lactams such as ampicillin, amoxicillin, and 
third-generation cephalosporins (cefixime); quinolones such as nalidixic acid and norfloxacin; and finally, 
macrolides such as azithromycin. However, in addition to serious side effects that may be caused by some 
antibiotics such as hypersensitivity, dehydration - particularly of small children, anaphylactic shock and 
encephalopathy48, there is a rising resistance to standard antibiotics such as sulfonamides, tetracyclines, 
ampicillin, and trimethoprim-sulfamethoxazole (TMP-SMX) reported worldwide, and therefore therapeutic 
options with a novel mode-of-action are necessary to target Shigellosis.49   
 
2.1.2 tRNA Guanine Transglycosylase   
 
2.1.2.1 Role in Shigellosis   
 
The pathogenicity of Shigella is dependent on virulence factors (VirF), which are required to invade epithelial cells. 
The expression of these virulence factors is modulated by the enzyme tRNA Guanine Transglycosylase (TGT, EC 
2.4.2.29), which catalyzes an anticodon modification of tRNAs specific for Asn, Asp, His and Tyr, leading to the 
replacement of guanine-34 at the wobble position by the hypermodified base preQ1  as seen in Scheme 2.1, which 
is further modified by other enzymes to queuine.50 As this modification is a prerequisite for the formation of 
Shigella virulence factors,  the inhibition of TGT has a direct impact on reducing the pathogenicity of Shigella.51 
This positive correlation between VirF and TGT was demonstrated by Durand and Björk, where a mutant of 
Shigella flexneri with an inactivated tgt gene could not invade host cells due to a reduction in translation of VirF 
but unchanged levels of virF mRNA. Additionally, transforming the aforementioned mutant with a plasmid 
containing functional shigella tgt gene restored queuine modification in the mutant as well as exhibiting VirF 
expression and virulence.52 
 
Scheme 2.1: Schematic representation of anticodon modification of tRNA by TGT. 





2.1.2.2 Structure of Zymomonas mobilis TGT 
 
TGT is a homodimer of 86 kDa and adopts the highly populated triose-phosphate isomerase (ß/a)8- barrel (TIM) 
with a tightly attached C-terminal zinc-containing subdomain. The packing of the subdomain against the barrel is 
mediated by an α-helix, located close to the C-terminus, which displaces the eighth helix of the barrel. 50  The 
interface between the two monomers is stabilized by a hot spot of four aromatic amino acids which form a well-
organized hydrophobic patch as seen in Figure 2.1. One monomer contributes residues Trp326, Tyr330, and 
His333 while the Phe92’ comes from the adjacent protein dimer. TGT is only functional as a homodimer, where 
one monomer carries out the catalytic reaction and the other stabilizes the dimer and positions the tRNA correctly 
for the base exchange reaction as seen in Figure 2.2. The active center of the Z. mobilis TGT is located in the area 
of the β-strands of the C-terminus of the TIM- barrel motifs and accepts tRNA molecules with the sequence 
U33 G34 U35 as a substrate. There are three sub-pockets in the active site of TGT: 
1) The Ribose-33 pocket, formed by the residues Ala232, Gly261 to Lys264, Asp267, Cys281 to Leu283 and 
Arg286. 
2) The Ribose-34 / phosphate 35 pocket, a hydrophobic pocket formed by residues Val282, Leu68, and 
Val45. A hydrophilic portion formed by Asp280 and Asp102. Additionally, Thr47, Asn70, and Gln107. 





Figure 2.1: Tertiary structure of TGT monomer (a) displaying the TIM barrel and the described active site (b). Quaternary structure of 
TGT dimer (c) and the residues of the aromatic hotspot at the dimer interface (d). 
a b 
c d 







2.1.2.3 Eukaryotic vs. Bacterial TGT 
 
Eubacteria, eukaryotes, and archaebacteria all have the tRNA-modifying enzyme TGT, whereas the incorporation 
of the modified 7-substituted 7-deazaguanine bases into tRNAs occurs in a kingdom-specific manner. To start 
with, eubacterial TGTs catalyze the exchange of the guanine base by the pre-modified base 7-(aminomethyl)-7-
deazaguanine (preQ1) which is further modified into queuine in another two-step catalysis not involving TGT. 
Eukaryotic TGTs, which show a high sequence identity to eubacterial TGTs (43.2 % between Homo sapiens and 
Shigella Flexneri) directly incorporate queuine at the wobble position of tRNAs. Archaebacterial TGTs on the other 
hand show only about 20–25% sequence identity to eubacterial TGTs and address guanine at a different site, 
namely position 15 of the D-arm in the majority of archaeal tRNAs.53 In addition to these substrate differences 
(as shown in Figure 2.3), there are some differences in the sequences of TGT across the different kingdoms (as 






Figure 2.2: a) TGT dimer with a tRNA intermediate substrate in yellow bound to active site. b) One of the TGT monomers (light green) 
carries out the catalytic reaction while the other monomer (dark green) stabilizes the dimer and holds the tRNA molecule in position.  
(PDB:1Q2S). Residues Tyr106, Glu107, Val108, Met109, and Ser 110 have been omitted for image clarity. 
























Figure 2.4: Sequence alignment of TGT in different kingdoms. Color coding is used to distinguish the common amino acids in all the 
sequences. Residue 158 in each organism is encircled in red. Sequence alignment was done in Clustal Omega.8 




2.1.2.4 Disrupting TGT Function 
 
Strategies developed to inhibit TGT include potent active-site inhibitors to block the binding of tRNA, thereby 
preventing the transcription of the virulence factors. Over the years, several of these active-site inhibitors have 
been developed and co-crystallized to yield high-resolution X-ray structures.51,55,56,46 The most common and 
successful ligand series have been lin-benzoguanine derivatives addressing the ribose-33 or ribose-34 sub-
pockets. As TGT is only functional as a homodimer, other strategies include the disruption of the homodimer at 
the interface. In addition to the ribose-33 and ribose-34 sub-pockets, MD simulations of the apo wild type TGT 
have predicted the opening of a transient sub-pocket located above the guanine/preQ1 pocket.57 These 
simulations showed a pronounced flexibility in the region between the crucial residues Val233 and Cys158, 
creating a small sub-pocket that allows the binding pocket to reach volumes even larger than the eukaryotic TGT 
models. The observation suggested a strategy to target in our project this new binding site for the design of new 
inhibitors against TGT following a structure- based drug design concept. The ligands developed to address this 
transient sub-pocket with a ligand will be described in further detail in this chapter (sections 2.3). The transient 
sub-pocket opens upon shifting of Cys158 backwards, which we can consider the gatekeeper of this sub-pocket. 
Ligands that putatively attach covalently to this Cys158 can also be a mean to achieve selective inhibition, as the 
amino acid sequence of eukaryotic and prokaryotic TGT reveals that the eukaryotic TGT lacks the Cys158 residue 
and has a Val145 residue instead.  
2.2 Fragment Screening 
 
The fragment library used in this project is an inhouse initial screening library consisting of 96 structurally diverse 
fragments developed in collaboration with the Helmholtz Zentrum in Berlin and Jena Bioscience to a commercially 
available screening kit.16 These fragments were selected specifically with a potential to harbor several assorted 
interactions to a large scope of target proteins. The 96 fragments contain a subset of a larger 361 fragment library 
that was designed to study whether a library with fragments non-adhering to the Astex rule of 39 could still 
provide hits that could be used as starting points for lead compounds. This library was tested against 
endothiapepsin and more than 50% of the resulting hits did not adhere to the rule of 3, which meant that, had 
the rule of 3 been applied, several fragment hits would have been missed.58 These fragment hits, in addition to 
others, were then selected to compile the 96-fragment library. 
It is common for fragment-based hit finding projects  to perform a screening campaign in a cascade manner, 
starting with the less demanding screening methods first and apply the more time and resource-requiring screens 
at a later stage. 59,11,60 In our work, we did not follow such an approach but rather screened the entire fragment 
library with three methods in parallel, particularly to make unbiased comparative analysis possible. The 
assessment of the results of the three different screening methods will allow us to prioritize which method to 
begin the screening cascade with. 
In this section we present the results of our comparative analysis, and our findings for the low overlap in the hit 
rates between the applied screening methods. 
2.2.1 Fragment Screen by Surface Plasmon Resonance (SPR)  
 
A typical SPR-based fragment screening workflow to prioritize binders and select the most promising hits consists 
of the three steps, the Clean Screen, the Binding Level Screen and the Affinity Screen. Subsequent to the affinity 
screen, a competition screen is performed to validate the screening hits. 
2.2.1.1 Clean Screen  
 
A low molecular weight clean screen was performed to identify and exclude compounds that bind non-specifically 
or show residual binding to the sensor chip matrix. It is important to remove such compounds because their 
residual binding can adversely affect the quality of the data of subsequent compound injections, as the biosensor 





surface is typically used in an iterative fashion. All 96 fragments were screened against the dextran surface of the 
sensor chip without any immobilized protein, and there were 15 fragments that had to be excluded due to 
undesirable properties and technical reasons as mentioned earlier. Their chemical structures are shown in Table 
S1 of the Supplementary Information.  
2.2.1.2 Binding Level Screen and Affinity Screen  
 
The binding level screen was performed with a total of 81 fragments at a concentration of 1 mM and the resulting 
response units (RUs) were double-referenced against both 61, the reference channel and the buffer blanks. From 
the binders, 10 fragments were prioritized as hits (those that had an RU below 13 RUs were excluded, as this was 
the cut-off value chosen based on binding to reference channel by the negative control). Their structures and 
responses are given in Table 1 below and correspond to a quite high hit rate of 12.3%. 
An affinity screen with a full dose-response was performed with the hits to estimate their binding affinity. From 
the resulting dose-response curves, the dissociation constant (KD) could only be determined for J50 and amounts 
to 1.5 mM (+/- error limits) (Figure 2.5). 
 
2.2.1.3 Competition Screen  
 
To determine whether the fragment hits were specific active-site binders or non-active-site binders, two separate 
competitive experiments were performed. In the first, compound 2 (Scheme 2.2) was measured at 40 nM in the 
presence and absence of the fragment hits and the responses were compared. If the response of compound 2 
was attenuated in the presence of a fragment, this indicated competitive binding and hence the fragment was 
deemed as an active-site binder. Likewise, if the response of compound 2 was fortified in the presence of the 
Figure 2.5: Dose-response curve of J50. KD determined to be 1.5 mM. 




fragment, this indicated non-competitive binding and hence the fragment was deemed a non-active-site binder. 
Only the binding response of J50, J09, J79, and J92 caused a reduction of the potent inhibitor used for 
displacement, whereas J50 caused the strongest reduction in binding response. In the second experiment, dose-
response experiments were run in the presence of 8 nM of the potent active-site inhibitor compound 2 62 (SPR KD 
= 7.7 nM). These second experiments did not include J92, J09, J51, J55, and J79 because of limited availability of 
material. In these experiments the binding response of J50 was reduced in the presence of the potent inhibitor 
used for displacement.   
 
Table 2.1: TGT fragment hits from a binding level screen. 






































2.2.2 Fragment Screen by NMR 
 
For binding studies and screening with NMR, the CPMG (Carr-Purcell-Meiboom-Gill)63 and the WaterLOGSY 
(Water-Ligand Observed via Gradient SpectroscopY)61   techniques were used. Experimental details can be found 
in the Materials and Methods section.  
2.2.2.1 Validation of NMR Setup  
   
A binding test was performed using J50 (SPR KD=1.5 mM) as a reporter and compound 1 46 (Scheme 2) (SPR KD =68 
± 5 nM) as a potent inhibitor. A sample with 200 µM of the reporter compound in NMR buffer is measured first 
(Figure 2.6). Then a stepwise addition of sub-stochiometric amounts of the TGT protein follows and further 
spectra are collected. Upon addition of the TGT protein, the CPMG peak of J50 is attenuated and the WaterLOGSY 
peak turns positive, confirming the weak binding of J50 to the TGT protein. The attenuation of the CPMG peak 
can be explained by the exchange between free J50 in solution and J50 bound to TGT and indicates that the 
exchange rate is on an intermediate time scale, compatible with the affinity obtained from SPR (c.f. above). Upon 
addition of a more potent competitive inhibitor such as inhibitor 1 (Scheme 2.2) the bound J50 is displaced from 
the binding site of TGT and the intensity of the J50 peak is regained. The intensity changes in the WaterLOGSY 
spectrum can be explained in a similar fashion.61  
 
1 2 
Scheme 2.2: Chemical structures of reporter ligands 116: 6-amino-4-[2-(3,4-dihydroxy-5-methoxyoxolan-2-yl)ethyl]-2-(methylamino)-
1H,5H-imidazo[4,5-g]quinazolin-8-one and 215: 6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1H,5H,6H,7H-
imidazo[4,5-g]quinazolin-8-one. 
 





2.2.2.2 Fragment Solubility  
 
To ensure that the fragments are sufficiently soluble in the NMR buffer, samples of the fragments alone without 
protein were prepared and tested in NMR. The recorded spectra were analyzed. Amongst the 96 fragments, 12 
had very limited solubility and were therefore excluded from the NMR screen. In addition to these 12 excluded 
fragments, J67 showed impurity (the spectrum shows signals in the typical range of aromatic portions, however 
J67 is aliphatic) and J69 has only exchangeable NH protons, thus it cannot be detected by proton NMR. 
Considering the requirement of rather large amounts of fragment material in NMR, five fragments could not be 
included due to limited availability of the compounds (J35, J53, J54, J55, J57). These fragments were also excluded 
from the screen (Table 19 in Appendix). In the end only 77 of the 96 fragments remained to be screened. 
2.2.2.3 Binding Screen   
 
The NMR screen was performed following the same protocol as applied for the initial binding test. Fragments 
were studied at a concentration of 200 µM in the absence of TGT protein, and then 3 µM of TGT were added to 
the same sample. If attenuation of the resonance signal of the studied fragment was experienced, the fragment 
was considered as a potential hit. Out of 77 fragments, 22 fragments showed attenuation in their NMR signals 
after TGT addition (Figure 2.7). To confirm specific binding of these hits, 20 µM of the more potent competitive 
inhibitor 1 (Scheme 2.2) was added to the sample and a potential regain of the fragment’s NMR resonance was 
recorded. If the fragment’s signal intensity continued to become attenuated, it indicated that the fragment 
continued to bind in the presence of the competitive inhibitor and therefore it was classified as a non-active site 
binder, and vice versa. From the 22 fragment hits, only four fragments showed a significant regain (more than 
4%) including the originally used reporter fragment J50 (Table 2.1). This corresponds to a hit rate of 5%. Figure 
2.7 shows the relative intensity of the signals after protein addition and after addition of inhibitor 1.  
 
200 µM J50 
+ 3 µM TGT 
+ 3 µM TGT 
+ 3 µM TGT 
+ 10 µM inhibitor 1 
+ 10 µM inhibitor 1 
b 
Figure 2.6: a) CPMG and b) WaterLOGSY spectra of J50 binding to TGT. The CPMG spectra in (a) show attenuation of the signal of the 
freely solvated J50 upon addition of TGT (red, green, violet), which is a proof of weak binding. Upon addition of inhibitor 1, an increase 
of the signal is detected, returning to that of the freely solvated J50, which is a proof for the displacement of J50 by the more potent 
inhibitor 1. The WaterLOGSY spectra (b) can be interpreted in a similar way. 



















2.2.3 Fragment Screen by X-ray Crystallography  
  
All fragments of the 96 entry library16 were soaked at concentrations of 100 mM into apo crystals of TGT, for an 
exposure time ranging between three minutes and twenty hours depending on the crystal stability in the 
fragment solution. For the 96 fragments, eight hits were found to bind to TGT (PDB codes: 5SW3, 5N6F, 5UTI, 
5UTJ, 5V3C, 6FS0) as listed in Table 2.3, five of which bind to the active site and three at the surface in the crystal 
packing (Figure 2.8). The structures were successfully refined to resolutions between 1.10 Å and 1.63 Å, giving 
clearly defined difference electron densities for the bound fragments. The interactions of the detected fragment 
hits are described below, where they have been classified based on their spatial locations. 
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Yes (molecule 1) 













































Peak intensity after protein addition Peak intensity after inhibitor 1 addition
Figure 2.7: Fragments peak intensities difference after protein addition (blue) and after inhibitor 1 addition (orange). 
 







2.2.3.1 Fragments Binding to the Recognition Pocket Hosting the Nucleobases in the Catalytic Reaction 
 
As described in the introduction, TGT catalyzes an anticodon modification of tRNAs by replacing guanine against 
the hypermodified base preQ1. To accomplish this exchange, the nucleobase must be recognized in a deep pocket 
composed of two adjacent Asp residues (Asp103, Asp156). The site is complemented by the carboxamide 
terminus of Gln203 and the backbone NH of Gly230. The imidazole moiety of guanine and the exocyclic amino 
group of preQ1 bind to the atoms of the peptide bond between Ala232 and Leu231. This peptide bond proved to 
be flexible and by a concerted backbone flip, it either exposed its H-bond donor or acceptor facility toward the 
bound substrate molecule.64  
Fragment J41. Two copies of fragment J41 bind to TGT. The first molecule binds with full occupancy to the preQ1 
recognition pocket where one oxygen atom of its carboxylate group forms two hydrogen bonds to the 
carboxamide nitrogen atom of Gln203 and backbone nitrogen atom of Gly230. The second oxygen atom of this 
carboxylate group forms one direct hydrogen bond to the carboxylate group of Asp156 and a second water-
mediated interaction (W137) to the other oxygen atom of the same residue. J41 additionally forms a π-π stacking 
interaction to Tyr106 (Figure 2.9). The binding interactions of the second molecule of J41 will be described below. 
a b 
J41 







J72, J79, J64  
J86, J41 
a b 
Figure 2.8: a) Overview of the spatial accommodation of the fragments detected in a crystallographic screen directly on protein crystals. 
Solvent accessible surface representation of TGT viewed toward the catalytic center with the discovered bound fragments in CPK 
representation, heteroatoms type-coded, carbon atoms of the individual fragments displayed with the same color as the corresponding 
fragment labels b) the same overview with the image rotated 180° to the left. 
Figure 2.9: a) Binding mode of fragment J41 (PDB: 5SW3) in the preQ1 pocket. Hydrogen bonds and π-π stacking interactions are shown 
as yellow dotted lines, water molecules as red spheres, all distances in Å. b) Protein displayed by the gray solvent accessible surface. 
Residues Tyr106, Cys158, and Val159 have been omitted for image clarity.  




Fragment J64. Guanine is present as a search fragment in the screened library. As a matter of fact, our screen 
also retrieved the natural substrate of TGT as a bound fragment hit. It binds with an occupancy of 100% to the 
recognition pocket and forms two separate pairs of bidentate hydrogen bonds to the carboxylate groups of 
Asp156 and Asp102. To accomplish this interaction pattern, one of the two carboxylic acid groups must be 
assumed to be protonated. Additionally, the carbonyl group of its pyrimidine ring forms a hydrogen bond with 
the carboxamide nitrogen atom of Gln203 and the backbone nitrogen atom of Gly230. J64 also forms the π-π 
stacking interaction with Tyr106 at a distance of 3.3 Å (not shown) (Figure 2.).  
 
Fragment J79. The fragment refines to an occupancy of 94% in the preQ1 pocket where its triazole ring forms four 
hydrogen bonds with the enzyme; one with the backbone nitrogen atom of Gly230, one with the carboxamide 
nitrogen atom of Gln203, and a bidentate hydrogen bond (strong at 2.7 Å and weak at 3.8 Å) with the carboxylate 
oxygen atoms of Asp156. Additionally, the pyrimidinedione ring of J79 forms a hydrogen bond via its 5-carbonyl 
group to the nitrogen of Gly261 (weak H-bond 3.8 Å) and a hydrogen bond via its 7-carbonyl group to the 
carboxamide nitrogen of Gln107. The 4-nitrogen of J79 forms a water-mediated interaction (W28) to the nitrogen 
atoms of both, Ala232 and Gly230. J79 also forms the π-π stacking interaction with Tyr106 at a distance of 3.5 Å 
(data not shown) (Figure 2.). 
b a 
a b 
Figure 2.10: a) Binding mode of fragment J64 (PDB: 5N6F), guanine to the preQ1 pocket. Hydrogen bonds are shown as yellow dotted lines, 
water molecules as red spheres, all distances in Å. b) Protein displayed by the gray solvent accessible surface. Residues Tyr106 and Met109 
have been omitted for image clarity. 
Figure 2.11: Binding mode of fragment J79 (PDB: 5UTJ) to preQ1 pocket. Hydrogen bonds are shown as yellow dotted lines, water molecules 
as red spheres, all distances in Å. b) Protein displayed by the gray solvent accessible surface. Residues Cys158 and Met109 have been 
omitted for image clarity.   





Fragment J86. This fragment binds with an occupancy of 100% to the preQ1 recognition pocket and forms a 
hydrogen bond to the carboxamide nitrogen atom of Gln203 and backbone nitrogen atom of Gly230 via one 
oxygen atom of its carboxylate group. The second oxygen atom of the acid group faces in monodentate fashion 
the carboxylate of Asp156. Thus, one of the facing carboxylic acid groups must be assumed to be protonated. 
Additionally, the terminal primary amine of J86 forms direct hydrogen bonds with the carbonyl oxygen atoms of 
Leu231 and Ala232, as well as a water-mediated interaction (W120) to the carbonyl oxygen atom of Gly261 




Fragment J72. This fragment, a derivative of the amino acid arginine, is amongst the most interesting fragment 
hits as it induces the opening of a sub-pocket next to the preQ1 recognition site. This opening was previously only 
reported in co-crystallized structure of mutated variants of TGT in complex with the nucleobase queuine (PDB 
code 3BLO).65 The latter substrate is related to preQ1 but comprises an attached sidechain bearing an unsaturated 
five-membered carbo-cycle.  The opening of the preQ1 sub-pocket is brought on by the shifting of the Cys158 
gatekeeper residue by 4 Å from its original position in the uncomplexed enzyme. J72 binds with full occupancy to 
the preQ1 recognition pocket where the fragment’s guanidinium moiety forms two bidentate hydrogen-bond 
interaction with the carboxylate groups of both, Asp156 and Asp102. The fragment adopts a bend, back-folded 
geometry and forms with its carboxylate group a two-membered water-water chain (W263 and W302) that 
mediates a H-bond interaction to the carboxamide nitrogen of Gln203 and two direct hydrogen bonds with the 
nitrogen of Gly230. The amino nitrogen of J72 forms a hydrogen bond with the amide oxygens of Leu231 and 
Met260. Additionally, this likely charged and protonated amino group forms a water-mediated interaction (W80) 










Figure 2.10: a) Binding mode of fragment J86 (PDB: 5V3C) to the preQ1 pocket. Hydrogen bonds as yellow dotted lines, water molecules 
as red spheres, all distances in Å. b) Protein displayed by the gray solvent accessible surface. Residues Tyr106 and Ser110 have been 
omitted for image clarity. 















2.2.3.2 Fragments Binding to the Surface of the Protein or into the Interface of Other Crystal Mates.  
 
Fragment J41. Some fragment hits bind to exposed pockets and depressions on the surface of TGT rather than to 
the active site pocket. The second molecule of fragment J41 binds with an occupancy of 100% to the surface of 
TGT via its carboxylate group forming hydrogen bonds with the imidazole side chain of His133 and backbone 
nitrogen atom of Met134. Upon comparison with PDB codes 5N6F, 5UTI, 5UTJ, 5V3C, and 6FS0, the Arg139 side 
chain is always found oriented in the same position as fragment J41. The flexibility of the Arg139 sidechain is what 
allows J41 to bind in its place. Additionally, J41 forms a water-mediated interaction (W34) to the backbone 






a b c 
Figure 2.11: a) Binding mode of fragment J72 (PDB: 5UTI) to the preQ1 pocket leading to the opening of a sub-pocket next to the latter 
pocket. b) The opened pocket, filled by water molecules, is indicated, protein displayed by the gray solvent accessible surface. c) A spatial 
movement of the Cys158 residue (carbons violet) by 4 Å is detected compared to the original position of this amino acid in the apo TGT 
structure (PDB: 1PUD, carbons pink) which indicates the opening of the sub-pocket. Residues Tyr106 and Ser110 have been omitted for 
image clarity. Hydrogen bonds are shown as yellow dotted lines, water molecules as red spheres, all distances in Å. 
Figure 2.12: a) Fragment J41 (PDB: 5SW3) binding mode to the surface of TGT. Hydrogen bonds are shown as yellow dotted lines, water 
molecules as red spheres, all distances in Å.  b) Protein displayed by the gray solvent accessible surface. 





Fragment J14. The fragment binds at an occupancy of 100% to the surface of TGT. Its furan moiety establishes a 
water-mediated contact (W157) to the backbone nitrogen atom of Ala217 and carbonyl oxygen atom of Gln213 
(Figure 2.13). Its secondary and likely charged amino group addresses both, the carboxamide oxygen atom of 
Gln213 as well as a carboxylate oxygen atom of Glu173 through hydrogen bonds (2.6, 2.7 Å). Additionally, the 
nitrogen atom of the pyridine moiety of J14 accepts a hydrogen bond from one nitrogen atom of the terminal 
Arg177 guanidinium head group. 
 
Fragment J19. This fragment binds with a refined occupancy of 56% to the surface of TGT via a weak hydrogen 
bond (3.8 Å) between its benzodioxine ring and the backbone nitrogen atom of Lys85 (Figure 2.14b). Additionally, 
it forms two water-mediated interactions, one by the nitrogen atom of its pyrrolidine ring via W102 to the 
carbonyl oxygen atom of Leu146, and a second between the pyrrolidine ring via W269 to the carbonyl oxygen 
atom of His145. The entire pyrrolidine moiety could not be resolved in the difference electron density (Figure 
2.14c). The target protein is only active as a homodimer.66 Elaborate mutational studies showed that a cluster of 
four aromatic residues is important for the stability of the dimer interface.67 Interestingly, while generating the 
symmetry mate to complete the dimer, it becomes obvious that although J19 does not form direct contacts with 
the aromatic hot spot formed by residues Trp326, Tyr330, His333 and Phe92’ from the other crystal mate, it binds 
to the interface of the crystallographic symmetry mate in direct contact to residues Ser188, Arg189, and Lys190, 
which shift by 3.3 Å, 3.8 Å, and 3.7 Å respectively in comparison to the structure of TGT in complex with J41 (PDB: 
5SW3) (Figure 2.14d). Obviously, the fragment shifts the adjacent residues in space to create sufficient space for 
its accommodation. This shifting also causes the residues of the aromatic cluster to shift by at least 3.8 Å in space 
compared to their positions in the interface for the unperturbed dimer (Figure 2.14g).  
b a 
Figure 2.13: a) Binding mode of fragment J14 (PDB: 6FSO) to a surface depression of TGT where the fragment forms some polar contacts 
to the protein. Hydrogen bonds are shown as yellow dotted lines, water molecules as red spheres, all distances in Å. b) Protein displayed 
by the gray solvent accessible surface. 





Fragment J33. The fragment binds with a refined occupancy of 73% to the surface of TGT via a bidentate salt 
bridge to Glu31’ from a neighboring crystal packing mate using its likely charged amidino function. Additionally, 
the p-trifluoromethyl group forms van der Waals contacts with the methyl group of Ala217 and carbonyl oxygen 
atom of Gln213. The benzene ring of J33 is involved in a water-mediated contact (W212) to the side chain of 
Arg177 (Figure 2.15).This fragment was detected by running the program PanDDA (Pan-Dataset Density Analysis) 
68, 69 designed to analyze multiple datasets and identify ligand binding. When checking the generated “event 
maps” we took notice of this fragment that otherwise could not be identified in the usual m|Fo|-|Fc| density 
map contoured at a sigma level of 3σ. This prompted us to reevaluate the structure and we could see more of the 
fragment when reducing the m|Fo|-|Fc| density map contouring to a sigma level of 2.3. After refinement was 
complete, the density for the fragment becomes more apparent as seen in Figure 2.16. The B-factors of the 

















Figure 2.14: a) Binding mode of fragment J19 to the surface of TGT. b) The fragment is held in position by some weak polar interactions. c) 
In the refinement, the pyrrolidine moiety of J19 could not be fully resolved due to a partially defined electron density. The m|Fo|-|Fc| 
density map (blue) is contoured at a sigma level of 3σ and the 2m|Fo|-|Fc| density map (green) is contoured at a sigma level of 1σ. d) 
Fragment J19 binds where usually a DMSO molecule can be found in other soaked crystals like the structure of TGT in complex with J41 
(orange, PDB: 5SW3). e) When J19 binds it induces a shifting of the residues at the interface of the crystallographic symmetry mate to 
accommodate itself. These residues are Lys190, Arg189, and Ser188, which are shifted by 3.3 Å, 3.8 Å, and 3.7 Å respectively. f) This shifting 
can also be seen in the gap produced at this interface. g) Additionally, the residues that contribute to the aromatic hotspot at this interface 
are also shifted by at least 3.8 Å. In green: dimer with J19, in orange: dimer without J19. The symmetry mates are not shown. 
Figure 2.15: a) Binding mode of fragment J33 to the surface of TGT. b) The fragment bridges a contact between two crystal mates in the 
packing by interacting with Glu31’ of an adjacent TGT molecule in the packing. 







Before comparing the results of the three biophysical fragment screenings, we must consider that one obvious 
reason for the observed deviating hit rates by the distinct methods originates from differences in the biophysical 
principles of the methods as well as their sensitivity. The concentrations by which the fragments are exposed to 
TGT deviate in each method. While X-ray crystallography typically screens at very high fragment concentrations 
(up to 100 mM), fragment concentrations used in SPR are limited to 2 mM due to the risk of unspecific adhesion 
on the dextran surface chips, and  in NMR, fragment concentration were tested at 200 µM to ensure significant 
binding effect (see Materials and Methods). This makes detecting of very weak binders more likely at the high 
concentrations applied in X-ray crystallography. It should also be noted that the NMR binding experiment, 
contrary to SPR, is able to detect binding at significantly lower concentrations than KD which warrants the NMR 
technique being designated as a “spying technique”. However, in a recent comparative analysis performed by us, 
the higher hit rate obtained by crystallography is not simply explained by the fact that the additional hits were 
only weak binders which show up in the crystals due to the applied high concentrations, as the measured binding 
affinities of the hits showed strong binders as well.70 Another obvious deviation between the applied assays may 












Figure 2.16: a) Event map generated by PAnDDA shows electron density for J33. b) The m|Fo|-|Fc| density map (blue) is contoured at a  
sigma level of 2.3σ and the 2m|Fo|-|Fc| density map (green)  is contoured at a  sigma level of 1σ. c) J33 after refinement, the 2m|Fo|-
|Fc| density map (green) is contoured at a sigma level of 1σ. d) B-factors [Å2] of the refined J33 fragment of the non-hydrogen atoms. 






2.2.4.1 Overlap in Hit Rates of X-ray Crystallography and SPR 
 
There is only one overlapping fragment hit, namely J79, between the crystallographic and SPR fragment screens 
(Figure 2.17a). In crystallography, J79 binds to the preQ1 pocket with an occupancy of 94%. In SPR, the binding 
response of J79 was only 13.5 RU, attributing it with very low response in comparison to the other detected 
fragment hits. J79 was amongst the fragments that were active-site binders when measured in the SPR 
competitive experiments. Amongst these fragments were also J09, J50, and J92, which are not from the 
crystallographically documented hits, even after attempts to soak crystals in the same solution used for 
crystallization at a pH of 5.5. A possible reason for J50 not being detected by X-ray crystallography may be the 
clashing of the piperidine ring of J50 with Ala232 which prevents it from binding as seen in Figure 2.18.  A similar 
observation has been reported before, where the affinities of several pterin derivatives discovered through virtual 
screening showed that a compound similar to J50 had a reduced affinity due to the unfavorable conformation the 
compound would need to adopt in the binding pocket.71 In contrast, while J33 is a fragment hit in crystallography, 
it was among the fragments excluded from the SPR assay due to residual binding to the dextran matrix. Therefore, 










Figure 2.17: a) Overlap in hit rates between crystallography (left, magenta) and SPR (right, yellow) along with the formula of the 
overlapping hit J79. b) Overlap in hit rates between crystallography (left, magenta) and NMR (right, orange) and formulae of the 
overlapping hit J19. c) Overlap in hit rates between SPR (left, yellow) and NMR (right, orange) and formulae of the overlapping hits 
J24, J50, J92. d) Zero overlap in hit rates between crystallography (magenta), SPR (yellow) and NMR (orange). e) Correlation between 
active-site and non-active-site binders as detected by the three methods. 







2.2.4.2 Overlap in Hit Rates of X-ray Crystallography and NMR  
 
There is one overlapping hit between the crystallographic and the NMR-based fragment screens, 
namely J19 (Figure 2.17b). It was picked up by the two screening methods and was confirmed as a non-
active-site binder. J19 binds with an occupancy of 56% to the crystal packing interface of TGT. In NMR, 
the difference in signal peak intensity of J19 was positive, which indicates that it continued to bind in 
the presence of the potent active-site inhibitor 1. It is also worth mentioning that the crystallographic 
fragment hits J14, J64, J79 were excluded from the NMR screening due to insufficient solubility.  
 
2.2.4.3 Overlap in Hit Rates between SPR and NMR   
 
There are three overlapping fragment hits between the SPR and NMR fragment screens: J24, J50, and 
J92 (Figure 2.17c). Among them, J50 is confirmed by both approaches to be a specific active-site binder. 
In SPR, J50 produces the highest amount of response units from all discovered hits (RU of 45.6). In 
NMR, it also shows the largest difference in signal intensity for the experiments after protein and after 
inhibitor addition (+0.48 (48%) relative intensity). Furthermore, it has to be remembered that the SPR 
hit J79 was excluded from the NMR screening due to insufficient solubility. J24 and J92 did not come 
up as hits neither after soaking at a pH of 7 nor 5.5. A possible explanation is that J24 may be a surface 
binder, which makes it difficult to bind in the crystal packing. In solution with the solvated protein 
molecule however, it does not face this obstacle of packing and thus can bind.  Additionally, the pH at 
which the SPR and NMR were done is 7.4. It has been reported before that a peptide bond flip occurs 
between Leu231 and Ala232 at this pH, which allows the amide of Ala232-Leu231 to present its donor 
moiety.64 This peptide flip does not occur at a pH of 5.5 which may hinder binding. 
 
2.2.4.4 Overlap in Hit Rates of Crystallography, SPR, and NMR  
 
Upon comparison of all fragment hits, there were no overlapping fragment hits from all three methods 
(Figure 2.17d). As mentioned, several factors are responsible for this finding, at first exclusion of 
fragments from individual screens due to technical reasons, e.g. insufficient solubility, undesirable 
Ala232 
Figure 2.18: The published structure of TGT in complex with J64 (yellow, PDB: 5N6F) superimposed with one orientation of 
J50 (pink). The piperadine ring clashes with Ala232, demonstrating the unfavorable binding of the fragment in the binding 





adhesion to sensor chip, or resolving of crystals upon soaking. In detail, four X-ray hits (J33 and J14, 
J64, J79) were excluded from the SPR and NMR screens, respectively. Additionally, two SPR hits (J55 
and J79) were discarded from the NMR screen and five NMR hits (J16, J21, J26, J48, J83) were never 
subjected to the SPR screen. 
Considering the hits in detail, crystallography had the highest correlation between fragment hits 
detected and percentage of specific active-site binders (Figure 2.17e) whereas NMR suggested a large 
amount of non-active-site binders.  
 
2.2.5 Conclusions  
 
SPR and NMR are currently the most commonly applied primary fragment screening techniques72, 
however, our results suggest that, if they would have been applied as incipient methods of a screening 
cascade, they would have missed three specific binders J41, J72, and J86 discovered by a subsequently 
applied, more elaborate crystallographic screen.  
In summary, X-ray crystallography allows the detection of specific binders that may be too weak 
binders to be detected by SPR and even by NMR. Albeit weak, these specific binders can still provide 
valid structural information to support the search for appropriate starting points in lead discovery.73 
Additionally, SPR and NMR detected a significantly higher percentage of non-active-site binders 
relative to crystallography, which shows the importance of also running competition based screenings 
in SPR and NMR, a requirement not needed in crystallography. NMR proved to be a more sensitive 
method relative to SPR, as it appeared to pick up the highest numbers of putative binders to the TGT 
protein.  
 
2.3 Structure-based Drug Design 
 
2.3.1 Definition  
 
Structure-based drug design is a technique adopted when a 3D-structure or model of the target is 
available. It focuses on the optimization of a molecule that fits into the binding pocket of the target 
protein and forms interactions that are energetically favorable. Appropriate molecules are either 




Fragment-based lead discovery is a rather novel approach to generate first hits primarily as promising 
starting points for drug development projects. However, general purpose fragment libraries usually 
compile a broad range of chemotypes and can therefore probe protein binding sites efficiently. They 
are able to provide surprising insights into unexpected features of the studied protein. The 
crystallographic fragment screening on TGT brought about a small fragment, chemically related to the 
amino acid arginine, which opens a new, obviously transient sub-pocket when bound to the 
recognition pocket of the target protein (PDB: 5UTI). Via its guanidinium group the discovered 
fragment binds to the Asp102/Asp156 motif in the active center and perturbs the spatial arrangement 
of the remaining recognition pattern next to Gly230 and Gln203 (Figure 2.19b). As a result, a small 
transient pocket opens, which increases the volume of the recognition site significantly. Two water 
molecules, stabilized by the nearby carboxylate group of the fragment, are found in the transient 
pocket. The observed structure immediately provokes some interesting questions. Is the opening of 





the transient pocket just an uncommon and reinforced but functionally useless adaptation of the 
protein or does it indicate a functionally essential feature of the enzyme? Furthermore, can a ligand 
successfully accommodate this transient pocket and does this support the development of more 





Here we study parameters which feature the opening of the transient recognition pocket and elucidate 
whether the observed adaptations relate to any functional properties of the enzyme family that could 
be exploited for the development of potent and selective anti-infective drugs. Starting with the well-
characterized lin-benzoguanine scaffold 1, appropriate to inhibit eubacterial TGT, we first designed 
some ligands capable to perturb the recognition pattern next to the residues Gly230/Gln203 as 
suggested by our fragment structure. By chemical synthesis of suitable model compounds, 
determination of their binding affinity to the enzyme and crystal structure analysis along with a 
molecular dynamics-based hydration site analysis, we succeeded to trace the role and trigger of the 
opening of the transient pocket and its potential impact on the development of selective inhibitors of 











Figure 2.19: a) Schematic binding mode of lin-benzoguanine (1) to TGT. b) Crystallographically determined binding mode of 
a small fragment binding to TGT. The fragment succeeds in opening a transient binding pocket next to Gly230 and Gln203, 





2.3.3 Ligand Design 
 
In the past, the design of our ligands aimed at inhibiting bacterial TGT was focused on lin-benzoguanine 
derivatives as this parent scaffold perfectly occupies the recognition pocket (Figure 2.19a). Without 
further decoration, it already shows an inhibition with a Ki = 58 ± 36 nM74 and provides multiple options 
for exit vectors to efficiently address the various sub-pockets surrounding the central recognition site. 
Thus, sub-nanomolar potency could be achieved.75 Stimulated by the binding geometry of the above-
mentioned fragment complex and the surprising opening of a transient pocket, we decided, either to 
open the aminopyrimidine ring of the lin-benzoguanine scaffold or to reduce the carbonyl group in the 
pyrimidine ring of the parent scaffold. The resulting dihydro-imidazoquinazolines allow the attachment 
of substituents at C8 that may penetrate into the opened transient pocket (s. Scheme). Thereby, the 
carbonyl function of the pyrimidine ring, interacting with the backbone NH of Gly230 and the 
carboxamide nitrogen of Gln203, would be lost. As indicated by the fragment complex, some inherent 
flexibility with respect to the latter residues might be given. In order to start our ring opening exercise 
conservatively and to study the impact of the abandoned hydrogen-bonding interactions of the core 
scaffold to Gly230 and Gln203, we decided to also investigate benzimidazole derivatives with 
substituents attached to the 5-position. For this purpose, we considered amides and hydrazides. With 
respect to R1 in Scheme 1, we studied all ligands with an attached methyl group. For some selected 









































R1 = Me, 







4.1, 4.2  
Scheme 2.3: Design of pyrimidine ring-opened 5- (2) and 4-benzimidazole (3) derivatives and tricyclic dihydro-




The synthesis of 2-substituted lin-benzoguanine 176 and lin-benzohypoxanthines 577 was previously 
reported by the group of Prof. Dr. François Diederich of ETH Zurich. The 5-substituted benzimidazole 
ligands were synthesized in 5 steps from 5-benzimidazole carboxylic acid (6) (Scheme 2.4).76, 78 The 
synthesis commenced with an esterification to give 7. The benzimidazole nitrogen was sulfamoyl 
protected to give an inseparable, tautomeric mixture of 8 and 8’, followed by selective bromination at 
the 2-position. Partial separation of the tautomers was possible by column flash chromatography and 
the enriched tautomer 9 was subjected to nucleophilic aromatic substitution with primary amines to 
afford 2-aminobenzimidazoles 10.1 and 10.2. Functional group interconversion of the ester with aq. 
ammonia, methanolic methylamine or aq. hydrazine under microwave irradiation afforded the 





protected carboxamides 11.1-11.6. Final deprotection with HCl and reverse phase flash 
chromatography purification yielded the ligands 2.1-2.6. 
 
For the 4-substituted benzimidazole ligands 3.1 and 3.2 we persued an alternative synthetic strategy 
(Scheme 2.5).78 2-Aminoaniline 12 was converted into 2-aminobenzimidazoles 13.1 and 13.2 via a two-
step protocol with isothiocyanates followed by treatment with EDCI.79 The nitro group was reduced 
using PtO2 and Pd/C under H2 and the obtained aniline was guanylated with N,N′-di-boc-1H-pyrazole-
1-carboxamidine to afford 14.1 and 14.2. The N-Boc protecting groups were cleaved with HCl and 










Scheme 2.4: Synthesis of 5-substituted Benzimidazole Ligands 2. Conditions: a) H2SO4, MeOH, 65 °C, 18 h, quant.; b) 
Me2SO2Cl, NEt3, toluene, 23 °C, 24 h, 66 % (1/0.6 mixture with 1N tautomer 8’); c) LiN(SiMe3)2, THF, –78 °C, 1h, then NBS, 
THF, –78 °C to 23 °C, 15 min, 56 % (1/0.05 mixture with 1N tautomer 9’); d) for 10.1: MeNH2, EtOAc/MeOH, 23 °C, 14 h, 
quant.; for 10.2,: 2-morpholinoethylamine, iPr2NEt, EtOAc/MeOH, 23 °C, 15 h, 54%; e) for 11.1 and 11.2: aq. NH4OH, MeOH, 
100 °C (MW), 15-30 min, 11.1: 37%; 11.2: 31%; for 11.3 and 11.4: MeNH2, MeOH 140 °C (MW), 1.5-2.5 h, 11.3: 67%; 11.4:
75%; for 11.5 and 11.6: N2H4, H2O, 100 °C (MW), 30 min, 11.5: 80%; 11.6: 47%; e) HCl, dioxane, reflux, 14-45 h, 2.1: 23%; 2.2: 







Our synthetic strategy for the tricyclic dihydroimidazoquinazoline analogs 4.1 and 4.2 relied on an 
intramolecular cyclization of N-Boc protected guanidines on activated benzylic alcohols (Scheme 2.6 
and Scheme 2.7). The synthesis of precursor 15 was previously described by our group.80 The methyl 
ester of 15 was reduced with LiAlH4 to afford benzylic alcohol 16. Chemoselective N-guanylation gave 
N-Boc protected 17. Tosyl chloride was used to activate the benzylic alcohol for cyclization. Final 
cleavage of the SEM and the N-Boc protecting groups of 18 was achieved with HBF4 and 
recrystallization yielded the ligand 4.1. 
 
Scheme 2.6: Synthesis of the Tricyclic Dihydroimidazoquinazoline Ligand 4.1. Conditions: a) LiAlH4, THF, 0 °C, 1 h, 58%; b) 
N'-di-boc-1H-pyrazole-1-carboxamidine, iPr2NEt, DMF, 23 °C, 2 h, 44%; c) TsCl, KOH, THF, reflux, 1 h, 52%; d) HBF4Et2O, 
CH2Cl2, 23 °C, 30 min, 57%. SEM = 2-(trimethylsilyl)ethoxymethyl, Ts = toluenesulfonyl. 
We applied a similar synthetic strategy to construct the 2-amino-benzimidazole core of 4.2 as for 3 
starting from 4-bromo-5-nitrobenzene-1,2-diamine (19). Regioselective nitration via a three-step 
protocol,81 followed by benzimidazole formation gave 20. Introduction of the SEM protecting group 
(21) and carbonylation via a sequence of a palladium catalyzed Heck reaction with ethyl acrylate 
followed by oxidative cleavage with catalytic OsO4 afforded a mixture of N-tautomeric 
nitrobenzaldehydes 22 and 22’ which was separated by careful column flash chromatography. 
Alkynylation with in situ generated propynyllithium gave the racemic propargylic alcohol (±)-23. The 
nitro group was reduced selectively with zinc and aq. NH4Cl and subsequently the activated 
guanylation reagent N,N’-di-boc-1H-pyrazole-1-carboxamidine was used to prepare (±)-24. 
Intramolecular cyclization of the guanidine (±)-24 on the propagylic alcohol was again achieved by 
Scheme 2.5: Synthesis of 4-substituted Benzimidazole Ligands 2. Conditions: a) for 13.1 and 13.2: R1NCS, DMF, 90 °C, 2 h, 
then EDCI, 90 °C, 2 h; 13.1: 69%; 13.2: 63% b) for 14.1 and 14.2: H2, Pd/C, PtO2, EtOH, 4 h, 23 °C, c) N,N'-di-boc-1H-pyrazole-
1-carboxamidine, iPr2NEt, DMF, 23 °C, 16 h; 14.1: 55%; 14.2: 50%; d) for 3.1 and 3.2: HCl, Et2O/CH2Cl2, 23 °C, 10 min, 3.1: 
59%; 3.2: 52%. DMF = N,N-dimethylformamide, EDCI = 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. Boc = tert-
butyloxycarbonyl. 





activation with tosyl chloride under basic conditions to yield (±)-25. Final deprotection with SnCl4 and 
subsequent purification by reverse-phase HPLC afforded the hydrochloride salt of racemic (±)-4.2. 
 
Scheme 2.7: Synthesis of the Tricyclic Dihydroimidazoquinazoline Ligand 4.2. Conditions: a) TsCl, pyridine, 65 °C, 17 h, 83%; 
b) HNO3, AcOH, 50 °C, 1 h, 69%; c) H2SO4, H2O, 85 °C, 2 h, 87%; d) MeNCS, (CH3)2SO, 70 °C, 21 h, then EDCI, 70 °C, 1 h, 44%; 
e) SEM chloride, NaH, DMF, 0 °C, 1.5 h, 79% (1.2/1 mixture with 1N tautomer 22’); f) CH2=CHCO2Et, [Pd(OAc)2], PPh3, toluene, 
110 °C, 48 h; g) OsO4, NaIO4, THF/H2O, 23 °C, 36 h, 52% of 23 and 32% of 23’ (over 2 steps). h) H3CCH=CHBr, n–BuLi, 
THF/hexane, –78 °C to 23 °C, 3 h, 83%; i) Zn, aq. NH4Cl, MeOH, 0 °C, 2 h; j) N'-di-boc-1H-pyrazole-1-carboxamidine, iPr2NEt, 
CH2Cl2, 21 h, 50 °C, 57% (over 2 steps); k) TsCl, Cs2CO3, 23 °C, 4 h, 58%; l) SnCl4, CH2Cl2, 0 °C to 23 °C, 6 h, 34%. 
 
2.3.4 Affinity Determination 
Table 2.4: Chemical formulas, binding constants in µM and pdb-codes of the complexes of the studied compounds.a 










0.058 ± 0.036 76  
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a) Binding constants were determined via a radioactive assay with the exception of ligands 4.1 and 4.2 for which SPR 
measurements were used. b) Reported values are only rough estimates of the KD, further details are found in the 
experimental methods. 
  





2.3.5 Crystal Structure Determinations 
 
The crystal structures were obtained by co-crystallizing the corresponding ligands with the enzyme. In 
all cases, structures with the common twofold dimer packing in space group C2 could be determined 
at a resolution between 1.21 – 1.82 Å. In some cases, both a structure with R1= Me and R1= 
morpholinoethyl could be resolved. However, as previously observed, the morpholino substituent 
showed pronounced positional disorder in all examples apart 1.2 76 and no difference electron density 
could be attributed to this part of the structures. Furthermore, as a structural comparison of the 
corresponding complexes with the R1 = Me and morpholino ethyl showed, identical binding modes are 
adopted in all cases. Accordingly, in the following only the crystals structures of the R3 = Me derivatives 
will be described. However, the crystallographic tables of all here investigated complexes can be found 
in the Appendix and the coordinates of all complexes have been deposited with the Protein Data Bank 
(PDB; www.rcsb.org).  
2.3.5.1 Crystal Structures with the Ring Opened 5-amide and 5-hydrazide Benzimidazoles 2.1, 2.5 
 
As observed in previous studies, the bicyclic benzimidazole core scaffold forms the expected H-bonding 
pattern to the backbone atoms of the amino acids Ala232, Leu231 and Gly230 (Figure 2.20a,b). 75,76,83 
The carboxamide terminus of Gln203 acts as H-bond donor to the carbonyl groups of the attached 5-
amide or 5-hydrazide substituents of 2.1 and 2.5. Furthermore, the bicyclic core structure establishes 
π-stacking interactions with the adjacent amino acids Tyr106 and Met260. The side chain of the 
catalytically essential Asp102 adopts two alternative, equally populated conformations in the complex 
with 2.1, whereas in the complex with the hydrazide substituent 2.5, only the conformer with the 
carboxylate group oriented into the recognition pocket is observed. The geometry with the side chain 
rotated off the catalytic center is also found in the structure of the apo protein84 and complexes 
accommodating lin-benzohypoxanthines (5.1, 5.2). 77 The alternative orientation towards the ligand-
binding site is generally found for complexes with lin-benzoguanines.74 In TGT·2.1, the carboxylate 
group of Asp102 binds to the primary amide function of the ligand (2.9 and 3.0 Å) via the interstitial 
water molecule W1. The second oxygen of this carboxylate is solvated by additional water molecules 




Figure 2.20: Crystallographically determined binding mode of a) 2.1, b) 2.5 in the recognition pocket of TGT, heteroatoms type-
coded, water molecules small spheres, all distances in Å, hydrogen-bonds as dashed lines; c) superposition of 2.1 (carbon atoms 





The carboxylate group of Asp156 also forms an H-bond to the terminal amide nitrogen of 2.1 (3.0 Å) 
and water W1 additionally solvates the neighboring oxygen of the Asp156 carboxylate (3.1 Å). In the 
complex with the hydrazide-based benzimidazole 2.5 (Figure 2.20b), the terminal nitrogen of the 
hydrazide protrudes directly toward the carboxylic acid carbon of the Asp156 side chain and forms two 
H-bonds to its oxygens (2.3 - 2.9 Å). The hydrazide group adopts trans geometry (179°) and pushes the 
central carbon of Asp156 by approx. 0.9 Å (Cα---Cα) out of the recognition pocket compared to the 
complex with 5.1. This push back of Asp156 is associated with a reorganization of further neighboring 
amino acids and leads to a change in the secondary structure of the loop between the amino acids 
Glu157 and Thr161 (Figure 2.21a).  
As mentioned above, the carboxylate group of Asp102 refines to one fully populated orientation 
toward the ligand. Nevertheless, its oxygens do not build a water-mediated interaction network with 
the ligand, as found for 2.1. No sufficiently well-defined difference electron density for a water 
molecule could be detected. In contrast, the interactions to the water molecules in the ribose-34 
pocket are also established here (2.7 - 3.2 Å). 
The affinities of the amide 2.1 (Ki = 300 ± 37 µM) and the morpholino analog 2.2 (Ki = 544 ± 43 µM) 
decrease by a factor of 46 and 132, respectively, compared to the analog lin-benzohypoxanthines 5.1 
(Ki = 6.5 ± 2.9 µM) and 5.2 (Ki = 4.1 µM). In the crystal structures with the latter ligands a well-defined 
water network between the ligand and Asp102 is formed (Figure 2.20c).77 A similar network is 
impossible to establish with 2.1, which likely explains the reduced affinity of the 5-amide derivatives 
2.1 and 2.2. The affinity loss compared to the parent lin-benzoguanine scaffold (1.1, 1.2) is even more 
dramatic and accounts for nearly five orders of magnitude with respect to 2.1 (Table 2.4). 
The structural rearrangement of the loop extending from Glu157 to Thr161 along with the ruptured or 
newly formed interactions and the reorganization of water molecules makes it difficult to compare the 
hydrazide-based ligands 2.5 and 2.6 with the 5-amide analogs 2.1 and 2.2. Nevertheless, it appears 
surprising that for 2.5 (Ki = 283 ± 40 µM) and 2.6 (Ki = 282 ± 18 µM) the affinity falls into the same 
range. This suggests that energetically nearly no costs are involved in the structural rearrangement of 
the protein, which may represent the transformation to a conformation linked to a protein function 
that stabilizes the bound ligands.  
 
 
b a) c) 
Figure 2.21: a) Superposition of 2.5 (carbon atoms cyan) and 5.1 (carbon atoms orange, PDB: 3S1G36) in the recognition 
pocket of TGT, heteroatoms type-coded, water molecules small spheres, all distances in Å, hydrogen-bonds as dashed lines; 
b) binding mode of 3.1, c) superposition of 3.1 (carbon atoms cyan) and 5.1 (carbon atoms orange, PDB: 3S1G36). 





2.3.5.2 Crystal Structures with the Ring Opened 4-guanidino-benzimidazole 3.1 
 
Compared to the lin-benzoguanine scaffold, the 4-guanidino-benzimindazole 3.1 lacks the endocyclic 
carbonyl function to establish direct H-bonding interactions with Gly230 and Gln203. The 
corresponding crystal structure shows (Figure 2.21b) that these amino acids are now solvated and 
stabilized (3.3 - 3.5 Å) via hydrogen bonds to an interstitial water molecule (W1). The carboxylate 
groups of Asp102 and Asp156 each adopt an orientation which is analogously observed with the bound 
lin-benzoguanine scaffold 1.1.74 The basic guanidine group (pKa >12) likely binds in charged state. 
Consequently, salt bridges are expected to form with both aspartates. Furthermore, the 2-
aminoimidazole ring interacts with the carbonyl groups of Ala232 and Leu231 (2.9 Å) via H-bonds. 
At first sight, the loss of the H-bonds to Gly230 and Gln203 also leads to a drop in affinity as observed 
for the 5-amide analogs 2.1 and 2.5 with respect to the corresponding lin-benzoguanine 1.1 or lin-
benzohypoxanthine 5.1. With Ki = 19 ± 2 µM for 3.1 and Ki = 58 ± 2 µM for 3.2, the 4-guanidine-
substituted ligands bind slightly stronger to TGT than the studied 5-benzimidazoles. This suggests that 
the gained charge-assisted interactions to Asp102 and Asp156 can only partially compensate for the 
lost interactions to the nitrogen atoms of Gly230 and Gln203. However, also a second, perhaps even 
more important effect has to be considered. By opening the pyrimidine ring of the lin-benzoguanine 
scaffold, the ligand scaffold loses its correct preorganization. Instead, the guanidine portion, attached 
to the benzimidazole, must adopt one single conformation, which supposedly is not the most favored 
one. This, along with the loss of conformational degrees of freedom, will have a detrimental effect on 
binding affinity. In other studies we saw that this effect can reduce the binding constant by two to 
three orders of magnitude.85 
Interestingly, as with hydrazide-substituted benzimidazoles 2.5 and 2.6, the structural transformation 
of the secondary structural element (Glu157 to Thr161) is also observed with the guanidine-
substituted ligands 3.1 and 3.2 (Figure 2.21c). Also here, a spatial shift of Asp156 is observed, as seen 
in TGT·5.1 (Cα---Cα = 0.3 Å). However, a second aspect may be important in this complex to transfer the 
enzyme into the alternative state with the opened transient pocket. The above-mentioned water W1, 
which binds in the vicinity of the original position of carbonyl function of the lin-benzoguanine scaffold, 
solvates the polar groups of Gly230 and Gln203, but in addition, it fills the created void and exerts 
steric pressure onto the flexible loop of Glu157 to Thr161 (Figure 2.21c). Accordingly, W1 supports the 
expansion of the opening pocket.  
To study the impact of steric pressure in this region of the binding pocket by a bound ligand in more 
detail, we designed chemically reduced tricyclic analogs of the lin-benzoguanine scaffold bearing an 
sp3 carbon atom at the former spatial position of the carbonyl group in pyrimidine ring (4 in Scheme 
2.3). Through the attachment of substituents at this carbon atom, a chiral center is created. Therefore, 
we first decided to study the achiral unsubstituted derivative 4.1 and subsequently the propinyl analog 
(4.2). Modeling considerations strongly supported the hypothesis that only the R-enantiomers will 
orient the attached substituents in a way to fit into the possibly opened transient pocket. The 







2.3.5.3 Crystal Structures with Dihydro-imidazoquinazolines 4.1 and 4.2 of the Lin-benzoguanine 
Scaffold 
 
Ligand 4.1 binds with an occupancy of 87% to the recognition pocket. The guanidine moiety in the six-
membered ring forms two bidentate hydrogen bonds with the carboxylate groups of Asp156 and 
Asp102. The second guanidine moiety in the imidazole ring interacts via a hydrogen bond with the 
carbonyl oxygen of Leu231, while the exocyclic amino group hydrogen-bonds the carbonyl oxygen of 
Ala232. Furthermore, 4.1 establishes a π-π stacking with Tyr106 and Met260. Thus, a very similar 
recognition pattern as seen for lin-benzoguanine 1.1 74  is found in this area. Nevertheless, the ligand 
also induces the structural transformation of the secondary structural element (loop Glu157 to 
Thr161), which leads to an opening of the transient sub-pocket (Figure 2.22c) and the carboxamide 
group of Gln203 forms a van der Waals contact to C8 of the dihydro-imidazoquinazoline scaffold. Due 
to the pocket opening, the distance between Val233 Cα and Cys158 Sγ expands in TGT·4.1 to 10.2 Å. 
The complex formed with 4.2 shows very similar geometry as TGT·4.1 with nearly identical recognition 
pattern. In contrast to the latter complex, Gln203 adopts an altered conformation providing additional 
space to accommodate the needle-like propinyl side-chain. Even though the complex was co-
crystallized from a racemic mixture, the enzyme only picks the R-enantiomer. Supposedly, the S-
enantiomer does not bind as it would have to poke into the protein and create substantial steric 
clashes. The difference density allows placement of all atoms of the propinyl side chain, even though 
the less-well defined density next to the terminal methyl group indicates enhanced residual mobility 
of the extended side chain. As for the other complex, 4.2 induces a spatial shift of the loop comprising 
Glu157 to Thr161. Asp156 is, compared to TGT·1.1, pushed by 0.6 Å out of the recognition pocket and 
helps to trigger the structural transformation of the loop (Figure 2.23c). The opening of the transient 
pocket results in a mutual distance between Val233 Cα and Cys158 Sγ of 10.8 Å.  
 
Figure 2.22: Crystallographically determined binding mode of a) 4.1 in the recognition pocket of TGT, heteroatoms type-
coded, all distances in Å, hydrogen-bonds as dashed lines; b) 4.1 difference electron density (|Fo|-|Fc| omit map) contoured 
at 3σ, protein displayed with the solvent accessible surface showing the recognition site together with the opened transient 
pocket; c) binding mode of 4.1. 










Figure 2.23: Crystallographically determined binding mode of a) 4.2 in the recognition pocket of TGT, heteroatoms type-
coded, all distances in Å, hydrogen-bonds as dashed lines; b) 4.2 together the difference electron density (m|Fo|-|Fc| omit 
map) contoured at 3σ, protein displayed with the solvent accessible surface showing the recognition site together with the 
opened transient pocket; c) binding mode of 4.2. 
2.3.6 Expansion of the recognition pocket by a transient sub-pocket 
 
The enzyme TGT is capable of performing large conformational adaptations upon ligand binding. An 
opening of a small transient pocket is not only observed in the initially described fragment structure 
(Figure 2.19) but also in the here described subset of complexes, that push Asp156 slightly out of the 
recognition pocket and create sufficient steric pressure onto residues Gly230 and Gln203. Transient 
pockets may open as intermediate states under dynamic conditions in conformational equilibrium and 
they can be stabilized by a well-fitting and energetically favorably binding ligand. To study the 
occurrence of such transient pockets, usually molecular dynamics simulations are consulted. Already 
earlier on, we speculated about the existence of such a transient pocket based on the results of an MD 
simulation of TGT.57 This former study revealed transient openings of a pocket along the trajectory of 
the protein. By analyzing individual frames along the trajectory in terms of the mutual distance 
between Sγ of Cys158 and Cα of Val233, values between 6 Å (closed pocket) to 12 Å (opened pocket) 
reflecting a binding site volume which varies between 250 and 750 Å3 were recorded. Remarkably, the 
various complexes described here, also show a strong variation of this distance, which matches with 
the range indicated by the MD simulation (Table 2.5). Thus, the incipient simulations suggest that, 
under physiological conditions, the apo-enzyme is capable to open such a transient pocket.  
Table 2.5: Mutual Cys158Sγ -Val233Cα distances and backwards push of Asp156 Cγ in different TGT·ligand complexes with 




Asp156 push compared 
to TGT·1.1 [Å]a) 
PDB code 
TGT·1.1 6.5 0.0 4PUK 
TGT·frag 9.8 0.4 5UTI 
TGT·2.1 6.4 0.2 5J9M 
TGT·2.2 6.2 0.1 5JT5 
TGT·2.5 10.2 0.9 5J9N 











TGT·3.1 10.5 0.7 5J9O 
TGT·3.2 10.6 0.7 5JT7 
TGT·5.1 6.2 0.3 3S1G 
TGT·4.1 10.2 0.3 6RKT 
TGT·4.2 10.8 0.6 6RKQ 
a) The amount by which Asp156 is pushed out of the recognition pocket was determined by performing an overall RMSD Cα 
atom superposition of the studied complex with TGT·1.1 and measuring the mutual distances of Asp156Cγs in both structures.  
 
Obviously, the reorganization of the protein, leading to the expansion of the binding pocket, correlates 
with the properties of the substituents in 2.1 – 2.6, 3.1, and 3.2 attached to the benzimidazole or the 
dihydro-imidazoquinazoline scaffold (4.1 and 4.2). The primary amide stabilizes the closed 
conformation found in most TGT-ligand complexes. The extension of the amide by an additional amino 
group to a hydrazide leads to the structural transformation. The attached terminal amino group of the 
hydrazide exerts steric pressure on Asp156 and thus induces the protein rearrangement leading to its 
stabilization. The guanidine-substituted ligands show the same reorganization as a combined effect of 
steric pressure and altered solvation of the amino acids Gly230 and Gln203. The water molecule W1 
and the slight spatial shift of Asp156 are responsible for this effect. In the complexes with the dihydro-
imidazoquinazolines 4.1 and 4.2 the steric pressure is exerted by the attachment at C8. Obviously, 
solely a hydrogen as substituent is sufficient to trigger the pocket opening. 
The newly formed cavity is occupied and stabilized by several water molecules, which indicates the 
hydrophilic character of the created pocket (Figure 2.24). A complex water network with short 
distances between 2.5 and 3.5 Å is detected involving the carbonyl groups of the Glu157, Thr159, 
Ala168 and Gly230 and the backbone amide nitrogens of Gly204, Ser205 and Thr159 which protrude 
toward the expanded pocket. In addition, the side chains of Gln203, Ser171 and Ser205 form H-bonds 
to the accommodated water molecules. 
 
Figure 2.24: a) Binding pose of 3.1 together with the opened transient pocket, which is filled with a cluster of water molecules. 
The protein is displayed by its solvent accessible surface and the residues involved in interactions with the water cluster are 
indicated, hydrogen bonds as dashed lines. b) 4.2 together with the difference electron density (m|Fo|-|Fc| omit map) 
contoured at 3σ, protein displayed with the solvent accessible surface showing the recognition site together with the opened 
transient pocket which is filled by water molecules; c) comparison of the spatial arrangement of computed hydration sites 
(numbered pink balls, Table 2.6) together with the crystallographically determined waters in TGT·4.1 (orange spheres, cf. b). 
Depending on the achieved resolution, the amount of water molecules captured by crystallography 
will differ. 86 Furthermore, crystal structures do not provide information about the thermodynamic 
properties of the water molecules found in such the transient pocket. However, upon ligand binding 
to the protein, the solvent molecules occupying the pocket will be displaced to the surrounding bulk 
a) c) b) 





solvent phase. To estimate the contribution of the water displacement to the overall inventory of 
ligand binding, the energetics displacing the waters are important. Waters displaced from hydration 
sites that are energetically less favorable than in the bulk, will contribute to ligand binding. While 
displacement from hydration sites that are more favorable in the protein than in the bulk, will 
counteract binding. We therefore performed MD simulations to perform a hydration site analysis 
(SSTMap calculation)87 to determine the enthalpic and entropic contributions of the bound water 
molecules and the corresponding Gibbs free energy contribution for their release to the bulk phase 
(Table 2.6). Our calculations suggest that individual water molecules cluster at representative sites 
which reasonably well reproduce the crystallographically determined water sites (Figure 2.24b,c). 
Thus, the crystal structure of TGT·4.1 reveals the presence of eight water molecules, while MD 
simulations suggests a similar cluster nine of water molecules. The distances between the assigned 
crystallographic water molecules and the centers of the computed water clusters are listed in Table 
2.6. 














9 0.5 12.51 -16.40 28.91 
1 0.89 5.23 -22.64 27.87 
4 1.37 1.42 -19.00 20.42 
0 0.68 -1.17 -21.34 20.13 
2 0.72 -3.18 -22.38 19.16 
5 0.73 -2.85 -20.29 17.49 
7 1.08 -3.31 -16.95 13.64 
8 2.3 -5.27 -18.24 12.97 
6 1.55 0.63 -12.30 12.93 
 
The HSA calculations suggest that all the waters in the transient pocket have unfavorable Gibbs free 
binding energies with respect to the bulk phase. Hydration sites 9 and 1 are energetically highly 
depleted, suggesting unfavorable interactions in the transient binding pocket compared to bulk 
solvent. We therefore expect that their displacement favorably contributes to ligand binding. This 
hypothesis is supported by the observation that the ligands which open the transient pocket and 
displace some of the water molecules in the pocket (e.g. 4.2) are surprisingly potent compared to the 
members of series 2 and 3. 
2.3.7 Functional Role of the Transient Pocket and Outlook for Further Inhibitor Design 
 
We inspected the Z. mobilis TGT complex structures, deposited in the protein data bank (PDB, 
www.rcsb.org).88 The multiple structures show that even though the loop between Glu157 and Thr161 
is structurally in most complexes spatially highly conserved, the side chain of Cys158 occurred already 
in a few structures with alternative conformations. In these examples, the Cys158Sγ - Val233Cα 
distances vary from 6.6 Å to 9.8 Å. However, the examples with expanded distances are predominantly 
mutated variants of TGT in the guanine/preQ1 recognition pocket. These variants were produced to 
investigate the differences of the eubacterial and eukaryotic TGTs.65 The latter enzymes recognize 





Cys158 is replaced by Val and the opposing Val233 is exchanged to Gly.89 Remarkably, the crystal 
structure of queuine (PDB code: 3BLO65) with this variant shows a similar expansion of the recognition 
pocket as observed in complexes studied here. Possibly, the latter complexes indicate an intrinsic 
conformational flexibility the architecture of TGT enzymes exhibits in this area that is functionally 
important for the eukaryotic species to recognize its extended substrate.  
The pronounced similarity of the recognition site in eubacterial variant, which hosts the nucleobases 
guanine and preQ1, and the eukaryotic one means a real challenge developing species-selective 
inhibitors. However, one observation with our expanded inhibitors might provide a promising 
opportunity to approach this problem. Remarkably, the Cys158 residue is highly conserved across all 
eubacterial enzymes but lacking in the eukaryotic species (Figure 2.4). The thiol group of a cysteine 
residue is a potential anchor to covalently attach an inhibitor, e.g. via a Michael acceptor or a 
potentially alkylating group. For the development of a potent anti-infective, irreversible inhibitors may 
constitute a desired strategy to follow. The ligands studied here based on the 4-guanidino 
benzimidazoles or the C(8)-functionalized dihydro-imidazoquinazoline scaffold induce the opening of 
the transient pocket and make the thiol group of the crucial cysteine accessible for chemical 
modification. Via appropriate design, it may be possible to develop inhibitors, preferentially based on 
the latter likely more potent dihydro-imidazoquinazoline scaffold, that selectively and irreversibly 
block the bacterial TGT isoforms via a warhead capable to covalently bind to the thiol group of Cys158. 
2.4 Materials & Methods 
 
2.4.1 Expression and Purification of the Z. mobilis TGT  
 
The expression and purification protocol was adapted as previously described by Jakobi et al.67  The E. 
coli cells BL21-CodonPlus (DE3) -RIPL (Cam r), transformed with the plasmid vector pPR-IBA2-ZM10 
(Amp r), were incubated in a pre-culture of 100 mL LB medium containing 100 mg · L-1 ampicillin and 
34 mg · L-1 chloramphenicol for 17 h at 37 °C and 220 rpm. In addition to ampicillin and chloramphenicol 
resistance, the plasmid contained a sequence encoding for an N-terminal Strep-tag II® separated from 
the tgt start codon by a spacer sequence and a sequence encoding a thrombin cleavage site. The pre-
culture was added to 2 × 2 L main culture (LB medium including 100 mg · L -1 ampicillin and 34 mg · L-1 
chloramphenicol) which is incubated at 37 °C and 220 rpm until the OD600 = 0.7. This main culture was 
then cooled to 15 °C and the protein expression induced by addition of IPTG (final concentration 1 
mM). The main culture was then incubated at 15 °C and 220 rpm for a further 16-18 h. Afterwards, the 
cell pellets were harvested by centrifugation (10,000 rpm at 4 °C). They were subsequently re-
suspended in 100 mL lysis buffer (20 mM TRIS pH 7.8, 10 mM EDTA, 1 mM DTT and 2 cOmplete™-
Protease Inhibitor Cocktail Tablets (Roche) per 4 L of bacterial culture) and cell disruption was achieved 
via three rounds of sonification using a Branson Sonifier 250, with 90 seconds intervals (duty cycle 30%, 
output control 7). Alternatively, cell disruption was achieved via an EmulsiFlex-C5™ high-pressure 
homogenizer (Avestin Europe GmbH). The soluble protein in the supernatant was then separated by 
centrifugation from the insoluble cell constituents in the pellets (centrifugation speed 19,000 rpm, 45 
min, 4 °C). Purification of the protein was achieved at room temperature by two FPLC steps using an 
ÄKTA Purifier LC system. A Q-Sepharose Fast Flow Anion Exchange Column (XK 26/15; GE Healthcare) 
was equilibrated with buffer A (10 mM TRIS pH 7.8, 1 mM EDTA, 1 mM DTT) and the clear cell lysate 
was passed through the column. The protein was then eluted by a buffer B containing 10 mM TRIS pH 
7.8, 1 mM EDTA, 1 mM DTT, 1 M NaCl through gradient elution (a linear increase in the proportion of 
buffer B (from 0 - 100% at 4 mL· min -1 column flow) and fractioning of the eluted portion. Fractions 
containing the target protein Z. mobilis TGT with the Strep tag II were determined by SDS-PAGE. A 
Strep-Tactin® Superflow® column (XK 16/10, IBA) was equilibrated with buffer W (100 mM TRIS pH 7.8, 
1M NaCl, 1 mM EDTA) and the corresponding fractions were passed through the column. The target 
protein was eluted by buffer E (100 mM TRIS pH 7.8, 1 M NaCL, 1 mM EDTA, 2.5 mM D-desthiobiotin). 





The fractions containing TGT protein were then concentrated in a VIVASPIN®20 centrifugal 
concentrator (Sartorius, MWCO = 30,000) to a concentration of approximately 2 mg · mL-1 in a high salt 
buffer containing 10 mM TRIS pH 7.8, 2M NaCl, 1mM EDTA. Subsequently, the Strep-tag® II was cleaved 
off and separated from the TGT protein via a Thrombin Cleavage Capture Kit (Novagen®) following the 
manufacturer's instructions where 2.5 U of biotinylated thrombin per mg TGT protein was incubated 
with the TGT protein for 16-18 h at 20 °C. The cleaved TGT protein was separated from the Strep-tag® 
II, the biotinylated thrombin from the kit, and the streptavidin-agarose beads by filtration using the 
filters of the kit. The separated TGT protein was then dialyzed against high salt buffer and concentrated 
via VIVASPIN®20 centrifugal concentrator until a final protein concentration of 12 mg · mL-1. Finally, 
the protein was flash frozen into aliquots of 70 μL and stored at -80 °C.  
 
SDS-PAGE. The purity of Z. mobilis TGT was checked with SDS-PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis). The SDS gels consist of two components; the Collecting Gel and 
the Separating Gel. 
 
Composition of the Collecting Gel and Separating Gel (amount adds up to 9 SDS gels) are shown in 
Table 2.7. 
Table 2.7 Composition of SDS Separating and Collecting gels. 
Reagent volume in Separating Gel Reagent volume in Collecting Gel 
Demineralized water 6.26 mL Demineralized water 18.7 mL 
1M Tris pH 8.8 13.33 mL 1M Tris pH 6.8 6 mL 
10% SDS solution 0.4 mL 10% SDS solution 0.3 mL 
Rotiphorese® Gel 30 (Acrylamides: N, 
NMethylenbisacrylamide 37.5: 1) 20 mL 
Rotiphorese® Gel 30 (Acrylamides: N, 
NMethylenbisacrylamide 37.5: 1) 5 mL 
TEMED 40 µL TEMED 30 µL 
10% APS 400 µL 10% APS 300 µL 
 
The Separating Gel was prepared first and poured into an SDS gel cast. 1 mL of isopropanol was added 
to cover each gel. After the Separating Gel had hardened, the isopropanol was removed and the 
Collecting Gel was poured onto the Separating Gel and the combs were inserted. After the Collecting 
Gel also hardened, the SDS gels were separated and individually wrapped in moist paper towels and 
stored in the fridge. To run an SDS-PAGE, 2.5 μL of 4x SDS sample buffer was added to 10μL sample 
solution, vortexed, and heated at 95°C for 5 min. The samples were centrifuged and loaded onto the 
SDS gel in a Bio-Core electrophoresis chamber. As a reference, PageRuler™ Prestained Protein 
Ladder (SM0671 / 2) was used. LaemmLi buffer was used to cover the SDS gel, 130V was applied, and 
the gel left to run. Afterwards the gel was left to stain overnight in Coomassie Blue staining solution. 
The gel was de-stained the next day in Coomassie Blue decolorization solution, whereupon the protein 
bands became visible. 
 
2.4.2 Crystallization and Structure Refinement of Z. mobilis TGT 
 
Z. mobilis TGT apo crystals were grown at 18 °C using the sitting-drop and hanging-drop vapor diffusion 
methods. 1.5 µL of 12 mg · mL-1 were mixed with 1.5 µL of reservoir solution containing 100 mM MES 
pH 5.5, 1 mM DTT, 13% (w/v) PEG8000, 10% (v/v) DMSO in the wells of a crystallization plate containing 
650 μL reservoir solution. Crystals could be seen within three days. Crystals were soaked into a solution 





mM NaCl, for a time ranging between 3 minutes and 20 hours depending on crystal stability to the 
fragment solution. Crystals did not need a cryo-buffer as the amount of PEG was sufficient, so they 
were directly flash-frozen in liquid nitrogen.  
Z. mobilis TGT co-crystals were grown at 18°C using the sitting-drop vapor diffusion method. A solution 
of 0.23 mM of Z. mobilis TGT (stored in high salt buffer) was mixed with 6.6 mM of the respective 
inhibitor (stock solution in 100% DMSO) and incubated at 18°C for 1 hour. The solution was then 
centrifuged and 1.5 µL of this mixture was mixed with 1.5 µL of reservoir solution (100 mM MES pH 
5.5, 1 mM DTT, 13% (w/v) PEG8000, 10% (v/v) DMSO) in the wells of a crystallization plate containing 
650 μL reservoir solution. Co-crystals could be seen within three days up to one week. They were 
transferred into cryo-buffer (50 mM MES pH 5.5, 0.5mM DTT, 300mM NaCl, 2% (v/v) DMSO, 4% (w/v) 
PEG 8000, 30% (v/v) glycerol) for several seconds and flash-frozen in liquid nitrogen. 
Data collection and refinement statistics are shown in the Appendix (Table 1- Table 5). The 
crystallographic tables for PDB codes 5J9M, 5JT5, 5J9N, 5JT6, 5J9O, and 5JT7 were taken from the 
dissertation of Dr. Frederik R. Ehrmann, 2016. The diffraction data were indexed, scaled, and merged 
using XDS90 and XDSAPP.91 Molecular replacement from the program PHASER MR92 from the CCP4 
suite93 was used to determine all crystal structures. The structure 4LBU was used as a search model. In 
the refinement, a 5% subset of all reflections was omitted during refinement to be used for Rfree 
calculation. Model building was achieved in COOT44 and refinement using PHENIX.refine version 
1.10.1-2155.94  Cartesian simulated annealing with default parameters was used as a first refinement 
step for all the structures. This was followed by refinement of XYZ coordinates and occupancies of 
protein residues and fragments (with the exception of water molecules whose occupancies were 
fixed). In the case of protein residues that gave additional density, they were refined in double 
confirmation and kept if their refined occupancy was ≥ 20%. The structure of TGT in complex with J14 
(PDB: 6FSO) was refined isotropically with 6 TLS groups. The structures of TGT in complex with J41 
(PDB: 5SW3), TGT in complex with J72 (PDB: 5UTI), TGT in complex with J79 (PDB: 5UTJ), and TGT in 
complex with J86 (PDB: 5V3C) were all refined anisotropically except for water molecules. The 
structure of TGT in complex with J64 (PDB: 5N6F) was refined anisotropically. Hydrogen atoms were 
added to the refined structures in the last refinement step in PHENIX.refine. For two of the structures; 
TGT in complex with J19 and TGT in complex with J33, the resulting m|Fo|-|Fc| density maps could 
not identify the fragments. Only after observing the event maps created by PanDDA (Pan-Dataset 
Density Analysis) could the fragments be identified. As these two structures do not meet the criteria 
for PDB depositions, they were not deposited. For the structure of TGT in complex with J79 (PDB: 5UTJ) 
the average B-factor of the ligand remains high despite refining occupancy. The structure of TGT in 
complex with ligand 4.1 (PDB: 6RKT) and TGT in complex with ligand 4.2 (PDB: 6RKQ) was refined 
isotropically with 6 TLS groups. Details of structural refinements of TGT in complex with ligand 2.1 – 
2.6, 3.1, and 3.2 can be found in the dissertation of Dr. Frederik R. Ehrmann, 2016.95  Chemicalize96 
developed by ChemAxon97 was used for name-to-structure generation and SMILES code notation. The 
ligand PDB and restraint files were generated with the Grade Web Server.98   
 
2.4.3 Applied Buffers for the Screening Experiments  
 
The conditions applied in the experiments were all close to neutral pH (pH 7 in soaking, Hepes and 
dTris buffers pH of 7.4 in SPR and NMR, respectively). TCEP is used in SPR and NMR as a reducing agent 
to prevent the formation of disulfide bridges in protein-protein interfaces. During crystal growths, 
TCEP was also added to the crystallization condition. Since soaking involves the use of pre-formed apo 
crystals, TCEP was not present in the soaking solutions. All screening conditions had high salt 
concentration. In SPR, the salt concentration is important to prevent non-specific binding to the 
dextran surface in the reference channels99 while in NMR, this salt concentration is important to 
prevent nonspecific binding through non-specific ionic interactions.100 A notable difference between 
the screening buffers is the concentration of DMSO. The soaking conditions had a concentration of 





10% DMSO, in comparison to 1% DMSO in SPR and 0.2% in NMR. Higher DMSO concentrations will 
enhance fragment solubility and reduces the risk of precipitation. The applied SPR conditions require 
0.05% Tween, which the soaking conditions did not contain. This may bring about a similar effect, even 
though Tween and DMSO unlikely function in the same way. While DMSO is used as co-solvent to 
enhance compound solubility, Tween is used to reduce compound aggregation.101 The fact that the 
NMR buffer did not contain a high percentage of DMSO explains why several fragments had to be 
excluded from the screen for limited solubility. PEG is used in the soaking conditions as a cryo-
protectant, it is neither used in the SPR nor NMR screening buffers. Despite PEG being noninvasive and 
thus less likely to interact within the interior of protein crystals102,35 it can still be found in some 
structures if the soaking conditions apply PEG in high concentration and PEG molecules have suitable 
size. The drawback of this is that a PEG molecule may even bind in the position where a fragment could 
accommodate, thus interfering with ligand binding. We found such a displacement of small PEG 
molecules in a study using crystals of endothiapepsin.103  Fragments need a certain potency to displace 
the PEGs. EDTA is a chelating agent added to coordinate metal ions. In SPR and crystallography it is not 
necessary to add EDTA but in NMR it is primarily added to chelate paramagnetic impurities.104 The 
sodium salt of trimethylsilylpropanoic acid deuterated in the propionic part (TMSP-d4) is used as 
internal NMR reference. It contains nine equivalent methyl hydrogens and therefore its 1H NMR 
spectrum consists of a sharp singlet which is set as chemical shift of 0 ppm. As most compounds studied 
by 1H NMR spectroscopy show resonances downfield of the TMSP signal (especially organic 
compounds), there is usually no overlap with the signals of the samples.  
 
2.4.4 SPR Conditions  
 
The SPR studies have been performed at 20 °C using a BIAcore 3000 instrument for the clean screen, 
and a BIAcore T200 instrument for the fragment screen and determining binding affinities of ligands 
4.1 and 4.2. The Z. mobilis TGT was immobilized via amine coupling to a dextran sensor chip at a pH of 
5.5. For the BIAcore 3000 experiments, a Xantec CMD 500L sensor chip was used and for the BIAcore 
T200 experiments a BIAcore CM7 sensor chip was used.  The functional groups of the Xantec CMD 500L 
chip surface were first activated by injecting for 10 min at 10 µL/min with a 1:1 mixture of 0.5 M 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 0.5 M N-hydroxysuccinimide 
(NHS), immediately followed by injecting the TGT protein for 7 min at a flow rate of 10 µL/min to 2623 
RU. Remaining activated carboxyl groups on the surface were blocked with 4 x 1.5 min pulses of 0.5 M 
ethanolamine or 150 mM ethylenediamine to overcome sticking of compounds to the reference 
channel. Immobilization levels achieved on the CM7 sensor chip were 9400 RU for the fragment screen 
and 4200 RU for the binding affinities measurements. The running buffer used for the immobilization 
was 10 mM Hepes buffer pH 7.4, 0.05% Tween 20, 150 mM NaCl, 1 mM TCEP, 1% DMSO. 
Before the final immobilization of the protein, a pH scouting was performed to find the appropriate 
pH conditions for TGT coupling onto the surface (the pH of the buffer in which the protein will be 
diluted). The running buffer used for pH scouting was 10 mM Hepes buffer pH 7.4, 0.05% Tween 20, 
150 mM NaCl, 1 mM TCEP, 1% DMSO. To find the appropriate pH for TGT immobilization, the pI of the 
protein was considered. The selected pH must be below the TGT pI of 6.3 but above the pKa values of 
3.5 of the carboxylates in the dextran matrix. A 50 µg · mL-1 stock solution of TGT was prepared in 
buffers of 10 mM sodium acetate at various pHs of 5.5, 5.0, 4.5, and 4.0, respectively. The protein 
samples in different buffers were injected onto the activated sensor chip surface separately in 20 µL 
volumes at a flow rate of 10 µL · min -1. Before each injection the sensor chip was preconditioned with 
a solution of 50 mM NaOH and 1 M NaCl at 10 µL · min-1 for 2 minutes. The corresponding curves and 
response values were monitored and the suitable pH of 5.5 was selected.  A tool compound is used to 
test the correct immobilization of a protein to the sensor chip, and to also test the protein activity after 
consecutive uses of the sensor chip. A tool compound should have a known binding affinity that gives 





compound.   
 
 
Clean Screen  
 
A clean screen with the fragments alone in the running buffer without protein was done to exclude 
the problematic fragments from the binding level screen. For this clean screen, the fragments were 
prepared in a 96-well plate in 2 mM concentrations by diluting them in the running buffer. The running 
buffer was 10 mM Hepes, pH 7.4, 0.05% Tween 20, 150 mM NaCl, 1 mM TCEP, and 1% DMSO. The 
plates were spun down, and half of the volume was transferred into a new plate and diluted again 1:1 
with the running buffer to give a final fragment concentration of 1 mM. The fragments were then 
passed over the CMD 500L sensor chip at a flow rate of 20 µL/min for 1.5 min. To remove compounds 
from the biosensor surfaces, the flow channels were regenerated by a 90 s pulse of 0.5% SDS. 
Fragments with irregular curves (very slow dissociation rate, jump in RU) were excluded from the 
fragment screening.  
 
Binding Level Screen (Fragment Screen)  
  
The fragments were screened at 1 mM concentrations, in a fragment binding level screen, and a 
standard solvent correction procedure was performed to correct for potential deviations in DMSO 
concentration between samples and running buffer. The running buffer used was 10 mM Hepes, pH 
7.4, 0.05% Tween 20, 150 mM NaCl, 1 mM TCEP, and 1% DMSO. To remove compounds from the 
biosensor surfaces the flow channels were regenerated after each cycle with 50% DMSO (a 1:1 dilution 
of running buffer and DMSO).  
 
Affinity Screen (Determining Binding Kinetics)  
 
For fragments, the affinity screen was done using 9 different concentrations and 3 blanks as follows: 0 
µM, 0 µM, 0 µM, 20 µM, 35.6 µM, 63.2 µM, 112 µM, 200 µM, 356 µM, 632 µM, 1125 µM, 2000 µM. 
The running buffer used was 10 mM Hepes buffer pH 7.4, 0.1% Tween 20, 250 mM NaCl, 1 mM TCEP, 
and 2% DMSO.  
Single Cell Kinetics was used to determine the binding affinity of ligands 4.1 and 4.2. The direct binding 
screen for was done at 1/3 log concentrations of 1 µM, 3.16 µM, 10 µM, 31.6 µM, and 100 µM. Due to 
the sticky nature of the ligands 4.1 and 4.2, an exaggerated response could be observed at a 
concentration of 100 µM so kinetic analysis was not possible. Instead, the apparent KD value was 
extrapolated from the saturation points, where the last point at 100 µM was not considered. For ligand 
4.1, another direct binding screen was done at concentrations of 3 µM, 10 µM, 30 µM, 100 µM and 
300 µM to reach saturation but in both experiments secondary effects could be seen at the higher 
concentrations and complete saturation could not be achieved, thus the exact KD value cannot be 
determined. Hence, we only report from the SPR measurements that the KD value for ligand 4.1 lies in 
the double-digit micromolar range. The running buffer used was 10mM Hepes buffer pH 7.4, 0.1% 
Tween 20, 250 mM NaCl, 1 mM TCEP, and 2% DMSO. 
 
2.4.5 NMR Conditions 
 
NMR experiments for fragment screening were performed at 25 °C using a Bruker Avance Neo 600 
MHz spectrometer equipped with a cryogenically cooled probe-head. Automatic sample changing was 
accomplished with a Bruker SampleJet system. For the initial validation experiments (Figure 2) a Bruker 





Avance III HD 800 MHz spectrometer equipped with a cryogenically cooled probe-head, was used. NMR 
samples contained 200 µM fragment in aqueous buffer with 20 mM deuterated TRIS at pH 7.4, 1 mM 
EDTA, 150 mM NaCl, 10% (vol/vol) D2O, 3 mM TCEP and 10 µM TMSP-d11. A TECAN EVO 100 liquid 
handling robot was used to fill 5 mm O.D (outer tube diameter) NMR tubes in a SampleJet rack. The 
interscan delay was 3 s and 64 scans were accumulated. Solvent suppression was accomplished with 
an excitation sculpting scheme105 using 2 ms sinc shape flip back pulses. In the CPMG experiment the 
DMSO peak was suppressed by off resonance irradiation during the interscan delay. For each 
compound the binding experiment was run in two or three steps. First CPMG and WaterLOGSY 
experiments were run on a sample containing the ligand alone to check solubility and integrity. Once 
the structure was confirmed from matching the spectra peaks to the predicted fragment peaks in the 
ACD/Labs software, 3 µM protein was added to check binding. For the samples with fragments that 
did bind, 10 µM of a potent inhibitor, inhibitor 1 (SPR KD of 68 ± 5 nM), was gradually added to the 
samples and a third set of NMR experiment were recorded. Inhibitor 1 binds to the active site and can 
therefore be used to identify specific active site binders. Spectra were processed and analyzed with 
TopSpin®.  
 
2.4.6 MD Simulations and HSA Calculations. 
 
MD Simulations. For the MD simulations we used the protein-ligand complex of TGT·4.1 (pdb-code 
6RKT). The structure was loaded into MOE106 and the ligand molecule was removed. Then missing 
atoms were built and protonation states were assigned using the protonate3D utility of MOE. The 
cysteine residues coordinating the Zn2+ ion, were modelled in their deprotonated form. Then, the 
protonated protein structure, crystallographic water molecules and the zinc ion were loaded into tLEaP 
from the AmberTools17 package.107 In tLEaP, parameters from the amber FF99SB108 force field were 
assigned to the protein atoms and TIP4P-Ew109 parameters were assigned to the water molecules. Two 
sodium counter ions were added using the addions2 utility in order ensure net neutrality through the 
MD simulation. Finally, the protein was embedded into a truncated octahedron simulation box filled 
with TIP4P-Ew water molecules. The box was built such that the minimum distance between each 
solute or crystallographically determined water molecule and any box edge was at minimum 10 Å, 
resulting in a simulation box with 12756 water molecules in total. 
In the following, all minimization operations were carried out using pmemd and all MD simulations 
were calculated using the pmemd.cuda110–112 for use with GPUs. Both programs were, as well as all 
other programs from the Amber program package, used from Amber16 together with 
AmberTools17.107 
Initially, the system energy was minimized with 2500 steps of steepest descent minimization followed 
by 2500 steps of conjugate gradient minimization. During this minimization operation, all solute heavy 
atoms were restrained to their crystallographically determined positions using a harmonic restraining 
potential with a force constant of 25 kcal·mol-1·Å-2. Subsequently, the force constant was set to 
2 kcal·mol-1·Å-2 and the minimization was repeated analogously to the first one. In the next step, the 
system was heat to 300 K within 25 ps using an integration time step of 1 fs. At this point, the solute 
heavy atoms are again positionally restrained with a force constant of 25 kcal·mol-1·Å-2. Now, the 
integration time step was switched to 2 fs and the system equilibrated under NPT conditions for 5 ns 
using the Berendsen barostat113 and a target pressure of 1 bar. The temperature was regulated at 300 K 
using a Langeving dynamics thermostat with a collision frequency value of  = 2 ps-1. In the final 
equilibration step, the system is run under NVT conditions for an additional 5 ns. 





During all MD runs, the system was treated using periodic boundary conditions and the particle-mesh 
Ewald technique together with a 9.0 Å real-space distance cutoff for the electrostatic interactions. 
Furthermore, all bonds involving hydrogen atoms were constrained using the SHAKE algorithm.113 
Hydration Site Calculations. For the HSA calculations, we used the program SSTMap87,114 (Version 
1.1.1). We used ligand molecule TGT·4.1 in its bound pose in order to define the binding site for the 
HSA analysis. After the HSA calculation, the hydration site energy values were manually referenced to 
the TIP4P-Ew bulk energy value.  















The following chapter is the preparation of a manuscript to be submitted. 
The expression and the purification of both constructs of the T. brucei PEX14 were optimized and done 
by the author of this thesis. The set up and screening for crystallization conditions was done by Ralf 
Poeschke from the MarXtal facility at the Philipps University of Marburg in Marburg, Germany. The 
additive screening with the compound TEW was done in collaboration with Dr. Anna Aagaard during 
an academic scientific secondment at Astrazeneca R&D in Gothenburg, Sweden.  
The virtual screening for novel compounds to inhibit PEX14 was done in collaboration with Ryan Byrne 
from the working group of Prof. Dr. Gisbert Schneider during an academic scientific secondment at 
ETH Zurich in Zurich, Switzerland. 
The SOFAST HMQC 2D NMR experiments on the virtually screened ligands and the AlphaScreen assay 
were done in collaboration with Charlotte Softley and Roberto Fino, respectively, from the working 
group of Prof. Dr. Michael Sattler during an academic scientific secondment at the Helmholtz Zentrum 
in Munich, Germany. 
The TSA (thermal shift assay) experiment trials were done by the author of this thesis. 
The DLS (dynamic light scattering) experiment was done by Patrick Walter from the working group of 
Prof. Dr. Helene Munier Lehmann at Louis Pasteur in Paris, France. 
Compound 1, designed from growing the fragment hit F5, was synthesized by Khang Ngo from the 
working group of Prof. Dr. Gerhard Klebe at the Philipps University of Marburg in Marburg, Germany.   
The trypanocoidal assay was done by Vishal Kalel from the Ruhr-Universität Bochum in Bochum, 
Germany. 

















3.1.1 Neglected Infectious Tropical Diseases  
 
Neglected tropical diseases (NTDs) are a group of chronic conditions affecting primarily the poorest 
500 million people living in sub-Saharan Africa (SSA), where the extreme poverty helps spread the 
diseases.  
These diseases include helminth infections, Schistosomiasis, and the protozoan infections; human 
African trypanosomiasis and visceral leishmaniasis, which affect around 100,000 people in areas of 
conflict in SSA and cause high mortality.115 
 
3.1.1.1 Human African Trypanosomiasis 
 
Epidemiology 
The human African trypanosomiasis (HAT), also known as the sleeping sickness, is endemic in 36 sub-
Saharan Africa countries, threatening millions of people. It is a vector-borne parasitic disease 
transmitted to humans by bites of the tsetse fly (Glossina genus).116 The parasite responsible for the 
infection is a protozoan parasite T. brucei belonging to the genus Trypanosoma.117 The tsetse fly can 
acquire the infection either from humans or animals that harbor the parasite. Only certain species of 
the tsetse fly transmit the disease and for reasons unknown, some regions where the tsetse flies are 
found do not have the sleeping sickness. However rural populations that depend on agriculture, fishing, 
animal husbandry or hunting are those most exposed to the tsetse fly and thus the disease.118 Other 
ways of disease transmission include transmission of the trypanosome from mother-to-child, 
mechanical transmission through other blood-sucking insects, accidental infections due to pricks with 
contaminated needles, as well as through sexual contact.119  
Since the last epidemic in 1970 until the late 1990s, the efforts of WHO, national control programs and 
non-governmental organizations (NGOs) have helped control the disease. The number of new HAT 
cases reported between 2000 and 2012 dropped by 73%. The estimated number of actual cases is 
below 10,000 and the estimated population at risk is 65 million people. Over the last 10 years, the 
Democratic Republic of Congo (DRC) has reported over 70% of the cases, and other countries have 
reported less than 100 new cases per year including Cameroon, Central African Republic, Nigeria, South 
Sudan, and United Republic of Tanzania.119 
Forms of HAT  
 
Depending on the parasite involved, HAT takes 2 forms118, their distribution is shown in Figure 3.1: 
1- Trypanosoma brucei gambiense which accounts for 98% of reported cases, is found in 24 countries 
in West and Central Africa. It may take months or even years for a person with this chronic infection 
to show symptoms of the disease. This makes it difficult to cure as the patient is often then already in 
the advanced stage of the disease where the central nervous system is affected.119  
2- Trypanosoma brucei rhodesiense is the less common form accounting for less than 2% of reported 
cases and is found in 13 countries in Eastern and Southern Africa. Contrary to the first form, the first 
symptoms in an infected person appear after a few weeks or months and the disease develops rapidly 
on from there, invading the central nervous system.119 
The disease is also found in cattle, where it is termed Nagana.116 Nagana is caused by other sub-species 
of the Trypanosoma genus that are pathogenic to both wild and domesticated animals. Animals can 









Stages of the disease  
 
There are two major stages of the disease:  
1- The haemo-lymphatic stage which involves fever, headaches, joint pains, and itching, occurs when 
multiplying trypanosomes are still in the subcutaneous tissues, blood, and lymph.120,119  
2-  The neurological or meningo-encephalic stage which occurs when parasites cross the blood-brain 
barrier and infect the central nervous system.120 It is in this stage when the obvious symptoms of the 
disease begin to appear including confusion, behavioral changes, sensory disturbances, poor 
coordination, and of course the disturbance in the sleep cycle – which coins the disease its name.119 If 
left untreated it could lead to coma and death.120 
Treatment 
Treatment of HAT depends on the stage of the disease.   
First stage treatments are safer and easier to administer than the second stage treatments, as the 
second stage treatments must cross the blood-brain barrier to reach the parasite and thus are toxic 
and complicated to administer. Assessment of treatment outcome requires a 24-month follow-up of 
the patient which includes laboratory examinations of cerebrospinal fluid by lumbar puncture to 
ensure there are no viable parasites that could reproduce the disease after the treatment.119   
There are five drugs that have been used for treatment depending on the stage of the disease, in 
addition to fexinidazole which is a new oral treatment for gambiense HAT. It is already registered in 
Figure 3.1: Distribution of human African trypanosomiasis with incidences and risk for travelers. The area above the black line is where 
Trypanosoma brucei gambiense predominates, whilst the area below the black line is where Trypanosoma brucei rhodesiense predominates 
(J Blum, Swiss Tropical Institute). 
Uganda: overlap T b gambiense 
and T b rhodesiense possible Incidence in local population, per 
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the Democratic Republic of Congo and has been received positively by the European Medicines 
Agency’s Committee for Medicinal Products for Human Use in November 2018.119  
Drugs used in treatment of first stage:  
       - Pentamidine: used for treatment of T.b. gambiense sleeping sickness. Has undesirable side effects 
but well tolerated by patients.119   
      - Suramin: used for treatment of T.b. rhodesiense. Has undesirable side effects including urinary 
tract and allergic reactions.118 
Drugs used in treatment of second stage:  
      - Melarsoprol: recommended as a second line-treatment of gambiense and first line-treatment of 
rhodesiense infections. It is derived from arsenic and so has several undesirable side effects including 
encephalopathic syndrome which can be fatal. There has been an observed increase in resistance 
especially in Central Africa.118  
      - Eflornithine: this complex treatment is only effective against T.b. gambiense and is difficult to 
apply.118 
      - Nifurtimox: a combination treatment of nifurtimox and eflornithine is used against T.b. 
gambiense. This combination makes it easier to use eflornithine as it reduces treatment duration and 
number of necessary IV perfusions.119  
 
3.1.2 Membrane Associated Protein PEX14  
 
3.1.2.1 Role in Trypanosomes  
 
Peroxisomes are membrane-enclosed organelles that compartmentalize a variety of metabolic 
reactions.121 Glycolysis in trypanosomes occurs within glycosomes, which are peroxisome-related 
organelles that contain metabolic enzymes including those required for glucose metabolism122 as seen 
in Figure 3.2. PEX14 is a peroxin protein that is essential for biogenesis of glycosomes.122 PEX14 forms 
an essential protein-protein interaction with PEX5, an import receptor which transports cytoplasmic 
glycosomal enzymes into the organelle.123 PEX5 has a C-terminal tetratricopeptide repeat (TPR) domain 
that recognizes a peroxisomal targeting signal (PTS) peptide motif in cargo proteins and binds to it.124 
The N-terminal of PEX5 on the other hand has diaromatic WxxxF peptide motifs that PEX14 recognizes 
through its globular N-terminal domain.125 PEX5 docks onto PEX14 in the peroxisomal transmembrane 
and together they form a complex which imports cargo protein.126   
Dependence of trypanosomes on glycolysis and thus the importance of the formed PEX14/PEX5 
complex depends on the host of the deadly T. brucei parasite.  When T. brucei is in its mammalian host 
- or its bloodstream form, it receives a constant millimolar level of glucose as it lives extracellularly in 
the bloodstream and cerebrospinal fluid. Therefore ATP is generated through glycolysis and the 
majority of proteins in the glycosome are thus glycolytic enzymes.121 The exact process of glycolysis in 
this stage is described in Figure 3.2.  ATP is generated not in the glycosome, but rather the cytosol 
where pyruvate kinase transfers the high energy phosphate from phosphoenolpyruvate to ADP. When 
T. brucei is in its insect host - or its procyclic form, glucose of the digesting bloodmeal of the tsetse flies 













3.1.2.2 Quaternary Structure of PEX14 
 
The N-terminal domain of PEX14 is a 7 kDa monomer consisting of a three helical bundle (Figure 3.3a). 
The α1 and α2 helices are antiparallel, whilst the α3 helix forms a diagonal scaffold. The binding site of 
PEX14 with PEX5 is formed by helices α1 and α2 and has two hydrophobic pockets, separated by two 
Figure 3.2:  The glycosome, cytosol, and mitochondria (Mito) are all involved in the energy metabolism of bloodstream form 
T. brucei. The flow of metabolites of glucose is indicated by the black arrows. ATP generated in the glycosome is in balance as 
two equivalents of ATPs are required to start the metabolic process, whilst the net ATP is generated in the cytosol. The 
mitochondria is also involved in the glycerophosphate shunt where dihydroxyacetone phosphate (DHAP) is cycled to glycerol-
3-phosphate and back, allowing the glycosome to maintain the NAD+/NADH balance. (Parsons, M. et al. Molecular 
Microbiology (2004)). 
Figure 3.3: a) PDB: 2W84 Structure of NTD of PEX14 consists of a three helical bundle, where the PEX5 binding site is formed 
by helices α1 and α2 and has two hydrophobic pockets, shown as green circles, separated by two aromatic residues (Phe35 
and Phe52) shown as sticks. b) PEX5 (blue) binds diagonally across helices α1 and α2 in PEX14 and buries its conserved 
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aromatic residues (Phe35 and Phe52). The PEX14/PEX5 complex is formed when PEX5 binds diagonally 
across helices α1 and α2 in PEX14 (Figure 3.3b), pointing its conserved aromatic residues Trp103 and 
Phe107 into the two hydrophobic pockets in PEX14, where they are deeply buried.   
3.1.2.3 How to Disrupt Function of PEX14 
 
T. brucei lacks feedback allosteric regulation of early steps in glycolysis but compartmentalizes the 
relevant enzymes within low permeable organelles called glycosomes. This compartmentalization 
separates enzymes and metabolites in the cytosol and glycosome from one another, which prevents 
toxic accumulation of intermediates.121,127 This hypothesis has been proven through PEX14 RNA 
interference studies which confirmed that glucose becomes toxic to T. brucei upon glycosomal import 
disruption. 127,128 This was done by showing that in PEX14 deficient trypanosomes, addition of glucose 
led to accumulation of glucose-6-phosphate due to the impairment of glycosomal protein import in 
these trypanosomes. Additionally, loss of glycosomal compartmentation led to dramatic increases of 
glycerol-3-phosphate upon addition of glycerol due  to the depletion of glycerol kinase which also 
saved the cells from glycerol toxicity.127 It has been reported before that disrupting the PEX14/PEX5 
interaction leads to the accumulation of glycosomal enzymes in the cytosol, depletion of ATP, and 
glucose toxicity which leads to the metabolic collapse and ultimately death of T. brucei.129 This 
disruption can be achieved through small molecules that bind to PEX14 and block it, preventing the 
binding of PEX5. One way of finding such molecules is through fragment screening.  A previous NMR 
screening of a fragment library resulted in fragment hits that bind to PEX14.130 In this project, we 
attempt to validate these hits through X-ray crystallography which will allows us to visualize the 
interactions of these fragments. The promising fragment hits can then be optimized into more potent 
lead compounds.  
Selectivity can be achieved for T. brucei PEX14 as there are structural differences between the human 
PEX14 and the trypanosomal PEX14, as seen in Figure 3.4. The overall folds are very similar, except that 
the PEX14 of T. brucei exhibits an additional C-terminal helix. There are also some amino-acid 
differences in the PEX5 binding pockets of both species, whereas the human PEX14 has Leu28, Thr31, 
Lys34, and Asn38, the trypanosome PEX14 has instead an Arg, Asn, Glu, and Asp, respectively. This 
suggests that specific polar interactions can be used to selectively target T. brucei PEX14.129 The 


















3.2 Crystallization and Fragment Screening of Mutated PEX14 
 
3.2.1 Expression Constructs  
 
Wild-Type Vs. Mutated PEX14 T. Brucei 
Given the nature of PEX14 being a transmembrane protein, the entire construct is difficult to express 
and crystallize due to the high flexibility of the amino acid residues. 131 Additionally, our PEX5 
interaction of interest occurs at the N-terminal domain, and for these reasons we have used a 
truncated version of the full construct where we have taken the residues 19-84 of the PEX14 N-
terminus (Figure 3.5a).  In our project, we worked with two different constructs of this N-terminal 
domain; the wild-type construct with a glutamate residue as the first residue, and a mutated construct 
E1W with a tryptophan residue as the first residue (Figure 3.5b). The purpose of the tryptophan was 
to render 280 nm absorbance properties to the construct, as the short 66 residues did not contain any 
280 nm absorbing amino acids which makes it difficult to handle the protein in purification and 
standard protein concentration measurements. After purification a GAM expression tag (Gly-2, Ala-1, 
Met0) sometimes remains.  
Figure 3.4: a) Superimposition of the human PEX14 (PDB: 2W84) in blue and the T. brucei PEX14 in salmon shows structural 
differences including amino acid residues surrounding PEX5 binding pocket in addition to the additional C-terminal helix 
shown in T. brucei PEX14. This indicates that selective inhibitors can be designed for T. brucei PEX14. b) Sequence alignment 













After expression and purification of the mutated construct, crystallization screens using Hampton 
Research plates were set up at a protein concentration of 17 mg/mL at 18°C and 4°C. From the two 
subsequent hits, one of them was reproducible inhouse. To obtain single crystals that did not grow in 
clusters 5% of glycerol was added as suggested by literature to reduce the nucleation rate and crystal 
growth132 (Figure 3.6). 
Table 3.1: Crystallization Conditions from screening for the mutated PEX14 construct. Only one of the conditions was 
reproducible. 
Protein Concentration Buffer Salt Precipitant Temp Reproducible 
Mutated 























Figure 3.5: a) T. brucei Pex14 full sequence consists of 366 amino acids, whereas the truncated N-terminal domain consist of 
only 66 amino acids, as highlighted in yellow. b) First residue was mutated from a glutamate to a tryptophan. The first residue 













3.2.3 Fragment Screening 
 
In a previous STD NMR fragment screen done at the Helmholtz Zentrum in Munich, a set of fragments 
were discovered that bind to E1W PEX14130 (Table 3.2). Apo crystals of the protein (Figure 3.6b) were 
soaked into these fragments at a final fragment concentration of 100 mM for a time ranging between 
20-24 hours. Among these 11 fragments, only one was found to bind in the crystal structure (crystal 
form 2, Figure 3.7a). Additionally, this fragment does not address either of the two known hydrophobic 
pockets of PEX14. To further evaluate the reason behind this we ran the structure through a script 
developed by Dr. Alexander Metz (personal communication) called “XTunnel”, which visualizes the 
crystal packing in a protein crystal by generating crystal mates within 4 Å of the asymmetric crystal 
unit. This allows us to also visualize the channels available in the protein crystal and assess whether 
the binding pocket of the protein crystal is accessible by the fragments or not. This visualization of the 
entire crystal packing revealed blocked binding pockets in the crystal structure (Figure 3.7b). It was 
clear that the additional tryptophan residue at the N-terminus of the protein construct binds into and 
blocks one of the hydrophobic pockets of the neighboring crystal mate, while the second hydrophobic 
pocket of the crystal mate is also blocked by a threonine residue of another neighboring crystal (Figure 
3.7c). This explained why the fragments were not able to bind into the binding pockets, and why the 
only bound fragment managed to squeeze itself into the available space found in the protein crystal. 
Accordingly, for fragments to bind to the other pockets, they would have to displace the residues of 








Unit Cell Dimensions 
A b c α β γ 
43.2 43.2 81.0 90.0 90.0 90.0 
a b 
tetragonal P41212  
1 molecule/ asymmetric unit 
Figure 3.6: Crystal form 1. Crystals of E1W PEX14 grown in the a) absence of glycerol where they grow in clusters and in the 
b) presence of 5% glycerol where they grow as single formed crystals, which are more suitable for soaking experiments. 





Table 3.2: Fragment hits for T. brucei PEX14 detected by NMR screening. 
Fragment Number Chemical Name Chemical Structure 
F1 1-benzothiophene-3-carboxylic acid 
 






F5 1H-indole-7-carboxylic acid 
 
F6 benzo[b]thiophene-7-carboxylic acid 
 
F8 3-benzofuranacetic acid 
 
F9a alpha, alpha-dimethyl-6-methoxy-2-napthalenemethanol 
 
F10 4H-Thieno[3,2-b]pyrrole-5-carboxylic acid 
 
F11 Ethyl 3-indoleacetate 
 















3.2.4 The Search for New Crystal Forms  
 
Since fragment diffusion into free binding pockets is a prerequisite for fragment screening by soaking, 
we set up more crystallization screens using the MarXtal Screening Facility and evaluated over 1,500 
conditions to find new crystal packing with more promising spatial arrangements of the protein 
molecules to study ligand binding. From the discovered crystallization hits (Figure 3.8), two conditions 
were reproducible. We collected datasets for these two crystals, D5 MBCII was collected using our 
inhouse MAR345 detector, and F12 Memgold was collected at BL14.1 at the BESSY II electron storage 
ring operated by the Helmholtz-Zentrum Berlin.133 MBCII was refined to a resolution of 2.6 Å while F12 
Memgold was refined to a resolution of 2.3 Å. Despite crystallizing under different conditions and in 
two different space groups, both crystal forms also revealed a blocked binding pocket (
Unit Cell Dimensions 
a b c α β γ 







Figure 3.7: a) Fragment 5 (crystal form 2) was a hit in X-ray crystallography, but it is shown to stack against the phenylalanine residues 
separating the binding pockets without addressing either pocket. b) XTunnel revealed a dense packing of the protein crystal 
(asymmetric unit is shown in blue, crystal mates within 4 Å are shown in yellow, Phe34 and Phe17 are highlighted in pink, and the 
first four residues of the construct including the E1W mutation are highlighted in orange) and a blocked binding pocket where c) a 
tryptophan residue from a neighboring crystal mate blocks the pocket where the tryptophan of PEX5 binds, and another threonine 
residue blocks the second pocket where the phenylalanine residue of PEX5 binds. PDB: 6S6R. The fragment chemical structure, unit 
cell dimensions, space group, and number of molecules per asymmetric unit is also shown. 
tetragonal P41212  













Figure 3.8: a) Additional hits from the crystallization screen of mutated PEX14. Only D5 MBCII and F12 Memgold were 
reproducible, however both revealed blocked binding pockets (phenylalanine residues separating the two pockets are 
highlighted in pink.  b). The binding pockets were blocked by a neighboring crystal mate or another molecule in the 









Table 3.3: Crystallization conditions of the crystallization hits from mutated PEX14 crystallization screen. The images of the 
crystal hits are also shown.a 
Crystallization Conditions Crystal Image Unit Cell Dimensions  
and Space Group a 
D5 MBCII – Crystal form 3 
Temperature: 18°C 
Concentration: 28mg/ml 
Salt: 0.1M Lithium Sulphate 
Buffer: 0.1M Trisodium Citrate 
pH 5.6 




Unit Cell Dimensions 
a b c α β γ 
42.6 42.6 81.1 90.0 90.0 90.0 
F12 Memgold – Crystal form 4 
Temperature: 18°C 
Concentration: 28mg/ml 
Salt: 0.07M Sodium Chloride 
Buffer: 0.05M Trisodium 
Citrate pH 4.5 











Unit Cell Dimensions 
a b c α β γ 
38.9 82.1 39.4 90.0 92.9 90.0 
a) Both crystal forms crystallize in different space groups, however both of them have blocked binding pockets. 
Co-crystallization of the fragments was also attempted by drying 0.5 µL of a 1M stock solution of 
fragment (approx. 142mM) onto a crystallization well of a hanging drop plate and crystallizing the 
protein into the drop. We attempted all three crystallization conditions found to crystallize this 
mutated PEX14 construct, including published conditions129 as seen in Table 3.4. However, no co-
crystals grew under these conditions. 




Concentration Buffer Salt Precipitant Temp. 
2mM 20mM 0.1M Tris HCl pH 8.5 0.2M MgCl2 30% PEG 4000 4°C 
2mM 20mM 0.1M Tris HCl pH 8.5 0.22M Lithium Sulphate 29% PEG 4000 18°C 
2mM 20mM 0.1M Bis Tris Propane pH 7.5 
0.2M Sodium 
Sulphate 20% PEG 3350 18°C 
2mM 20mM  0.2M Ammonium Sulphate 
30% PEG 8000 
5% Glycerol 4°C 
1mM 100mM 0.1M Tris HCl pH 8.5 0.2M MgCl2 30% PEG 4000 4°C 
1mM 100mM 0.1M Tris HCl pH 8.5 0.22M Lithium Sulphate 29% PEG 4000 18°C 
1mM 100mM 0.1M Bis Tris Propane pH 7.5 
0.2M Sodium 
Sulphate 20% PEG 3350 18°C 
1mM 100mM  0.2M Ammonium Sulphate 
30% PEG 8000 
5% Glycerol 4°C 
 
monoclinic P21  
4 molecules/ asymmetric unit 
tetragonal P43212  






3.2.5 Fragment Hit-to-Lead Generation  
 
With the initial fragment hit we had obtained from soaking (Figure 3.7a) we decided to initiate a lead 
generation by fragment growing, which was done by Khang Ngo (Philipps University of Marburg, 
personal communication). The synthetic pathway is shown below (Scheme 3.1). We further tested this 
compound in SOFAST HMQC NMR and in AlphaScreen to determine its KD and IC50 values, respectively 
(to be discussed in section 3.3). The co-crystallization of this lead compound with the mutated PEX14 
in a crystallization screen (0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6, 25.5% PEG 4000, 
15% glycerol) yielded a crystal structure with a resolution of 1.15 Å, but the synthesized ligand could 
not be resolved in the structure. However, we did manage to collect a crystal structure of this 
compound soaked in the wild-type PEX14 as will be discussed in the coming section 3.5.2. 
 
3.2.6 Soaking Co-Crystallized E1W PEX14  
 
The E1W PEX14 construct proved difficult to crystallize in a crystal form with an accessible binding 
pocket likely due to the highly directional impact of filling of the hydrophobic pocket next to Phe17 
and Phe34 with the accessible and spatially less restricted Trp1 residue of a second PEX14 molecule 
which was artificially introduced into parent protein for analytical reasons. Nevertheless, published 
structures of co-crystallized complexes with the E1W construct suggest that potent ligands can bind to 
the hydrophobic pockets before formation of the crystal contacts.129 Likely they have sufficient affinity 
to avoid displacement from the parent protein upon nucleation of the crystal packing. Some fragments 
with lower potency will likely be displaced by the contact of Trp1 in the binding pocket when the first 
protein molecules assemble to form a crystallization nucleus. With this in mind, we utilized 
computational methods to screen libraries for novel ligands as potential PEX14 inhibitors that would 
bind upon co-crystallization. Details of these methods and the virtual screening cascade implemented 
will be discussed in section 3.3.  
 
Screening for co-crystallization conditions of E1W PEX14 with the discovered virtual screen (VS) hit 
ligands (described in section 3.3) led to a new crystallization condition (1 mM protein, 20 mM ligand, 
0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6, 25.5% PEG 4000, 15% glycerol, 18°C) 
yielding a crystal in the P41212 space group but slightly different unit cell dimensions (Figure 3.9, crystal 
form 5). Solving the structure of these crystals and generating the crystal packing of the new co-crystal 
form revealed a packing similar to the crystal form 1 as seen in Figure 3.9b and Figure 3.9c and pockets 
that were still blocked by their neighboring crystal mates. It seems that the applied VS ligands 
somehow supported crystallization of the E1W PEX14 variant, as the crystallization conditions without 
adding the VS ligands did not yield any crystals. It may also be that the VS ligands are bound to the 
crystal but populated at only 10% or less, and thus cannot be seen in the structure. Superimposition of 
Scheme 3.1: Synthetic pathway of the lead compound 1 from the original fragment hit. 






the initial crystal form 1 of E1W PEX14 variant and the new crystal form 5 revealed a large shift in the 
positions of several residues along the protein structure including the first six residues of the sequence 
Gly-2, Ala-1, Met0, Trp1, His2, Thr3 that shift more than 0.6 Å. In total 25 residues in the protein 
structure are shifted by more than 0.4 Å, which already makes up 38% of the entire protein (Table 3.5). 
This perturbation in over a third of the protein could explain why the new crystal form 5 obtained by 
these co-crystallization attempts could accommodate the fragments while the apo crystal form could 









 Unit Cell Dimensions 
Crystal 
form 
a b c α β γ 
5 41.7 41.7 81.6 90.0 90.0 90.0 








1 molecule/ asymmetric 
unit 
Figure 3.9: Crystal form 5 a) Central asymmetric unit cell is in green, and the phenylalanine residues separating the two 
hydrophobic pockets are highlighted in pink. One pocket is blocked by a Thr50 residue of the neighboring crystal mate 
and the other pocket is blocked by a Trp1 residue from another neighboring crystal mate. b) The generated crystal mates, 
5 Å from the asymmetric unit shown in yellow, produce a crystal packing that is of similar density of crystal form 1 (c) and 







Table 3.5 : The measured distances indicating the extent of shifting of the residues in the crystal form 5 (crystallized in 





Nevertheless, the novel crystal form 5 crystals were used to rescreen the NMR fragment hits previously 
discussed (Table 3.2). Crystals were soaked in fragment solutions of 100 mM concentration for four 
hours. This resulted in a second E1W PEX14 fragment hit as seen below. The fragment F6 results in a 
crystal with eight independent molecules in the asymmetric unit for which the diffraction data 
suggested a setting of the crystal symmetry in the monoclinic space group P21. The crystals that 
generated this hit were crystallized upon addition of the ligand VS 7 (section 3.3). F6 seems to have 
altered the packing of the crystal, so that the symmetry of the diffraction data corresponded best to a 
different space group than the original crystals before soaking. This is likely due to the relatively small 
size of the protein, and the high concentration of the fragment solution used which overall perturbs 
the symmetry of the protein arrangement in a way that a symmetry reduction is experienced from a 
tetragonal P41212 to a monoclinic P21. Superimposition of the crystal packing in P41212 before soaking 
with the resulting crystal form P21 after soaking reveals perturbations of the residues at the N-terminus 
as seen in Figure 3.12. The measured distances indicating the extent of shifting of the residues in the 
“VS ligand influenced” crystal form 5 of the E1W PEX14 variant relative to the crystal obtained by 




Residue Distance Å 
Gly-2 Cα 0.85 
Ala-1 Cα 0.89 
Met0 Cα, Cε 0.32, 1.07 
Trp1 Cα, Cγ 0.85, 1.47 
His2 Cα, Cγ 0.68, 0.97 
Thr3 Cα 0.66 
His4 Cα 0.49 
Ser5 Cα 0.43 
Asp20 Cα 0.69 
Ser21 Cα 1.29 
Arg22 Cα 1.87 
Val23 Cα 0.81 
Arg24 Cα 0.81 
Arg25 Cα 0.49 
Thr26 Cα 0.77 
Pro27 Cα 1.06 
Thr28 N 0.94 
Ser29 Cα 0.99 
Ser30 Cα 0.44 
Gly53 Cα 0.43 
Gln54 Cα 0.42 
Lys56 Cα 0.77 
Thr57 Cα 0.83 
Leu58 Cα 0.80 
Asn59 Cα 0.44 
Figure 3.10: Superimposition of the entire structure of the crystal form 5 of the 
E1W PEX14 variant “VS ligand influenced” (pink) and the apo crystal of the E1W 
PEX14 (green). The residues that encounter the most perturbation in their 
positions are encircled in pink. Together these residues make up over one-third 
of the protein structure, and these structural differences could explain why one 















Unit Cell Dimensions 
a b c α β γ 
79.7 39.7 81.1 90.0 90.0 90.0 




Figure 3.11: Chemical structure of F6. This crystal structure after soaking gives 8 molecules per asymmetric unit corresponding 
to a different crystallographic setting in space group P21 compared to the symmetry of the un-soaked crystal which results in a 
crystal with a lower symmetry (crystal form 6). The unit cell dimensions are also displayed. The crystal structure was resolved to 
1.76 Å. 
Figure 3.12: Superimposition of the “VS ligand influenced” crystal form 5 of the E1W PEX14 variant obtained by co-crystallization 
(pink) with each of the eight molecules in the asymmetric unit (a - h) of the subsequently soaked crystal form obtained in complex 
with F6 (crystal form 6) (PDB: 6S7M). The residues that encounter the largest perturbations in their positions are the residues at 
the N-terminus namely the first 11 residues Ala-1, Met0, Trp1, His2, Thr3, His4, Ser5, Glu6, Arg7, Glu8, Lys9. In some of the eight 
copies, not all of these residues are resolved. These perturbations could explain the change in the crystal forms.  
a b c d 






Table 3.6: The measured distances indicating the extent of shifting of the residues in the “VS ligand influenced” crystal form 
5 of the E1W PEX14 variant relative to the subsequently soaked crystal of the fragment hit F6.  
 
F6 Hit crystal form 6 
Molecule A Distance Å Molecule D (cont.) Distance Å 
Met 0 Cα 2.8 His4 Cα, Cβ 1.5, 2.0 
Trp1 Cα 1.7 Ser5 Cα, Cβ 1.1, 1.4 
His2 Cα 1.0 Glu6 Cα, Cγ 0.9, 1.2 
Thr3 Cα   0.6 Arg7 Cα, Cγ 0.8, 1.1 
His4 Cα 0.4  Glu8 Cα, Cγ 0.7, 1.4 
Ser5 Cα 0.4 Lys9 Cα, Cγ 0.5, 3.0 
Glu6 Cα, Cγ 0.3, 0.6   
Arg7 Cα, Cβ 0.2, 0.3 Molecule E Distance Å 
Glu8 Cα, Cγ 0.3, 1.0 Met 0 Cα, Cγ, Sδ 2.8, 6.3, 7.8 
Lys9 Cα, Cγ 0.3, 2.5 Trp1 Cα 2.3 
  His2 Cα 1.3 
Molecule B Distance Å Thr3 Cα 1.2 
Ala -1 Cα 5.2 His4 Cα, Cβ 1.1, 1.4 
Met 0 Cα, Cγ, Sδ 3.2, 8.1, 8.8 Ser5 Cα, Cβ 0.7, 0.9 
Trp1 Cα 2.7 Glu6 Cα, Cγ 0.5, 0.8 
His2 Cα 1.4 Arg7 Cα, Cγ 0.5, 0.9 
Thr3 Cα 1.2 Glu8 Cα, Cγ 0.6, 1.3 
His4 Cα, Cβ 1.3, 1.7 Lys9 Cα 0.4 
Ser5 Cα, Cβ 1.0, 1.2   
Glu6 Cα, Cγ 0.7, 1.3 Molecule F Distance Å 
Arg7 Cα, Cγ 0.7, 0.9 Glu6 Cα 0.5 
Glu8 Cα, Cγ 0.6, 1.3 Arg7 Cα 0.5 
Lys9 Cα, Cγ 0.5, 2.8 Glu8 Cα 0.5 
  Lys9 Cα 0.6 
Molecule C Distance Å   
Met0 Cα, Cγ, Sδ 2.5, 6.7, 8.1 Molecule G Distance Å 
Trp1 Cα 2.4 Arg7 Cα 0.1 
His2 Cα 1.4 Glu8 Cα 0.6 
Thr3 Cα 1.2 Lys9 Cα 0.2 
His4 Cα, Cβ 1.2, 1.6   
Ser5 Cα, Cβ 0.8, 1.0 Molecule H Distance Å 
Glu6 Cα, Cγ 0.6, 0.4 Trp1 Cα 2.0 
Arg7 Cα, Cγ 0.6, 0.9 His2 Cα 1.0 
Glu8 Cα, Cγ 0.6, 1.2 Thr3 Cα 0.7 
Lys9 Cα 0.5 His4 Cα, Cβ 0.4, 0.5 
  Ser5 Cα, Cβ 0.3, 0.5 
Molecule D Distance Å Glu6 Cα, Cγ 0.2, 0.2 
Ala-1 Cα   5.4  Arg7 Cα, Cγ, Nε 0.3, 0.5, 2.5 
Met0 Cα, CE, Sδ 3.3, 8.1, 8.7 Glu8 Cα, Cγ 0.4, 1.1 
Trp1 Cα 2.7 Lys9 Cα 0.4 
His2 Cα 1.5   





As the fragment F6 contains a thiophene moiety, it has anomalous scattering attributes due to the 
sulfur atom.  This made it feasible to run an anomalous map on the collected dataset after molecular 




All eight copies of the protein in the asymmetric unit have either one or both binding pockets free 




Figure 3.14: Eight molecules make up the asymmetric unit of the protein crystal. The asymmetric unit of each molecule is colored 
in green, whereas the generated neighboring crystal mates within 4 Å of the asymmetric unit are shown in yellow. The residues
at the N terminus until the mutated tryptophan residue Trp1 are highlighted in orange, the Thr50 is highlighted in blue, and the 
two phenylalanine residues separating the binding pockets are highlighted in pink. Four protein molecules (a,b,c,d) have the 
binding pocket where the Phe107 of PEX5 binds free, while the other pocket where the Trp103 of PEX5 binds is blocked by the 
Trp1 of the neighboring crystal mate. Two molecules (e,f) have the Trp103 pocket free, and the Phe107 pocket is blocked by a 
Thr50 residue of the neighboring crystal mate. Two molecules (g,h) have both binding pockets unoccupied. 
Figure 3.13: Superimposition of the crystal structure of 
E1W PEX14 in complex with F6 (green, PDB: 6S7M) and 
the generated anomalous map shows a clear anomalous 
signal in the same position where the sulfur atom of F6 












The electron density in the binding pockets of PEX14 seen in protein molecules A, B, D, F, and G 
suggests that the fragments could be binding in the pockets (Figure 3.15). Additionally, their planar 
structure with the aromatic system would fit into the hydrophobic pocket and gives a negatively 
polarized π system capable of forming an interaction with the positive Arg25 seen in some cases 
beneath the electron density of the bound fragment. However, when the fragments were built into 
the electron density, they had very high B factors and their exact orientation could not be clearly 
resolved even after consecutive rounds of structural refinements. Therefore, they were not added into 
the final structure.  
F6 Molecule 1 
The first molecule of F6 (Figure 3.16a) binds in protein molecule A at an occupancy of 98%, where it 
forms a hydrogen bond between its carboxylic acid moiety and the nitrogen atom of Lys36/A (2.9 Å), 
and the backbone nitrogen of Ala42/A (2.7 Å). F6 forms another hydrogen bond to Lys36’/C of the 
neighboring crystal mate (2.8 Å), and a π-π stacking with the F6 from the neighboring crystal mate (4.2 
Å). It also stacks against Lys62/A. The bound fragments are shown with their 2m|Fo|-|Fc| density map 
in green which is contoured at a standard sigma level of 1σ, hydrogen bonds are shown as yellow 
dotted lines, and distances are in Å.  
F6 Molecule 2 
The second molecule of F6 (Figure 3.16b) binds in protein molecule B at an occupancy of 100%, where 
it forms a hydrogen bond between its carboxylic acid moiety and the nitrogen atom of Lys36/B (2.8 Å), 
and the backbone nitrogen of Ala42/B (3.0 Å). F6 forms another hydrogen bond to Lys36’/D of the 
neighboring crystal mate (2.8 Å), and a π-π stacking with the F6 from the neighboring crystal mate (4.0 
Å). It also stacks against Lys62/B. The bound fragments are shown with their 2m|Fo|-|Fc| density map 
in green which is contoured at a standard sigma level of 1σ, hydrogen bonds are shown as yellow 
dotted lines, and distances are in Å. 
F6 Molecule 3 
The third molecule of F6 (Figure 3.16c) binds in protein molecule C at an occupancy of 100%, where it 
forms a hydrogen bond between its carboxylic acid moiety and the nitrogen atom of Lys36/C (2.6 Å), 
and the backbone nitrogen of Ala42/C (3.0 Å). F6 forms another hydrogen bond to Lys36’/A of the 
neighboring crystal mate (2.8 Å), and a π-π stacking with the F6 from the neighboring crystal mate (4.1 
Å). It also stacks against Lys62/C. The bound fragments are shown with their 2m|Fo|-|Fc| density map 
in green which is contoured at a standard sigma level of 1σ, hydrogen bonds are shown as yellow 
dotted lines, and distances are in Å. 
F6 Molecule 4 
The fourth molecule of F6 (Figure 3.16d) binds in protein molecule D at an occupancy of 100%, where 
it forms a hydrogen bond between its carboxylic acid moiety and the nitrogen atom of Lys36/D (2.6 Å), 
and the backbone nitrogen of Ala42/D (3.0 Å). F6 forms another hydrogen bond to Lys36’/B of the 
neighboring crystal mate (2.9 Å), and a π-π stacking with the F6 from the neighboring crystal mate (4.0 
Å). It also stacks against Lys62/D. The bound fragments are shown with their 2m|Fo|-|Fc| density map 
in green which is contoured at a standard sigma level of 1σ, hydrogen bonds are shown as yellow 







F6 Molecule 5 and 6 
The fifth molecule of F6 (Figure 3.16e) binds in protein molecule E at an occupancy of 100% and the 
sixth molecule of F6 binds in protein molecule H at an occupancy of 100%. Both fragment molecules 
form a π-π stacking to each other (3.9 Å).  F6 molecule 5 forms a hydrogen bond between its carboxylic 
acid moiety and the nitrogen atom of Lys36/E (2.5 Å), and the backbone nitrogen of Ala42/E (3.0 Å). It 
also forms another hydrogen bond to Lys36/H (2.8 Å). F6 molecule 6 forms a hydrogen bond between 
its carboxylic acid moiety and the nitrogen atom of Lys36/H (2.7 Å), and the backbone nitrogen of 
Ala42/H (3.6 Å). It also forms another hydrogen bond to Lys36/E (2.6 Å). The bound fragments are 
shown with their 2m|Fo|-|Fc| density map in green which is contoured at a standard sigma level of 






Figure 3.15: The eight independent protein molecules A (a), B (b), D (c), F (d), G (e), and H (f) have electron densities near the 
Phe17 and Phe34 residues that separate the hydrophobic binding pocket, suggesting that F6 could also be binding. The 
fragments were left out of the final structure due to high B factors after refinement and the electron density being unclear 
for concluding the fragment orientation. The 2m|Fo|-|Fc| density map is shown in blue contoured at a standard sigma level 


















Figure 3.16: One fragment molecule is found in each of protein molecule A (a, pale green), B (b, blue), C (c, magenta), and D(d, 
yellow). Two fragment molecules are found stacking against one another in protein molecules E and H (e, E in salmon, H in 
orange). The interactions found for all fragment molecules are very similar where they form hydrogen bonds between their 
carboxylic acid moieties and the nitrogen of Lys36, and backbone nitrogen of Ala42. Additionally, the fragments stack against
Lys62 and form a second hydrogen bond to Lys36 of the symmetry equivalent crystal mate, or in the case of molecule E and H 
to the neighboring protein molecule. With the exception of the two fragment copies that stack against each other in protein 
molecules E and H (e), all other four fragment copies stack against the fragment of the symmetry equivalent mate (images a –
d, colored in wheat). An overview of the fragment binding positions is shown in (f). The bound fragments are shown with their 
2m|Fo|-|Fc| density map in green which is contoured at a standard sigma level of 1σ, hydrogen bonds are shown as yellow 





All crystal forms discussed above can be transformed into the other by applying a specific matrix, which 
includes a shift of the crystal origin. The matrices for transformation are listed in Table 3.7, and an 
image depicting the origins of the crystal forms is also shown.  
 
 
Table 3.7: A list of the transformation matrices that can be applied to transform one crystal form of PEX14 to the other. 
Transformation a Original Matrix Matrix Applied to 
Transform 
crystal form 5 to crystal form 1  (1.0, 0.0, 0.0, 0.0 
 0.0, 1.0, 0.0, 0.0 
 0.0, 0.0, 1.0, 0.0 
 0.0, 0.0, 0.0, 1.0) 
 
(-1.0, 0.0, 0.0, 20.9 
-0.0, -1.0, 0.0, 18.3 
0.0, 0.0, 1.0, -1.1 
0.0, 0.0, 0.0, 1.0) 
 
crystal form 6 to crystal form 5 (1.0, 0.0, 0.0, 0.0 
 0.0, 1.0, 0.0, 0.0 
 0.0, 0.0, 1.0, 0.0 






(0.1, -1, -0.0, 3.1 
 -1.0, -0.1, -0.0, 92.5 
 0.0, 0.0, -1.0, 191.7 
 0.0, 0.0, 0.0, 1.0) 
 
 






The mutated E1W residue at the N-terminal proved to be an obstacle in crystallization, despite 
selecting a residue far from the binding pocket. It appears that the small size of the construct yields 
crystals with crystal mates in proximity, and because of the hydrophobicity of tryptophan, it binds into 
the binding pockets of its neighboring crystal mates. These crystals are easily influenced by the 
fragment used to soak them, as seen by the fragment hit F6 where the fragment has lowered the 
symmetry of the crystals and suggested a setting within an alternative space group (Figure 3.11).  
As fragment soaking with the E1W PEX14 variant proved to be difficult, the more probable construct 
to work with for fragment soaking appeared to be the wild-type construct that bears a glutamate 




crystal form 5 crystal form 1 










In drug discovery, virtual screening (VS) is a computational approach used to search databases of 
compounds to find those that are most likely to bind to a drug target with a known structure either 
from X-ray crystallography or NMR, or high confidence homology models.134,135 The databases to be 
searched may contain up to millions of available compounds, and can be obtained from commercial 
libraries, public libraries, or commercial vendors. In VS, there are two broad categories; ligand-based 
(LBVS) and structure-based (SBVS) approaches. In LBVS, a set of known active compounds are used as 
a reference to define and subsequently identify candidate compounds. This approach includes 
similarity searching, quantitative structure-activity relationships (QSAR), pharmacophores, as well as 
3D shape matching.136 In SBVS, the 3D structure of the biological target is used as the reference to dock 
the candidate molecules and give them a rank based on how well they fit into the binding site.137 
3.3.2 Screening Methodology 
 
In the VS performed here, we used a combination of LBVS and SBVS utilizing several tools which include 
Scorpion138 (DesertSci), Anchor Query139, PocketPicker140, LIQUID, KNIME (The Konstanz Information 
Miner)141, as well as CATS light 2142,143  (Chemically Advanced Template Search) for molecular similarity 
search and DOGS144 (Design of Genuine Structures). 
The first part of the performed screen included the following steps: 
I. Scorpion.5 This online server was used to rank the protein-ligand interactions of a published 
PEX14 ligand, compound 2 (PDB:5L87, Figure 3.17a) and the protein-fragment interactions 
of the fragment hit (PDB:6S6R) to assess which moieties, in terms of anchors, are important 
for binding. 
II. Anchor Query.139 These anchors were then used individually to screen a database of MCR 
reactions that synthesize compounds possessing moieties with similar properties 
(pharmacophore search). The outcome of this screen with the fragment anchor was 250 
compounds, while the ligand anchor gave 500 compounds. 
III. PocketPicker140 & LIQUID (structure-based drug design). Pocket Picker is a grid-based 
detection that detects pockets on the surface of the protein. The PEX14 receptor was used 
here after removing all solvent molecules and ligands. “VirtualLigand”, an accompanying 
program, was then used to project pharmacophoric properties of the detected pocket 
residues into this receptor pocket, creating a “LIQUID” model of the protein pocket or a 
pseudo pharmacophore. This “LIQUID” is a set of descriptors that was then used to screen 
the ACC library, which is a library compiled from several available databases being Asinex 
Elite, Asinex Fragments, Asinex Gold + Platinum Collections, ChemBridge SC Collection, 
Enamine Advanced, Enamine HTS Collection, Specs Natural Products, and Specs Screening 
Compounds. This resulted in 2,000 molecules matching these descriptors. To ensure that all 
our compound data sets were defined using the same descriptors, the compounds from 
Anchor Query were also converted into LIQUID descriptors. 
IV. KNIME.141 KNIME was used to compare the distances (RMSD) between compounds from the 
screenings, and the original LIQUID model to assess which compounds were most similar to 







The second part of the screen: 
V. CATS142,143 (Ligand based drug design). CATS takes an input ligand and describes it using a set 
of descriptors called CATS. The published ligand, compound 3 (PDB: 5N8V, Figure 3.17b) with 
a Ki of 0.207µM129 was used. These CATS descriptors were also used to define the compounds 
from the first part of the screen. 
VI. KNIME.141 KNIME was used to compare the distances (RMSD) between the compounds and 
the published ligand compound 3 (PDB: 5N8V) ligand, to assess which of these compounds 
are most similar to the ligand. This was done as a cross validation of the Anchor Query results 
and PocketPicker. 
VII. DOGS.144 DOGS uses an input ligand (in our case we used the same ligand, compound 3) to 
suggest de novo design methods for synthesizing similar compounds. This screen gave 432 
compounds. 
The third part of the screen: 
VIII. Docking in MOE.145 All compounds were docked into the PEX14 receptor pocket after 
removing duplicates (10 poses each, rigid docking). The compounds were then filtered by 
visual inspection of the best binding poses. 
52 compounds were selected, and after filtering based on Lipinski RO5146, 28 compounds 
were selected for purchase based on the number of carbon-carbon double bonds, compound 
flexibility, and conformation (Table 3.8).  
Additionally, we also ran Haddock2.2147 from Utrecht University to study whether docking the E1W 
PEX14 variant monomer against itself would predict the energetics of the mutated tryptophan upon 
binding into the pocket of the other monomer. The result showed that there are some energy penalties 
to some of the other monomer residues, but the tryptophan residue docked into the binding pocket 
















Table 3.8: Chemical structures of the selected compounds for PEX14 binders found through a combination of SBVS and 
LBVS. 



































































3.3.3 Determining apparent KD and IC50 using 2D NMR and AlphaScreen 
 
3.3.3.1 SOFAST HMQC 2D NMR Screening 
 
The 28 purchased compounds suggested by the virtual screening campaign, in addition to lead 
compound 1 (Scheme 3.1), were screened in a SOFAST HMQC 2D NMR measurement to record their 
binding. The compounds leading to significant chemical shift perturbations were then measured with 
a SOFAST HMQC titration (Figure 3.18) to determine their apparent KD (Table 3.9).  SOFAST HMQC 
(selective optimized flip angle short transient heteronuclear multiple quantum correlation)148 allows 
recording of 2D 1H-15N correlation spectra of our protein. The protein used was the E1W PEX14 variant 
expressed and purified to have 15N labelling (further details can be found in the Materials and Methods 
of this chapter).  The ligands were added to the protein and spectra were recorded.  
 
 
Figure 3.18: SOFAST HMQC spectra of labelled PEX14 with the VS compounds. The 1H-15N correlation spectra that show 
pronounced shifts between protein alone (blue) and protein with the ligand (red) indicate ligand binding to the protein, as 





3.3.3.2 AlphaScreen Assay and 2D NMR Titrations 
 
AlphaScreen-based Competition Assay 
The AlphaScreenTM (Amplified Luminescent Proximity Homogenous Assay Screen) is a method to 
measure biological interactions and estimate affinities. It relies on the use of “Donor” and “Acceptor” 
beads that are bioconjugated with the protein and another molecule. In our experiment, the His-
tagged PEX14 was associated with a Nickel chelate Acceptor bead, while a biotinylated high affinity 
PEX5-derived peptide ALS (ALSENWAQEFLA)129 was associated with the Streptavidin-coated Donor 
bead.  If an interaction occurs between the protein and peptide, it will bring the two beads close 
together which starts a series of chemical reactions and produces a signal. Upon laser excitation at 680 
nm, the oxygen from ambient air is converted to a singlet state by a photosensitizer in the Donor bead. 
This excited singlet oxygen reacts with a chemiluminescer in the Acceptor bead which activates 
fluorophores that emit light at 520–620 nm (Figure 3.19a).149 If the compounds being tested bind to 
PEX14-associated Acceptor beads, the high-affinity peptide on the Donor beads will no longer be close 
to the Acceptor beads and the recorded signal will drop. The level of the recorded signal is then plotted 




We measured the NMR hits from the VS campaign in this orthogonal AlphaScreen-based assay 
described in the literature129 to obtain IC50 values for the discovered compounds. IC50 values are given 
in Table 3.2. VS 25 gave the highest IC50 value in our AlphaScreen and so was also measured in an in 
vitro trypanocoidal cell-based assay to give an IC50 of 18.5 µM, a promising value for a VS compound.  
 
 
SOFAST HMQC NMR Titrations 
The strength of a protein-ligand complex can be defined by a single quantity that sums its stability or 
its reciprocal – the dissociation constant (KD): KD= [P][L]/[PL]. This dissociation rate depends on the 
concentration of the bound ligand as well as the strength of the binding interaction.150 Protein-ligand 
complexes (except high-affinity ligands) coexist in solution in equilibrium with significant amounts of 
free protein and/or free ligand151. In titration NMR, the concentration of the unbound protein will 
gradually decrease upon increasing concentrations of the ligand, while the concentration of the bound 
a b
Figure 3.19: a) Scheme showing how the AlphaScreen functions (source of image from procomcure.com). A singlet oxygen 
released from the Donor bead diffuses across to the Acceptor bead where it is responsible for setting off a cascade of 
reactions that result in a light signal emitted, indicating an interaction due to close proximity of the two beads. b) Plot of the 






protein increases. This is reflected in the gradual movement of the NMR peak, which is the average of 
the bound and unbound states, towards the fully bound state. This is the concept we utilized in our 
experiments, assuming our ligands are in fast-exchange and form a 1:1 complex.  
Five out of the 28 VS ligands produced pronounced chemical shifts (in addition to lead compound 1 
(Scheme 3.1). Their SOFAST HMQC spectra were recorded at eight different concentrations and a fixed 
concentration of the protein. The chemical shifts of both, the 1H and 15N of our protein residues 
(relative to chemical shifts of blank measurements) at each ligand concentration were noted. An 







The weighted chemical shifts (Δδ) of each residue were then calculated by the following equation, 
accounting for the different weights of 15N and 1H chemical shifts (Equation 3.1).152  
 
 
Δδ/[L]0 is then calculated by dividing the Δδ at the ligand concentration. 
 
Using Scatchard Plots, the Δδ/[L]0 is then plotted against the Δδ as seen in Figure 3.21 to give a linear 
plot where the gradient = -1/KD  and x-intercept = Δδmax, based on (Equation 3.2).150  
       
 
The apparent KD values calculated from the Scatchard plots after removing anomalies, are given in 
Table 3.9.  
a b
Figure 3.20:  a) A strong chemical shift can be observed in the 2D correlation plot of lead compound 1 at consequently increasing 
concentrations from 0 mM until 1.5 mM (only 0 mM, 0.125mM, 0.375 mM, 0.75mM, 1mM, 1.5mM are displayed for clarity), 
where the y-axis representing the 15N and the x-axis representing the 1H chemical shifs are not displayed.  b) A chemical shift can 
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Figure 3.21: Scatchard plot where Δδ/[L]0 is plotted against the Δδ to give a linear line where the slope equals -K; the 






























VS 7 1578 ± 56 638 ± 155 















VS 19 2115 ± 96 487 ± 132 
VS 3 2331 ± 48 1875 ± 545 
























a) For our VS compounds are plotted below, where VS 25 gave the highest IC50 value and was measured in an in-vitro 
trypanocoidal assay to give an IC50 of 18.5µM. The SOFAST HMQC correlation plot spectra for each compound are also shown. 
3.3.4 Co-crystallization of Ligands  
 
The most potent VS compounds from the NMR titrations VS 19 and compound 1 were screened against 
almost 1500 conditions to find possible co-crystallization conditions. The co-crystallization screening 
of both compounds led to the common condition listed in Table 3.10. This condition was used to co-
crystallize also the other VS compounds from Table 3.2. High resolution data sets (1.25 - 1.90 Å) were 
collected for all the compounds, with the exception of VS 14, VS 16, and VS 17, as upon addition of 
these ligands to the protein during co-crystallization, the protein did not crystallize. However, even the 
X-ray structures collected for the VS compounds that did crystallize, did not show any difference 
electron density indicating the bound compounds. 
Table 3.10: Co-crystallization screen of the compound 1 and VS 19.a 
Compound Temp. Salt Buffer Precipitant Protein: Ligand 
Co-crystal 
Image 






Citrate pH 5.6 











Citrate pH 5.6 















It seems that the ligands are not potent enough to support co-crystallization and to assemble in formed 
crystals. In reported cases where ligands were co-crystallized with PEX14, the least potent compound 
which was a result of an optimized VS hit, had a Ki of 12.3 µM129, supposedly having a higher potency 
than the compounds studied here, where the most potent compound had a KD  above 450 µM. 
  
Nevertheless, the VS ligands somehow aid crystallization of the E1W PEX14 variant, as crystallization 
trials using the same crystallization conditions in the absence of any of the VS ligands does not yield 
any crystal formation. The obtained “VS ligand influenced” crystal form 5 has slightly different unit cell 
dimensions than the crystal form 1 we previously used for soaking, and thus were used for further 
fragment screening, as discussed in section 3.2.4. 
 
3.4 Crystallizing the Wild-Type  
 
3.4.1 Crystallization Screening  
 
A crystallization screen was set up for the wild-type construct, which resulted in only one reproducible 
hit out of almost 1500 conditions. The reproduced crystals differed in their morphology to the 
screening hit, where the latter gave a ‘shower’ of crystals meaning many crystals grew in the well 
resulting in very thin needles (Figure 3.22). As suggested in literature and applied earlier, 5% glycerol 
was added to the reservoir solution to reduce nucleation and crystal growth, which resulted in larger 
crystals thick enough for fishing and testing at a microfocus beamline.  





Protein Concentration Buffer Salt Precipitant Temperature 
Wild-Type 
PEX14 
95mg/ml 0.1M Trisodium 
Citrate pH 5.5 
none 40% PEG 600 
(+5% Glycerol) 
4°C 
a b c 
Figure 3.22:  Images of the a) original crystallization hit of the wild-type PEX14 and the b) reproduced crystals which grow in 






The wild-type PEX14 crystal was soaked in a soaking solution consisting of the crystallization solution, 
100 mM of compound 1, and 25% glycerol for 19 hours. The diffraction data of the crystal suggested a 
setting of the crystal symmetry in the monoclinic P21 space group with four molecules in the 
asymmetric unit (PDB: 6S9Y). The data was refined to a resolution of 1.64 Å, but no electron density 
could be seen for compound 1 (crystal form 7, Figure 3.23). 
 
Another dataset for the wild-type PEX14 was collected from a crystal that was not exposed to a ligand 
to be soaked. The diffraction data suggested a setting of the crystal symmetry in the orthorhombic 
space group C2221 with two molecules in the asymmetric unit. After structural refinement of the 
dataset, we noticed that both the Rwork (27.9%) and the Rfree (32.1%) values were in the high range for 
the collected resolution. Additionally, the average B-factor of the protein molecule A was 23.1 Å2, 
whereas the average B-factor of the protein molecule B was 33.3 Å2, which is almost twice. This made 
us question whether the data was processed in the correct space group.  To validate the chosen space 
group, the dataset was processed in the lowest symmetry space group P1 and the XDS_ASCII.HKL file 
from processing was run in XPREP153 to search for higher symmetry space groups. The practical 
processing statistics of all space groups, the dataset was processed in, are shown in Table 3.12. XPREP 
is a program used to analyze the symmetry of the data and to merge the reflections according to the 
space group found.  The output from XPREP is shown in Figure 3.24. The monoclinic P lattice with the 









Unit Cell Dimensions 
a b c α β γ 




4 molecules/ asymmetric unit 
Figure 3.23: Crystal of the wild-type PEX14 soaked in compound 1 yields a structure in P21 space group with four independent 
molecules in the asymmetric unit (A, green, B, blue, C, magenta, D, yellow), where compound 1 does not appear to bind. No 






Table 3.12: The data processing statistics after processing in three different space groups.a 
a) Data in parenthesis indicates the highest resolution shell.  
 
The processing in P21 gave the most promising statistics, and Matthew’s coefficient analysis suggested 
that four molecules in the asymmetric unit and 40.2% solvent content in the crystal, as well as three 
molecules in the asymmetric unit and 55.17% solvent content were the most likely states. Molecular 
replacement (MR) was performed using the MTZ file from the P21 processing with three molecules in 
the asymmetric unit. The solution from MR gave three molecules; A, B, and C. For molecules A and B, 
the average B factors were comparable (23.3 Å2 and 23.9 Å2, respectively) but for molecule C it had 
slightly higher values (32.7 Å2). Additionally, the built molecules had several overlapping residues which 
suggested an incorrect MR solution.  To check the correctness of this MR solution, the PDB file from 
MR was run in the program ARP/wARP 154 which is used to build macromolecular models in the electron 
density map. Only 56% of molecule A could be built into the electron density (residues Val23 until 
Glu60), and 20% of molecule B (residues Leu40 until Gly53). None of the residues of molecule C could 
be built.   
Despite better R-sym values of the dataset after processing in the P21 solution, the MR solution was 
not correct based on the results from ARP/wARP. Therefore, we proceeded with the original data 
processed in orthorhombic space group. This higher symmetry space group cannot be excluded for 
PEX14, as C2221 is in fact a supergroup of P21. The MR solution of two molecules in the asymmetric 
Space group C2221 P1 P21 
R-sym (%) 6.5 4.1 4.8 
R-sym (%) highest resolution shell 34.1 31.4 36.8 
R-sym (%) lowest resolution shell 2.8 1.8 2.1 
Completeness 96.7 (93.6) 82.5 (73.0) 93.6 (85.9) 
Multiplicity 6.1 1.9 3.3 
Resolution 1.93 Å 1.90 Å 1.90 Å 
Figure 3.24: Screenshot from the output of XPREP, showing the space groups of higher symmetry suggested for the dataset 





unit was tested in ARP/wARP 154, which built the entire protein molecule A in the electron density but 
was only able to build half of protein molecule B. Due to the poor dataset, the resulting electron density 
shows disorder for this second protein molecule. The obtained crystal structure (crystal form 8) can be 
seen in Figure 3.25, where the protein molecule B has also been built in for visualization purposes of 




This crystal form was soaked again in a higher concentration of the lead compound 1 at 143 mM, for a 
longer time of 23 hours. This yielded a crystal structure of the wild-type PEX14 in complex with 
compound 1, which will be described in section 3.5.1. 
 
3.4.2 Wild-Type Crystals Optimization 
 
3.4.2.1 Screening Around Buffer Components 
 
To improve the stability of the wild-type crystals when soaked in fragment solutions, systematic 
attempts to optimize the crystallization conditions were performed included screening around buffer 





Unit Cell Dimensions 
a b C α β γ 








2 molecules/ asymmetric 
unit
Figure 3.25: Crystal structure of the wild-type PEX14 at a resolution of 1.93 Å revealed two molecules in the asymmetric unit 
corresponding to the orthorhombic space group C2221. Protein molecule A was fully resolved in the electron density whereas 
protein molecule B was only partially resolved. The first resolved residue is Ser5 which indicates that even Glu1 from the wild-















a) This included screening around the buffer concentrations, buffer pH, precipitant concentration as well as addition of 
glycerol, to control crystal growth rate.2 
 
Another optimization screen included adding varying concentrations of salt to the crystallization 
conditions as seen in Table 3.14 . 
Table 3.14: Varying concentrations of salt in addition to varying concentrations of the components in our crystallization 
conditions. 
 
The optimization screening yielded crystals in some cases but did not seem to improve stability of the 
wild-type crystals. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
 1 2 3 4 5 6 
A       
B       
C       
D With and without 3% Glycerol 
E       
F       
G       
H       
%PEG600 
0.1M Trisodium Citrate 
1 2 3 4 5 6 7 8 9 10 11 12 
pH 4.5 pH 5.5 pH 4.5 pH 5.5 
A 45% PEG 600 
25mM NaCl 25mM NaCl 75mM NaCl 75mM NaCl 
B 50% PEG 600 
C 55% PEG 600 
D 60% PEG 600 
E 45% PEG 600 
50mM NaCl 50mM NaCl 100mM NaCl 100mM NaCl 
F 50% PEG 600 
G 55% PEG 600 
H 60% PEG 600 
                                       PEG600 
0%                                                                                  50%  
0.01 M 
 1 M 
       0.1M Trisodium Citrate               











3.4.2.2 Thermal Shift Analysis (TSA) 
 
To determine whether wild-type PEX14 was stable under the different buffer conditions, we applied 
TSA to screen for stabilizing effects on the studied protein. The concept of TSA is monitoring the 
thermal denaturation of protein in different conditions. This is done through incubating the folded 
protein with SYPRO Orange and systematically increasing the temperature. In case of stabilization this 
can give rise to a ‘thermal shift’ towards higher unfolding temperature and hence quantifies the 
stabilization of the protein in different buffers. The observed thermal shift is recorded by the change 
in fluorescence resulting from SYPRO Orange. Upon unfolding, the hydrophobic core of the protein 
becomes exposed to the solvent and the hydrophobic SYPRO Orange dye binds to the protein. A shift 
in the fluorescence peak and hence ‘thermal shift’ indicates whether the unfolding temperature of the 
protein indicates increasing stabilization in the studied buffer condition.155 We ran the experiments 
with the wild-type protein but could only observe a very noisy plot. When repeating the experiments 
with the E1W PEX14 variant, the plots were not noisy but they lacked any fluorescent peaks, and thus 
no differences in the thermal stability of the protein could be observed (Figure 3.26). As our 
experimental set up worked with other proteins like endothiapepsin, we attributed the inconclusive 
plots of PEX14 to the small size of the protein (only three alpha helices of 66 amino acids) and its 
hydrophobic nature, which would not produce any visible differences in the observed fluorescence 
upon unfolding, as has been reported with other small proteins that unfold in a two-state transition 
without having any detectable intermediates.156 
 
 
Figure 3.26: Melting plots produced from the thermal hift analysis of wild-type PEX14 at different concentrations (a) and (b) 
show only a noisy baseline, whereas the melting plots c) and d) of the E1W PEX14 variant show no signal, which indicates no 
observable differences with PEX14. This may be attributed to the small size of the PEX14 protein, with only three alpha helices 
and its hydrophobic nature which may not produce any visible differences upon unfolding of the protein from its quaternary 
structure.  
6mg/ml Wild-Type PEX14 28mg/ml Wild-Type PEX14 








3.4.2.3 Dynamic Light Scattering (DLS) for Stable Buffers 
 
DLS is a technique that is used to determine the size distribution profile of small particles in a 
suspension, as well as polymers in a solution.157 We used DLS to screen for another buffer that the 
wild-type protein would be more stable in, thus improving chances of finding promising crystallization 
hits. Thanks to Patrick Walter from the Pasteur Institute, the results of DLS revealed that the protein 
was already quite stable in its storage buffer (5 mM Tris pH 8, 150 mM NaCl) as seen in Figure 3.27a. 
Another buffer that gave a slightly more stable protein was 20 mM MES pH 6 and 300 mM NaCl as seen 
in Figure 3.27b. After performing a buffer exchange, a new crystallization screen of over 800 conditions 
for the wild-type protein resulted in a single hit (60 mg/mL of protein, 0.1 M Tris pH 8, 0.2 M Calcium 





Figure 3.27:  DLS measurements of the wild-type protein in its original storage buffer (top) showed that the protein was already 
monodispersed and stable. Upon screening the protein in different buffers, a second buffer was found to also keep the protein
particles monodispersed and stable (bottom). 
5mM Tris pH 8, 150mM NaCl 

















































3.4.2.4 Additives  
 
Our final attempt at optimizing the wild-type crystals for soaking, was using additives. We ran a screen 
using TEW [TeW6O24]6- (Tellurium-Centered Anderson-Evans Polyoxotungstate) (Figure 3.29), a 
technique reported in literature to facilitate crystal lattice formation by mediating and stabilizing 
crystal contacts by electrostatically cross-linking protein monomers.158   
We set up two crystallization plates, one with TEW added at a concentration of 2 mM to the protein, 
and the other plate with only protein. In addition to the TEW, the crystallization drops were set up in 
a way to allow screening around the crystallization conditions (Table 3.15). However, TEW did not 
enhance our crystallization. In fact, small crystals could be observed in the plate without TEW whilst 
the plate with TEW gave no crystals. In the case of the wild-type PEX14 it appears that TEW somehow 
















 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Figure 3. 28: Polyhedral (a) and ball and stick (b) representation of [TeW6O24]6−. Different coordination modes of the oxygen 













15% PEG600                                                             45% PEG600 
Table 3.15:  Crystallization screening conditions of wild-type PEX14 in the absence and presence of 2 mM of TEW. 
a b 
Figure 3.29: Image of the same crystallization 






3.5 Wild Type with a Bound Ligand  
 
3.5.1 Soaking of Wild Type Crystals 
 
As discussed above, trials to optimize the wild type crystals were not successful, and several attempts 
to yield crystals of the mutated PEX14 construct with unblocked binding pockets lead us to slightly 
different crystal forms, all of which did not have completely accessible pockets. The crystal structure 
of the wild type PEX14 proved to be more suited for fragment screening as it has unblocked binding 
pockets, which allowed it to accommodate compound 1 through soaking.  
 
3.5.2 Wild Type PEX14 in Complex with a Lead Compound  
 
We succeeded in resolving a structure of the wild-type PEX14 with a ligand, somewhat larger than 
fragments, which proves the suitability of the studied wild-type crystal form for soaking as it harbors 
solvent channels large enough for a ligand to diffuse into the crystal. To keep wild-type crystals as 
stable as possible during soaking and avoid mechanical damage that could occur upon transferring the 
crystals into soaking solutions, the DMSO stock of our lead compound 1 was added directly into the 
well with the wild-type crystals at a final concentration of 143 mM, for 23 hours. 
A dataset of 1.83 Å of the wild-type crystal in complex with our synthesized lead compound 1 (Scheme 
3.1) was collected. The compound 1 results in a crystal with two molecules in the asymmetric unit for 
which the diffraction data suggested a setting of the crystal symmetry in the orthorhombic space group 
C2221. After structural refinement of the dataset, we noticed that both the Rwork (27.9%) and the Rfree 
(33.0%) values were in the high range for the collected resolution, with a large gap of 5.1% between 
the values. Additionally, the average B-factor of the protein molecule A was 21.3 Å2, whereas the 
average B-factor of the protein molecule B was 37.7 Å2, which is almost twice as large. This made us 
question whether the data was processed in the correct space group. To validate the chosen space 
group, the dataset was processed in the lowest symmetry space group P1 and the XDS_ASCII.HKL file 
from processing was run in XPREP 153 to search for higher symmetry space groups. The practical 
processing statistics of all space groups the dataset was processed in are shown in Table 3.16. XPREP 
is a program used to analyze the symmetry of the data and to merge the reflections according to the 
space group found. The output from XPREP is shown in Figure 3. 30. The monoclinic P lattice with the 














Table 3.16: The data processing statistics of wild-type PEX14 in complex with compound 1 after processing in three different 
space groups.a 
 
a) Data in parenthesis indicates the higher resolution shell. 
 
The processing in P21 gave the most promising statistics, and Matthew’s coefficient suggested four 
molecules in the asymmetric unit and 39% solvent content in the crystal. MR was performed using the 
MTZ file from the P21 processing with four molecules in the asymmetric unit. The solution from MR 
gave four molecules; A, B, C, And D. For molecules A, B, and C the average B factors were comparable 
with molecule C having slightly higher values. For molecule D however, the B factors were significantly 
higher, suggesting an incorrect solution. MR was performed again but three molecules instead were 
searched for in the asymmetric unit. The solution gave three molecules in the asymmetric unit; A, B, 
and C. The B factors were comparable for all three molecules with molecule C having slightly higher B 
factors (molecule A 14.5 Å2, molecule B 17.9 Å2, molecule C 26.2 Å2). Despite better R-sym values of 
the dataset after processing in the P21 solution, refinement in PHENIX (simulated annealing : Cartesian, 
and XYZ coordinates) of the MR solution did not give a clear electron density for the binding ligand, so 
Space group C2221 P1 P21 
R-sym (%) 10.8 4.9 6.8 
R-sym (%) highest resolution 
shell 49.6 39.3 45.1 
R-sym (%) lowest resolution 
shell 5.4 2.4 3.4 
Completeness 98.9 (97.8) 76.3 (77.7) 91.0 (93.2) 
Multiplicity 4.5 1.6 2.6 
Resolution 1.83 Å 1.8 Å 1.8 Å 
Figure 3. 30: The space groups of higher symmetry suggested by XPREP for the dataset, based on the calculated R-sym value. 






we proceeded with the original data processed in orthorhombic space group. This is similar to the apo 
structure of the wild-type PEX14 described earlier in section 3.3.4, which was also processed in the 
higher symmetry space group.  To check the correctness of the MR solution which gave two protein 
molecules – A and B - in the asymmetric unit, the PDB file from MR was run in the program ARP/wARP 
154 which is used to build macromolecular models in the electron density map. ARP/wARP built the 
entire molecule A in the electron density but due to the poor dataset quality, it was only able to build 
half of molecule B, due to disorder in molecule B. This disorder was not seen in the refined structure 
due to model bias. For molecule A however, the electron density shows a completely resolved protein 
molecule in addition to the electron density seen for compound 1 binding to molecule A. Figure 3.31 
depicts the binding mode of the lead compound 1 to the binding pockets of molecule A (crystal form 
9).   
Superimposition of the structure of the wild-type in complex with compound 1 and the original 
fragment hit obtained from soaking the E1W PEX14 crystal form 1 as seen in Figure 3.32 shows the 
agreement between the benzimidazole moiety of compound 1 and the indole moiety of F5. The 
synthesized compound 1 is flipped in comparison to the fragment hit so that the phenyl ring of F5 
overlays with the imidazole of compound 1, and the phenyl ring of compound 1 overlays with the 
pyrrole of F5 (Figure 3.31). The overlay of the bicyclic systems however is preserved which fixes the 









Unit Cell Dimensions 
a b c α β γ 







Figure 3.31: First crystal structure of the wild-type PEX14 in complex with a ligand – compound 1. a) The ligand binds in the binding 
pocket that usually becomes occupied by Trp103 of PEX5. b) The benzimidazole moiety of the ligand forms a hydrogen bond (3.5 Å) 
between one of its nitrogens and the carboxylate of Asp20. The carboxamide of the ligand also interacts with the terminal nitrogen 
of Lys38 (3.9 Å). The ligand is shown with its 2m|Fo|-|Fc| density map in green which is contoured at a standard sigma level of 1,
hydrogen bonds are shown as yellow dotted lines, and distances shown are in Å. The phenylalanine residues separating the 
hydrophobic pockets are shown in pink. The chemical structure of lead compound 1, unit cell dimensions, space group, and number 
















3.6 Materials and Methods 
 
3.6.1 Protein Expression and Purification  
 
3.6.1.1 Wild-Type and Mutated T. brucei N-His-PEX14 (19-84) 
The E. coli cells BL21-CodonPlus (DE3)-RIPL (Cam r) were transformed with the plasmid vector pETM-
11 (EMBL) of interest (either the wild-type or E1W T. brucei N-His-PEX14 variant (19-84) provided by 
the group of Prof. Dr. Michael Sattler, HMGU Munich and incubated in a pre-culture of 125 mL LB 
medium containing 30 mg · L-1 kanamycin for 17 h at 37 °C and 220 rpm. In addition to kanamycin 
resistance, the plasmid contained a sequence encoding for an N-terminal 6xHis-tag® separated from 
the PEX14 start codon by a spacer sequence and a sequence encoding a TEV protease cleavage site. 
The pre-culture was added to 6 × 1 L main culture (ZY auto-induction159 medium including 100 mg . L-
1 kanamycin, 1 mg. L-1 thiamin, and 1 mg. L-1 biotin) which is incubated at 37 °C and 220 rpm until an 
OD600 of 0.6-0.8. and moved to a 20°C shaker overnight. The cell pellets were harvested by 
centrifugation (9,000 rpm at 4 °C for 8 min.) and re-suspended in 250 mL lysis/TRIS buffer (50 mM TRIS 
pH 8, 20 mM imidazole, 300 mM NaCl, 0.5 mM TCEP and 2 cOmplete™-Protease Inhibitor Cocktail 
Tablets (Roche) per 1.5 L of bacterial culture). Cell disruption was achieved via an EmulsiFlex-C5™ high-
pressure homogenizer (Avestin Europe GmbH). The lysate was clarified by centrifugation 
(centrifugation speed 19,000 rpm, 45 min, 4 °C). Purification of the protein was achieved at room 
temperature by a two-step purification including affinity chromatography and size-exclusion 
chromatography (SEC). The protein was loaded onto an affinity chromatography prepacked NiNTA 
column (HisTrap HP 5 mL column from GE Healthcare) that had been equilibrated with 5 column 
volumes of elution buffer (50 mM TRIS pH 8, 250 mM imidazole, 300 mM NaCl, 0.5 mM TCEP) followed 
by 10 column volumes of TRIS buffer. After loading the protein onto the column,  the column was 
washed with 5% of elution buffer, and the protein was eluted with 100% elution buffer.  The collected 
protein was checked for purity in an SDS gel, diluted with TRIS buffer in a 1:1 ratio, and the buffer was 
exchanged to remove imidazole using room temperature dialysis overnight (50 mM TRIS pH 8, 1 mM 
EDTA, 150 mM NaCl, 0.5 mM TCEP). The following day the protein was spun down to remove any 
precipitation and the protein concentration was measured. In a fresh dialysis buffer, 1 mg TEV protease 
Figure 3.32: Superimposition of the wild-type 
compound 1 complex (purple) and the original fragment 
hit F5 obtained from soaking the E1W PEX14 crystal 
form 1 (cyan). The benzimidazole moiety of compound 
1 overlays with the indole moiety of F5 but rather than 
the phenyl rings of both compounds overlaying, the 
superimposition is flipped so that the phenyl ring of F5 
overlays with the imidazole of compound 1, and the 







was added per 10 mg protein and left to cleave for 3 hrs at room temperature. Separation of the 
cleaved protein and His tag was achieved using a reverse NiNTA column equilibrated with 5 column 
volumes of TRIS buffer. The cleaved protein was eluted with 100% TRIS buffer and purified into 
crystallization buffer (5 mM TRIS pH 8, 150 mM NaCl, 0.5 mM TCEP) using a Superdex75 SEC column 
for the final purification step. The fractions containing PEX14 protein were then concentrated in a 
VIVASPIN®20 centrifugal concentrator (Sartorius, MWCO = 3,000) until a final concentration of 
approximately 16 mg · mL-1. Finally, the protein was flash frozen into aliquots of 100 μL and stored at -
80 °C. 
Pierce BCA Protein Assay 
For measuring the concentration of the wild-type PEX14, as it lacks any intrinsic fluorescence, the 
Pierce™ BCA (bicinchoninic acid) Protein Assay was used as indicated by Thermo Scientific™. This assay 
is based on the colorimetric detection and quantitation of total protein. It combines the reduction of 
Cu2+ to Cu+ by protein in an alkaline medium (the Biuret reaction) with the selective colorimetric 
detection of the cuprous cation (Cu+) using bicinchoninic acid. The chelation of two molecules of BCA 
with one cuprous ion produces a complex which gives the purple-colored reaction product of the assay. 
This complex exhibits a strong absorbance at 562nm nearly linear with increasing protein 
concentrations over a broad working range (20-2000 µg · mL-1). Protein concentrations are determined 
with reference to standards of a common protein bovine serum albumin (BSA).160 
3.6.1.2 15N labelled E1W T. brucei N-His-PEX14 (19-84) 
 
The isotopically labelled protein produced for NMR and also used in the AlphaScreenTM was prepared 
in a similar manner but expressed in a P-5052 minimal media159 and with an additional 3 mg. L-1 DNAse, 
3 mg. L-1 AEBSF.HCL, and lysozyme powder in the lysis buffer. Affinity chromatography was performed 
using a gravity-flow NiNTA column using the same buffers as the non-labelled PEX14, and the cleavage 
step was omitted as the His-tag is needed in AlphaScreen. The final purification was done using a 
Superdex75 SEC column using the NMR buffer (20 mM sodium phosphate pH 6.5 and 50 mM NaCl). 
3.6.2 Crystallization 
 
T. brucei E1W PEX14 crystal form 1 crystals were crystallized at 4°C using the sitting-drop vapor 
diffusion methods. 1.5 µL of protein were mixed with 1.5 µL of reservoir solution in the wells of a 
crystallization plate containing 550 µL of reservoir solution, where the protein concentration and the 
reservoir solution used varied, as has been previously discussed in detail in section 3.2. T. brucei E1W 
PEX14 crystal form 5 crystals were crystallized at 18°C using the sitting-drop vapor diffusion methods 
in presence of the VS ligands. 1.5 µL of the incubated protein and ligand solution (1 mM protein: 20 
mM ligand) were mixed with 1.5 µL of reservoir solution in the wells of a crystallization plate containing 
550 µL of reservoir solution (0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6, 25.5% PEG 
4000, 15% glycerol). Crystals and cocrystals were soaked for a time ranging between 4 hours and 16 
hours into a solution containing fragment or ligand solution (dissolved in 100% DMSO) in a soaking 
solution consisting of the reservoir solution with an additional 25% glycerol for cryoprotection. Crystals 
were directly flash-frozen in liquid nitrogen and stored for synchrotron data collection. Data collection 
and refinement statistics are described in the Appendix (Table 6 – Table 8). The diffraction data were 
indexed, scaled, and merged using XDS90 and XDSAPP.91 Molecular replacement from the program 
PHASER MR92 from the CCP4 suite93 was used to determine all crystal structures. Arcimboldo161 was 
used to create the model file using model helices from the PDB structure 5AON. In the refinement, a 
5% subset of all reflections was omitted during refinement to be used for Rfree calculation. Model 





simulated annealing with default parameters was used as a first refinement step for all the structures. 
This was followed by refinement of XYZ coordinates and occupancies of protein residues and fragments 
(with the exception of water molecules whose occupancies were fixed). In the case of protein residues 
that gave additional density, they were refined in double confirmation and kept if their refined 
occupancy was ≥ 20%. %. The structure of E1W PEX14 in complex with F5 (PDB: 6S6R) was refined 
anisotropically except for water molecules. The structure of E1W PEX14 in complex with F6 (PDB: 
6S7M) was refined isotropically with 30 TLS groups. The structure of wild-type PEX14 (PDB: 6S9Y) was 
refined isotropically with 6 TLS groups. The crystal structures of the un-soaked wild-type PEX14 and 
the structure of the wild-type PEX14 in complex with compound 1 contained unresolved motifs in the 
second protein molecule. Because they do not meet the criteria for PDB depositions, they were not 
deposited. Chemicalize96 developed by ChemAxon97 was used for name-to-structure generation and 
SMILES code notation. The ligand PDB and restraint files were generated with the Grade Web Server.98 
3.6.3 NMR Conditions 
 
All NMR 1H-15N correlation spectrum experiments were performed at 298K on a Bruker Avance 600 
MHz NMR spectrometer equipped with a cryogenically cooled probe head. Automatic sample changing 
was accomplished with a SampleJet system. NMR samples were prepared for screening in a buffer 
consisting of 20mM sodium phosphate pH 6.5 and 50 mM NaCl, 10% D2O, 100 µM of 15N labelled 
PEX14, and 1 mM of VS ligand (50 mM stock in d6-DMSO). A blank sample was prepared with the 
equivalent volume of DMSO instead of the ligand. For the titration experiments, samples were 
prepared in the same way but at different ligand concentrations of 0.125 mM, 0.25 mM, 0.375 mM, 
0.5 mM, 0.75 mM, 1 mM, 1.25 mM, and 1.5 mM. A liquid handling pipetting robot Gilson was used to 
fill 3mm NMR tubes in a SampleJet rack. A SOFAST HMQC pulse sequence with Watergate W5 water 
suppression162 (SFhmqcf3gpph) was used, with an interscan delay of 0.3 s and 16 scans. Shift 
perturbations between DMSO blanks and ligand samples were calculated with Pythagorus’ theorem. 
Since the measurement range (7–9 ppm) of observations of 1H is approximately one-tenth of that (105–
124 ppm) of 15N 163, the 15N chemical shifts were scaled one-tenth relative to 1H chemical shifts.  
3.6.4 AlphaScreen-based Competition Assay Conditions 
 
Experiments were carried out in a 96-well plate where 20 μL of DMSO were added to the first column 
while the rest of the wells were filled with 12.5 μL. In the first well of each row, 5 μL of 50 mM DMSO 
ligand stock solution were added. Serial dilutions were carried out by transferring 12.5 μL from each 
well to the next in every row, and discarding the volume from volume 11, leaving the final column with 
no compound. To every well, 200 μL of assay mixture (prepared by mixing 40 mL of AS Buffer 
(consisting of 0.250 mg of BSA, 50 mL of 1XPBS buffer, and 50 µL 10% Tween20), 48 µL AS donor beads, 
48 µL AS acceptor beads, 1.2 µL ALS  (0.1mM) biotinylated PEX5-derived peptide (ALSENWAQEFLA), 
and 12 µL 100 µM 15N labelled T. Brucei PEX14) were added and incubated for 1 hour at room 
temperature in dark conditions. Each well reaction was divided into 4 to fill a 384-well white Optiplate 
and measured as quadruplicates in an EnVision plate reader. The resulting curves were analyzed with 








3.6.5 Trypanocidal Assay 
 
Anti-trypanosomal activity of compound VS 25 was tested against the bloodstream form (BSF) of T. 
brucei brucei using resazurin-based 96-well plate assay.165 Two-fold serial dilutions of VS 25 were 
prepared in 96-well plates in HMI-11166 or SDM-79 medium167 (10 wells per row). As controls, one well 
was left without addition of any compound and one well contained only media. Into all the wells 
(except the well with only media) 100 μL of parasite cultures (4x103 · mL-1 BSF) were inoculated and 
the final concentration of parasites was 2x103· mL-1.The plates were then incubated for 66 h followed 
by addition of 25 μL resazurin (0.1 mg· mL-1 in Hanks Balanced Salt Solution) and the plates were further 
incubated to a total of 72 h. Reduction of resazurin by the living cells was quantified by measuring the 
fluorescence with Synergy™ H1 microplate reader (excitation 530 nm, emission 585 nm). The 
background fluorescence of the well with only media was subtracted and the percent survival values 
were calculated by setting the fluorescence of the well without any compound to "100% survival". 
GraphPad Prism (version 6.04) was used to plot non-linear regression graphs and the from the resulting 













The following chapter is the preparation of a manuscript to be submitted. 
The first STD NMR experiments were performed by Boeringer Ingelheim in a previous collaboration 
(Schiebel. J. et al., 2015). 
The second STD NMR experiments were performed in collaboration with Charlotte Softley from the 
group of Prof. Dr. Michael Sattler during an academic scientific secondment at the Helmholtz Zentrum 
in Munich, Germany. The analysis of the NMR spectra was done by Charlotte Softley and the author of 
this thesis. 
The WaterLOGSY NMR experiments were performed by Charlotte Softley. The analysis of the NMR 
spectra was done by the author of this thesis. 
Buffer exchange of endothiapepsin and its crystallization was done by the author of this thesis, in 
addition to the soaking experiments, structural refinements, and analysis of results.  
The SPR screen was done by the author of this thesis in collaboration with Dr. Stefan Geschwindner, 
and the deuterated versus non-deuterated STD NMR experiments and the images of their spectra used 
in this thesis were done by Dr. Per-Olof Eriksson during a scientific academic secondment at 
Astrazeneca R&D in Gothenburg, Sweden. 
As part of a previous project, the X-ray crystallography cocktail experiments were done by Dr. Johannes 
Schiebel and Helene Koester, structure refinements and detailed analysis for cocktails A, B, C, and D 
were done by Dr. Nedyalka Radeva, and autorefinement for the remaining cocktail sets was done by 
Dr. Johannes Schiebel. Refinement of cocktail L was done by Dr. Johannes Schiebel. The NMR cocktail 
experiments for cocktail sets A, B, C, D, and E, were done by the author of this thesis and Charlotte 
Softley during the academic scientific secondment. The NMR cocktail experiments for cocktail sets F, 
G, H, I, J, K, L, M, and N were done by Charlotte Softley. The comparative analysis for all cocktail sets 
and the structural refinements of cocktails E, F, G, H, I, J, K, M, and N were done by the author of this 
thesis. 
ITC measurements to determine binding affinities of the X-ray fragment hits were done by Dr. Johannes 
Schiebel as part of a previous project (Schiebel. J. et al., 2016). 
















4.1.1.1 Family  
 
Endothiapepsin belongs to the family of pepsin-like aspartic proteases. This class of enzymes is 
responsible for the hydrolytic cleavage of peptide substrates in vertebrates, fungi, plants, and viruses. 
Aspartic proteases gain their name from their conserved aspartic acid residues where the cleaving 
takes place by utilizing a catalytically activated water molecule.168 Endothiapepsin is an A1 subfamily 
aspartic protease from the chestnut blight fungus (Cryphonectria or Endothia parasitica), and has an 
acid pH optimum.169 It is often used in cheese production as a fungal rennet due to its lactic coagulation 
properties.170 Owing to the high degree of similarity between endothiapepsin and other 
pharmacologically relevant aspartic proteases, it has served as the model enzyme for studying the 
mechanism of aspartic proteases 171,172 as well as for the development of antihypertensives (inhibitors 
of renin)173 and treatment of Alzheimer’s disease (inhibitors of β-secretase)174. Additionally, 
endothiapepsin is pursued as a surrogate for drug targets in malaria (plasmepsins), cancer (cathepsin 
D), and AIDS (HIV1 protease (human immunodeficiency virus type 1) protease)).168  
 
4.1.1.2 Structure of Endothiapepsin 
 
Endothiapepsin is a monomer of 330 amino acids and has a molecular mass of 33.8 kDa. It crystallizes 
in space group P21. Its active site is rather large and covered by the so-called flap region. This region 
must open to give access for a substrate or ligand to enter the binding pocket and in most cases closes 
again upon their binding. Endothiapepsin has nine binding pockets in its active site (Figure 4.1) as listed 
below. 
1- S1’ pocket: surrounded by Ile300, Ile302, and Ile304. 
2- S2’ pocket: surrounded by Ile77, Leu133, and Phe194.  
3- Adjacent S3’ pocket: exhibiting Ser78, Tyr79, and Gly80. 
4- S2 pocket: surrounded by Thr222, Thr223, and Tyr226.  
5- S3 pocket: surrounded by Ile10, Ala16 and Ile122 and partially covered by the flap region.  
6- Adjacent S1 pocket: surrounded by Tyr79, Phe116 and Leu125.  
7- Solvent exposed S4 pocket. 
8- Solvent exposed S5 pocket. 











4.1.2 Characterization of Binding Using Orthogonal Biophysical Methods 
 
In previous work done by other members from our group to identify and characterize endothiapepsin 
binders, X-ray crystallography was consulted as a primary screening method and its hit identification 
potential or power was compared to several biochemical and biophysical screening methods which 
included high-concentration biochemical screens (HCS), microscale thermophoresis (MST), thermal 
shift assay (TSA), saturation transfer difference nuclear magnetic resonance (STD-NMR), reporter 
displacement assay (RDA), and native electrospray ionization mass spectrometry (ESI-MS) assay.175 The 
fragment library screened was designed for general purposes and contained 361 entries. Further 
details of this fragment library design have been described in Chapter 1. The entire library was first 
screened against endothiapepsin via a fluorescence-based assay (HCS), resulting in a hit rate of 15%. 
The obtained hits from HCS had then been analyzed crystallographically using cocktails of two, which 
resulted in a hit rate of 20% of the original HCS hits.10 The question that was raised at this point was 
whether an alternative screening method would have indicated similar promising hits to be followed 
up in a subsequent crystallographic study.176 This led to the consequent study of the hit rates using the 
aforementioned screening methods. The fragment library was also screened as individual soaks on 
separate crystals of endothiapepsin, resulting in a hit rate of 20%, much higher to that obtained by 
two-entry cocktail screenings done as a follow up to the HCS screen, which gave only 3% of the entire 
library. The analysis and comparison of these cocktails with the individual soaking experiments 
demonstrated that the use of cocktails in crystallography to accelerate hit identification often leads to 
loss of hits, not to mention the detrimental impact of using a prescreening assay like the HCS which 
had missed out on 70% of the individual soaked X-ray hits.175  
To understand the reason behind the low overlap of hit rates found in the aforementioned screening 
techniques, we decided to prioritize two of these screening techniques to analyze in closer detail the 
underlining differences between them and the obtained fragment hit rates. We did this by selecting 
the 71 fragment hits detected by individually soaked crystals for X-ray crystallography175 and 
rescreened them again with STD NMR under slightly different buffer conditions, in addition to 
Figure 4.1: Surface representation of endothiapepsin with its binding pockets represented as spheres. Hydrophobic pockets 
are colored in orange, hydrophilic ones in blue, and amphipathic ones in purple. The catalytic site consisting of the conserved 





WaterLOGSY NMR experiments. It is worth mentioning that 44% of these 71 X-ray hits were not 
detected by any of the previously mentioned biophysical screening approaches.175 The outcomes of 
these additional screens will be discussed in the coming sections.  
In addition to this comparative analysis, we added a new biophysical screen that was not analyzed in 
the previous studies, which was SPR. Thus, in this work we also screened the entire 361 fragment 
library with SPR, adding another biophysical method for our comparative hit rate analysis to give us 
further insight and understanding of which conditions are crucial to maintain while transferring across 
different techniques. Further details of this SPR screen are given in section 4.3. 
 
4.2 Fragment Screening using Water LOGSY and STD NMR 
 
The sequential NMR screening that we describe here was performed on only those confirmed 71 X-ray 
hits. These 71 fragments were screened with both Water LOGSY and a second slightly different STD 
NMR. The second STD NMR was a single fragment screen, rather than a cocktail screen, and a different 
NMR buffer was used. This was to test whether different experimental settings would yield similar 
results. In a previous STD NMR screen, 206 out of 361 fragments in our fragment library were initially 
screened176, thus leaving out 155 fragments. These 155 fragments were deemed either impure (HPLC 
MS purity ≥ 80%), poorly soluble (500µM), or prone to aggregation (self STD intensity <2% at 500µM), 
which is why they were left out of the initial STD NMR screen.176 When the 206 fragments were 
screened, they were studied as cocktails of two compounds and 71 hits were detected. 22 of these 
STD NMR hits were confirmed as active-site binders in a competitive displacement assay with a potent 
active-site ligand namely, ritonavir. Interestingly, an additional 8 hits were found only in the presence 







First STD NMR Screen
Fragments excluded Non-Binders Active-Site Binders Non-Active-Site Binders
8 only detected in presence 
of ritonavir. 2/8 also detected 
in X-ray crystallography.
12/22 also detected in 
X-ray crystallography.
Figure 4.2: A pie of pie chart indicating the total number of fragments screened in the first STD NMR. 206 fragments were 
screened, 135 of which were non-binders (blue) and 71 were binders (yellow). 155 fragments were excluded from the screen 
(gray). From the 71 binding fragments (yellow), 22 were active-site binders (green) and 49 were non-active-site binders 
(orange). Amongst the non-active-site binders, 8 were detected only in the presence of the potent active-site ligand ritonavir, 







The entire 361 fragment library was also screened with X-ray crystallography. This resulted in 71 hits. 
The number of hits is purely coincidental, as the hits detected in both methods are not the same (Figure 
4.3). 
Upon comparison of the hits, it was found that 12 of the 22 STD NMR hits were also detected as hits 
by crystallography. As for the additional 8 STD NMR hits found only in the presence of ritonavir, only 2 
of these were also detected as hits by crystallography. It is worth mentioning that 33 of the excluded 
fragments from the initial STD NMR screen were detected as hits by crystallography. Soothingly, 19 of 
these were detected as hits in the second STD NMR discussed here.  
In the coming sections we will discuss the sequential NMR screening that was performed on only the 
71 X-ray hits. This includes both a second STD NMR screen as well as a WaterLOGSY screen.  
 
 
4.2.1 Fragment Hit Rate with WaterLOGSY 
 
The 71 fragment hits detected by X-ray crystallography were screened by WaterLOGSY NMR. The 
concept of WaterLOGSY (Water-Ligand Observed via Gradient SpectroscopY) relies on the partial 
transfer of the magnetization of bulk water to the free ligands in solution via the protein-ligand 
complex. The resonances of free non-binding ligands appear in the spectra with an opposite sign to 
the resonances of the interacting ligands.177 By comparing the signs of the ligands with and without  
protein addition, the interacting ligands and thus hits can be identified. The number of hits in 
WaterLOGSY was 50 fragments, which corresponds to a 70% overlap in the fragments detected by X-
ray. The fragments that were not detected as hits in WaterLOGSY (30%) were also not detected by 















Figure 4.3: A pie chart indicating that from the 361 fragments screened using X-ray crystallography, 290 were non-binders 





Table 4.1: Chemical structures of fragments that were detected as hits in STD NMR but not in Water LOGSY. 
Fragment Chemical Structure Corresponding STD NMR that detected fragment as hit 




Second STD NMR screen 
(absence of salt) S1 pocket (Asp81) 
216 
 
Both initial and second STD 
NMR screens Catalytic Dyad 
306 
 
Both initial and second STD 
NMR screens Catalytic Dyad 
311 
 
Second STD NMR screen 
(absence of salt) S6 pocket (Phe291) 
333 
 
Second STD NMR screen 
(absence of salt) S6 pocket (Phe291) 
 
4.2.2 Comparison of Fragment Hits and Hit Rate with and without Salt in STD NMR 
 
The initial STD NMR screen was performed at a buffer concentration of 50mM CD3COOD in D2O at a 
pH of 4.3, in the presence of 100mM NaCl and 4mM NaN3 which is added as an antibacterial agent.178 
The resulting hit rate was 27% (when considering only the 71 X-ray hits).   
The second STD NMR screen was performed at a buffer concentration of 3mM CH3COOH in H2O at a 
pH of 4.6, in the absence of any salt. The resulting hit rate was 59% of the tested 71 fragments.    
 
Role of Buffer in NMR Sensitivity  
We must keep in mind that the presence of salt in a buffer increases the ionic strength of the solution, 
which can affect the binding interactions between the protein and the fragments. The strength of 
Figure 4.4: Venn Diagram depicting the number of fragment hits overlapping between both STD NMR screens, as well as the 
additional fragment hits of each screen independently. In the first STD NMR screen in green, a total of 19 fragments were 
detected, 14 of which were also detected in the second STD NMR screen in orange. An additional 28 fragments were detected 
in the second STD NMR screen but not in the first, 19 of which were not screened in the first STD NMR due to being deemed 






hydrophobic interactions in the protein will likely increase with increasing ionic strength. The addition 
of salt can also weaken the electrostatic interactions experienced between the ligand and the protein. 
Not only that, but the salt in an NMR buffer can affect the sensitivity of the NMR probes. A buffer with 
salt produces a conductive sample, where the conductivity is a function of both the salt concentration 
and the mobility of the ions in solution.179This electrical conductivity adds a resistance to the coil which 
causes significant reduction in the signal-to-noise ratio.180 Of course solutions buffered with salts are 
required in NMR measurements to keep the pH constant and the macromolecules in a defined 
protonation state, as well as to increase the solubility. But one must also keep in mind the additional 
ions of strong bases or acids that are added to the solution whilst adjusting pH values. When adjusting 
pH values, this is achieved through titration of weak acid with a strong base (HCl) or weak base with a 
strong acid (NaOH).181 These additional ions contribute greatly to the detrimental effect on the 
sensitivity because they are of a high mobility.181 Additionally, buffers with multiple charges reduce 
sensitivity more than buffers with single charges, especially if this translates to an increase in the 
counterion concentration. It has been shown by several researchers that the typical salt concentrations 
of 100-150 mM do decrease the sensitivity advantage of a cryogenic probe head to about a factor of 
two  compared to that of a conventional probe with the same sample182, and they can lead to longer 
pulses and decreased sensitivity.183 That been said, other researchers have reported that this effect is 
seen only at higher concentrations of salt between 200-300 mM. Additionally, as the first STD NMR 
screen in our work was performed in 2.5 mm NMR tubes, the effect is much less significant than if 
performed in a 5 mm tube as the total amount of salt in the sample is less.180 Finally,  the STD signal 
was interpreted as % STD_AV where it was compared to a regular 1H spectrum, and because both 
spectrums are affected just as much by salt, when they are divided to calculated the percentage the 
salt effect cancels out.  
To study this possible effect of salt on fragment binding, we examined fragments that were only 
detectable as binders in the presence of higher salt concentration (higher concentrations of acetate 
buffer, sodium azide, and sodium chloride which contribute more ions of CH3COO−, H+ , Na+, N-3, and 
Cl- ) in the screening buffer, and the fragments that appear to only bind in the absence of this salt. We 
analyzed their predicted charged state at a pH of 4.3 and 4.6, as seen in Table 4.2,as well as the charge 
of the protein. The predicted pKa values of the fragments were calculated using the webserver 
chemicalize.96 Endothiapepsin has a theoretical pI of 4.14 (calculated using Protparam184), which 
suggests that at a pH of 4.3 and 4.6, the protein is likely negatively charged.  As seen from Table 4.2, 
most of the fragments are also charged at a pH of 4.3 and 4.6. This means that the interactions they 
make could either be stabilized or destabilized by the change in salt concentration and thus ionic 
strength in the buffer solution. Additionally, the fragments that were not detected in the first STD NMR 
screen could have been missed due to the loss of sensitivity in the NMR probe as discussed above, 
although unlikely.180 Considering the four fragment hits that could only be detected in the initial STD 
NMR, for one of these fragments – F039 - the reason for its discovery is the use of deuterated buffer 
rather than non-deuterated buffer. The effect of using deuterated or non-deuterated buffers in STD 
NMR will be described in detail in section 4.2.3. As for the other four fragments we believe the reason 
could be due to the described effect of salt on the stability of the interaction between protein and 
fragment. The salt may be stabilizing the fragment binding to endothiapepsin and improving its binding 
efficiency. The presence of salt may be important for fragment solubility in NMR screens but not in X-
ray crystallography where the fragment is soaked at such high concentrations that absence of salt 
supposedly does not affect binding. To trace such dependencies, F236 and F114 were soaked into 
endothiapepsin crystals in a buffer of 100 mM NaCl to compare their binding to the protein in presence 
and absence of high salt concentrations. If the presence of salt in the solution enhances binding to the 
crystal even further, this may be possible to see in terms of achieved fragment occupancy in the crystal 





not see any density for the F114, even at a resolution of 1.15 Å for the collected data set. In addition 
to the effect of NaCl, we wanted to see whether the NaN3 in the first STD NMR buffer was interacting 
with endothiapepsin in a way that would hinder fragment binding. Apo crystals of endothiapepsin were 
soaked in a solution of 125 mM NaN3 and a data set was collected at a resolution of 1.16 Å. No electron 
density could be seen for NaN3 in the resulting crystal structure. Based on the crystal structure at least, 
we can eliminate hinderance of fragment binding by NaN3.  
Table 4.2: Chemical structures and predicted pKa values at pH 4.3 and 4.6 of fragment hits detected in only the first STD NMR 











































74% top species , 
13% bottom 
species. 
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a) pKa values and microspecies percentage were calculated using the server chemicalize.com  
Table 4.3: Chemical structures, binding affinities, and endothiapepsin binding positions of all seven X-ray fragment hits that 
were measured in both STD NMR screens but could not be detected in either of them. 
Fragment Structure Binding affinities 
a 
(Kd in mM) 




>10 Catalytic dyad (S1 and S1')  
56 
 
n. d Surface  
227 
 









1 S3/S5 pocket (Asp119)  
73 
 




Catalytic dyad, S1 pocket 
(Asp81)                                     
S6 pocket (Phe291) 
 





There are fragments that did not show up as hits in either of the STD NMR screens, as seen in Table 
4.3. There are several aspects that could explain this, most apparently is the low binding affinity. As 
seen in Table 4.3, the majority of these fragments - with the exception of fragments 51 and 207 - have 
binding affinities either too low to be quantified or weaker than 10 mM.   
In case of fragments of higher potency like F051 which has a Kd of 1 mM, the crystal structure reveals 
a direct interaction with Asp119 through the pyridine-type nitrogen atom (H-bond distance 2.7 Å). This 
suggests that either the Asp119 or the pyridine ring must be in a protonated state for the binding to 
occur. The calculated pKa of the pyridine-type nitrogen atom is predicted to be 4.09, meaning at a pH 
of 4.3 or 4.6 in equilibrium both the protonated and neutral species are present at a ratio of 35% and 
62%, respectively. With the higher probability of the neutral species being present, it is more likely 
that Asp119 is protonated. Additionally, a glycerol molecule is found at a van der Waals distance from 
the fragment which stabilizes F051 in position (Figure 4.5). In NMR, Asp119 may be deprotonated 
which could explain why F051 does not bind in NMR, in addition to the absence of glycerol in the NMR 
buffer to support fragment stabilization. Another factor that could explain why X-ray fragment hits do 
not show up in NMR is fragment solubility. In X-ray crystallography soaking a crystal in the presence of 
solid material of the fragment is still feasible, whereas in NMR clear solutions with no precipitation are 
preferred. This could be a possible explanation to why F207, with a binding affinity of 4.4 mM, could 




4.2.3 Displacement of Fragments by Reporter Ligands and Vice Versa. 
 
To test whether fragment hits were active-site binders or  non-active-site binders, a displacing 
compound with high affinity was used.185–187 In our experiments, this compound was an active-site 
specific inhibitor, ritonavir, with a Ki value of 15 nM for endothiapepsin (Figure 4.6).188 When ritonavir 
is bound to endothiapepsin, only non-active-site binders will continue to bind while active-site specific 
binders will be competing with the high affinity ligand ritonavir for the binding site.   
In the initial STD NMR screen, a total of 19 fragment hits were selected as binders. When tested in the 
presence of ritonavir, this number dropped to 14. However, we noticed that two of the fragment hits 
in the presence of ritonavir did not bind in the absence of ritonavir, which indicated that the presence 
of ritonavir somehow aided the binding of these additional hits. We also noticed this phenomena when 
Figure 4.5: The binding mode of F051 (PDB: 4Y4X) in the protein crystal shows a hydrogen bond (2.7Å) between the nitrogen 
of the pyrimidine moiety of F051 and the carboxylate of Asp119, suggesting that either the pyrimidine or the Asp119 must 
be protonated. Additionally, the fragment is further stabilized in its binding position by the presence of a glycerol molecule 














analyzing the results of the second STD NMR screen where a total of 39 fragment hits were selected 
as binders but when screened in the presence of ritonavir, the number of fragment hits dropped to 29 
and one of which was only binding in the presence of ritonavir.  Additionally, some fragments that bind 
to the catalytic dyad in the crystal structures obtained by the individual soaks continued to bind even 
in the presence of ritonavir. As ritonavir is an inhibitor smaller than the inhibitor pepstatin189, it still 
leaves some unoccupied sub-pockets in the binding cleft of endothiapepsin. This provides the 
opportunity for additional interaction sites for putative fragments, which can recruit additional 
fragment hits as we observed. To check whether these fragment hits were binding in the unoccupied 
clefts or perhaps to the ritonavir itself, we used crystallography to map the details of the interactions. 
Structures of these fragments in addition to their binding affinities are shown in Table 4.4. In the first 
set of experiments, endothiapepsin crystals, presoaked in ritonavir, were transferred into single 
soaking solutions of the fragments, however the crystal structures revealed only an electron density 
for the fragments with no sign of ritonavir. This made us consider whether the ritonavir was simply 
washed out of the crystals upon transfer into the new solution without ritonavir, rather than being 
displaced by the fragment. To avoid this potential limitation, the presoaked crystals were transferred 
into soaking solutions containing both the fragment to be studied and ritonavir, so that washing out 
of ritonavir is limited. The observed electron densities can be seen in the Figure 4.7– Figure 4.10 below, 
the 2m|Fo|-|Fc| density contoured at a σ level of 1 is colored in green, while the m|Fo|-|Fc| density 
contoured at a σ level of 3 is colored in blue.   
For some fragments, soaking into a solution of both, ritonavir and the fragment, resulted in an electron 
density of only ritonavir. Although it did not explain the result of the STD NMR where the fragment 
was seen to bind in the presence of ritonavir, it was indeed the expected outcome of soaking a 
fragment with such a high affinity reporter ligand like ritonavir. This holds true for F109, F236, F267, 
and F268, as seen in Figure 4.7. For other cases, the fragment manages to bind in the presence of 
ritonavir, and we can clearly fit both fragment and ritonavir into the electron density, which explains 
the results of the STD NMR. This holds true for F216 and F218 where they change their binding mode 
from the catalytic dyad to a new location where usually a PEG molecule can be found in the crystal 
structure obtained from endothiapepsin crystals soaked with the fragment alone. This can be seen in 
Figure 4.8.  Such an active-site fragment displacement of potent inhibitors was also observed by Dr. 
Alexander Metz and Dr. Jan Wollenhaupt with the potent endothiapepsin inhibitor SAP114, (Ki 560 
nM) (personal communication). Simultaneous soaking of SAP114 with a fragment-sized follow-up 
compound resulted in a crystal structure where the initial active-site fragment found in single soaking 
is displaced, but a second copy of the fragment can be seen that binds remotely. This second fragment 
copy binds in the same position where a PEG molecule is often seen in soaked crystal structures of 
endothiapepsin (PDBs 4YCT, 4YCY), and is conserved in soaking with and without SAP114 (Figure 4.9). 
To our surprise, we even found instances where the fragment managed to displace the ritonavir and 
bind instead of it. It is particularly astonishing as a strong binding displacer such as ritonavir with a 
binding affinity of 15 nM can still be displaced by weak binding fragments. This could be due to the 
exposure of the crystals to very high concentrations of the fragments up to 100 mM. But more 
importantly, ritonavir might have a different affinity in the crystal structure than in solution, due to 
packing contacts. This has been studied before with other protein and ligands. A prominent example 
is one where aldose reductase was used to study the extent to which the crystalline state of protein 
affects the binding and affinity of the ligand.190  This was done through a competition experiment 
where two ligands, with different potencies but targeting the same binding site of aldose reductase, 
where added simultaneously to the protein at different concentrations. The ratio of the ligand 
occupancies was measured by X-ray crystallography and by mass spectrometry. The results in solution 
showed a higher occupancy for the ligand with the higher affinity, whereas the results in crystal 





potency is influenced by crystal contacts. Displacement of ritonavir by the fragments is seen with F290, 
F306, and F063 (Figure 4.10). When considering the measured binding affinities of the fragments, there 
appears to be a relationship between the ability of a fragment to displace ritonavir, and its binding 
affinity. We see this displacement for the most potent fragments which are F290, F306, and F063 
whose binding affinities are 0.1 mM, 0.1 mM, and 0.5 mM, respectively. On the other hand, the binding 
affinities of fragments that could not displace ritonavir being F109, F236, F267, and F268, are 1 mM, 
0.6 mM, 0.7 mM, and 3.7 mM, respectively, thus close to the same range of the successful displacers. 
It can be speculated that this results from differences in the affinities experienced in solution and in 
the crystal, or that kinetic effects of the diffusion process in the crystal channels are responsible for 






Table 4.4: Chemical structures of catalytic dyad fragments that were found to bind in the competitive binding experiments in 
the presence of ritonavir. a  
Fragment Structure Binding Affinity (Kd mM) 
Observed Electron Density 






0.6 Fragment and Ritonavir 
218 
 











Figure 4.6: a) Binding position of the potent inhibitor ritonavir (PDB: 3PRS) in endothiapepsin and b) chemical structure. 















(a) Their binding affinities determined via displacement ITC are also listed, in addition to the resulting electron density 












Figure 4.7: Electron densities ( 2|Fo|-|Fc| density contoured at a σ level of 1 in green, |Fo|-|Fc| density contoured at a σ level 
of 3 in blue) of ritonavir seen in crystals soaked in a) F109, b) F236, c) F267, and d) F268. No electron densities for the fragments 
















Figure 4.9: Crystal structure of endothiapepsin 
soaked in a solution of an active site fragment 
(chemical structure shown) and potent inhibitor 
SAP114. The binding of SAP114 in the active site 
displaces the fragment, but a second copy of the 
fragment that binds remotely can still be seen to 
bind. This remote binding site is where a PEG 
molecule is seen in many published endothiapepsin 
structures obtained by soaking. Residues 79 – 83, and 
113 – 118 have been omitted for clarity.  
SAP114 Remotely bound 
fragment copy 
Figure 4.8: Electron densities (2|Fo|-|Fc| density contoured at a σ level of 1 in green, |Fo|-|Fc| density contoured at a σ level 
of 3 in blue) seen in structures of a) F216 where both fragment and ritonavir are binding, and the closest interacting distance 
is 3.16 Å between one molecule of the para-trifluoromethyl benzamidine and the nitrogen of the thiazole in ritonavir. The 
previously reported binding pose of F216 (PDB: 4YCT) can be seen in b) where F216 is in red, binding at the position of 
ritonavir. Additionally, the PEG molecule, also in red, in the original structure can also be seen binding in the position as found 
for the relocated fragment. The structure c) of F218 also shows simultaneous binding of reporter ligand and the fragment, 
and the previously reported binding site of F218 (PDB: 4YCY) shown in d) in magenta binding in the same position as ritonavir 
in the other complex, in addition to the PEG molecule in magenta seen in this structure to bind in the position where the 



































Figure 4.10: Electron densities (2|Fo|-|Fc| density contoured at a σ level of 1 in green, |Fo|-|Fc| density contoured 
at a σ level of 3 in blue) observed in the structures of a), b) F290 occupancy 77%, c), d) F306 occupancy 85%, and e), 
f) F063 occupancy 81%. There is dispersed density seen that is not resolved well enough to fit ritonavir and it 





4.2.4 Comparison of Light Water STD NMR and Heavy Water STD NMR 
 
The second STD NMR experiments were run in non-deuterated water (H2O). It is not uncommon to run 
STD NMR in non-deuterated solvents 191  considering costs of deuterated water, and the fact that 
shorter interscan delays can be used due to faster T1 relaxation in light water. In deuterated water, 
much longer interscan delays   are required to allow for full relaxation of small molecules. Otherwise 
artifacts may arise from ligands that are re-excited before being fully relaxed.  
To rationalize the differences between hits seen by STD NMR experiments and X-ray crystallography, 
we considered the role of protons in non-deuterated water. The concept of STD NMR is based on 
irradiating the protein, NMR transitions of which get saturated, this saturation is transferred from the 
protein to its bound ligand. The effect of the transferred saturation is recorded by directly observing 
NMR signals of the (large) fraction of free, unbound ligand, in typical applications of weak (micro to 
millimolar) interactions. The experiment is performed by applying a low-power irradiation in the region 
of a 1H NMR spectra that covers protein signals but no ligand signals. Through spin diffusion, the 
magnetization spreads quickly throughout the protein and saturates all the protein 1H NMR signals. If 
a ligand is temporarily bound to the protein, its 1H NMR signals also become saturated and upon its 
dissociation this leads to a decrease in the intensity of 1H NMR signals measured from the sample pool 
of screened free ligand in solution. Another experiment is then recorded where the irradiation pulse 
is directed to a spectral region where no protein and ligand atoms exhibit signals, to avoid saturation 
of protein and saturation transfer to the ligand. The first and second spectra are subtracted to yield 
the difference spectrum STD (Saturation Transfer Difference).192   
When magnetization is distributed through the protein by spin diffusion, it does not only saturate the 
1H NMR signals of bound ligands, but also those of water molecules associated with the protein. Once 
exchanged with bulk water molecules these waters can then transfer magnetization to the free ligand 
molecules in solution, which can affect the intensity of the 1H NMR signals measured from the pool of 
free ligands. In consequence, not only the bound ligand is irradiated via the protein, but also to some 
degree the unbound ligand is irradiated in solution.72 The magnetized bound ligand and magnetized 
free ligand molecules will have opposite signs in the 1H NMR signals. There will be a positive sign from 
protein bound ligand, and negative sign from ligand in solution that receives magnetization from the 
water. These signals will either cause attenuation of the NMR signal of interest making it difficult to 
observe it in the 1H NMR spectra, or even cancel each other out leading to false negatives. We can also 
observe false positives from the same phenomena, only in that case there is only a signal coming from 
the free ligand molecule in solution purely obtaining magnetization from protein released water. This 
will be explained in more detail in the discussion section.   
By using heavy water, this should theoretically reduce the aforementioned phenomena, as only a 
negligible fraction of protein spins will be in contact with protonated water molecules.  To test this, we 
selected eight fragments that were hits in crystallography, WaterLOGSY, and SPR but gave either 
ambiguous, weak, or no signals in STD NMR and screened them in light (90% H2O/10% D2O, referred 
to here as third NMR screen)  and heavy (100% D2O, referred to here as fourth STD NMR screen) water 
NMR. We also selected a fragment observed to bind in all assays, and therefore remained unaffected 
by light water, as a control. Only one of these fragments, F039, was screened in the initial STD NMR 
where CD3COOD in D2O was used and it showed up as a hit, however the other fragments were 
excluded from the screening due to inefficient solubility, impurity, or being prone to aggregation.175 






Table 4.5: Fragments selected for STD NMR in heavy water and light water comparison.a 

















Yes Yes Yes Ambiguous Yes 
54 
 
Yes Yes Yes Weak Yes 
63 
 
Yes Yes Yes Weak Yes 
66 
 
Yes Yes Yes Ambiguous Yes 
162 
 
Yes Yes Yes Weak Yes 
189 
 
Yes Yes Yes No Yes 
206 
 
Yes No Yes No No 
286 
 
Yes No Yes Ambiguous Yes 
41 
 
Yes Yes Yes Yes Yes 
 
a) All fragments were detected as hits in x-ray crystallography and SPR, with the exception of F206 and F286 which are not 
detected in SPR. All fragments bind when screened in heavy water STD NMR. 
The collected 1H NMR spectra for the fragments is shown below in addition to the STDD (Saturation 
Transfer Double Difference)193 spectra of the fragments in 90% H2O/10% D2O and 100% D2O buffers. 
The buffer used for the 90% H2O/10% D2O STD NMR was 3 mM CH3COOH at a pH of 4.6, whereas the 
buffer used for the 100% D2O STD NMR was 3 mM CD3COOD at a pD of 5. The fragments were tested 







Fragment 39  
The STDD NMR spectra of F039 in CH3COOH (Figure 4.11 red) shows only one fragment signal at 6.9 
ppm, whereas the spectra in CD3COOD (Figure 4.11 blue) shows two fragment signals at both 6.9 ppm 
and 7 ppm. 
 
Fragment 54  
The STDD NMR spectra of F054 in CH3COOH (Figure 4.12 red) shows weak signals for the fragment. 
However, the spectra in CD3COOD (Figure 4.12 blue) show three strong signals of the fragment in the 




1H 1D F039  
STDD protein and F039 in H2O/D2O 
STDD protein and F039 in D2O 
Figure 4.11: 1H 1D NMR reference 
spectra of F039 and endothiapepsin 
and STDD NMR spectra in CH3COOH 
(red) and CD3COOD (blue). More 
signals can be seen for fragment 039 
in the deuterated solvent (spectra 
region of interest is highlighted in 
pale blue). 
1H 1D F054  
STDD protein and F054 in H2O/D2O 
STDD protein and F054 in D2O 
Figure 4.12: 1H 1D NMR reference 
spectra of F054 and endothiapepsin 
and STDD NMR spectra in CH3COOH 
(red) and CD3COOD (blue). All three 
signals of the F054 in the aromatic 
region can be much more clearly
seen in the deuterated solvent 
(spectra region of interest is 







Fragment 63  
The STDD NMR spectra of F063 in CH3COOH (Figure 4.13 red) shows fragment binding, however the 
fragment signals have a low intensity. The spectra for the same fragment in CD3COOD (Figure 4.13 
blue) shows signals with higher intensity of the fragment binding.  
 
Fragment 66  
The STDD NMR spectra of F066 in CH3COOH (Figure 4.14 red) shows some fragment binding, however 
not all the fragment signals in the region 8 to 7.7 ppm can be seen to bind. The spectra for the same 
fragment in CD3COOD (Figure 4.14 blue) shows higher intensity for the fragment as well as all the 
signals in the region 8 to 7.7 ppm specifically at 8 ppm.  
 
 
1H 1D F063  
STDD protein and F063 in H2O/D2O 
STDD protein and F063 in D2O 
Figure 4.13: 1H 1D NMR reference 
spectra of F063 and endothiapepsin 
and STDD NMR spectra in CH3COOH
(red) and CD3COOD (blue). Signals for 
F063 can be detected in both the non-
deuterated and deuterated solvent 
(spectra region of interest is 
highlighted in pale blue) however the 
signals are more prominent in the 
spectra with the deuterated solvent. 
Figure 4.14: 1H 1D NMR reference 
spectra of F066 and endothiapepsin and 
STDD NMR spectra in CH3COOH (red)
and CD3COOD (blue). Fragment signals
can be seen for F066 in both the non-
deuterated and deuterated solvent 
(spectra region of interest is highlighted 
in pale blue) however all the fragment
signals can only be observed in the STDD 
spectra in deuterated solvent. 
1H 1D F066  
STDD protein and F066 in H2O/D2O 





                                                                                                                                                                                                                                                  
Fragment 162  
The STDD NMR spectra of F162 in CH3COOH (Figure 4.15 red) shows fragment binding, however the 
intensity of the fragment signal at 8.7 ppm is very weak, making it unclear whether it is a signal or 
noise. The intensity of the bound fragment in the STDD NMR in CD3COOD (Figure 4.15 blue) is stronger.  
 
Fragment 189  
The STDD NMR spectra of F189 in CH3COOH (Figure 4.16 red) shows no fragment peaks, indicating that 
the fragment is a non-binder. The spectra for the same fragment in CD3COOD (Figure 4.16 blue) shows 
fragment binding in the region between 8.6 and 7.7 ppm. This could be considered a false negative in 
H2O STD NMR.  
 
 
1H 1D F162  
STDD protein and F162 in H2O/D2O 
STDD protein and F162 in D2O 
Figure 4.15: 1H 1D NMR reference 
spectra of F162 and endothiapepsin 
and STDD NMR spectra in CH3COOH 
(red) and CD3COOD (blue). Both 
fragment signals are clearly 
observed in the spectra of the 
deuterated solvent, whereas the 
non-deuterated solvent spectra 
show one clear fragment peak, and a 
weaker signal difficult to observe 
within the noise of the spectra. 
1H 1D F189  
STDD protein and F189 in H2O/D2O 
STDD protein and F189 in D2O 
Figure 4.16: 1H 1D NMR reference 
spectra of F189 and endothiapepsin 
and STDD NMR spectra in CH3COOH 
(red) and CD3COOD (blue).  







Fragment 206  
The STDD NMR spectra of F206 in CH3COOH (Figure 4.17 red) shows no fragment signals, indicating 
that the fragment is a non-binder. The spectra for the same fragment in CD3COOD (Figure 4.17  blue) 
also shows no fragment binding. It is worth mentioning that F206 was also not detected as a hit in SPR.  
 
Fragment 286  
The STDD NMR spectra of F286 in CH3COOH (Figure 4.18 red) shows no fragment signals, indicating 
that the fragment is a non-binder. The spectra for the same fragment in CD3COOD (Figure 4.18 blue) 
shows a fragment signal at 7 ppm, indicating binding. This is another clear case of a false negative in 
H2O STD NMR.  
 
Figure 4.17: 1H 1D NMR reference 
spectra of F206 and endothiapepsin and 
STDD NMR spectra in CH3COOH (red) and 
CD3COOD (blue). Fragment binding 
cannot be seen in neither deuterated nor 
non-deuterated solvent. 
Figure 4.18: 1H 1D NMR reference 
spectra of F286 and endothiapepsin 
and STDD NMR spectra in CH3COOH 
(red) and CD3COOD (blue). 
Fragment binding can only be seen
in non-deuterated solvent. 
1H 1D F206 
STDD protein and F206 in H2O/D2O 
STDD protein and F206 in D2O 
1H 1D F286  
STDD protein and F286 in H2O/D2O 





4.2.5 Discussion of Comparative Analysis 
 
In addition to STD NMR, the 71 crystallographically discovered fragment hits were also screened by 
WaterLOGSY, which showed the highest correlation with the X-ray hits with a 70% overlap (Figure 
4.19). The sensitivity of WaterLOGSY has been reported to be higher than that of STD NMR194, which 
our studies also confirm. We can also attribute this higher sensitivity to the concept of WaterLOGSY, 
which eliminates false positives and negatives arising from non-deuterated solvents as previously 
discussed.  
In STD NMR, we have a negative NOE (nuclear Overhauser effect) between protein and bound ligand 
since the protein-fragment complex is big and tumbles slowly. On the other hand, we have a positive 
NOE between the water and unbound ligand in solution, since the motion here is much faster. The 
non-deuterated water in the solution that is associated with the protein has received polarization 
when it came in contact with the protein, where it received a negative NOE. When this water is 
released again into the bulk phase, it receives the positive NOE that dominates the magnetization 
transfer between water and unbound ligand in solution. These two processes are responsible for cross 
relaxation in opposite directions and accordingly they may cancel each other out. When the 
experiments are run in deuterated water, the cross relaxation between water and unbound ligand  is 
negligible since most protons in the solution are replaced by deuterium, and thus the magnetization 
transfer between the protein and bound ligand is the dominant effect observed (positive NOE) and this 
leads to a stronger STD effect being observed, and thus more intense 1H NMR signals can be seen in 
the spectra.   
The disadvantages of STD NMR have been described elsewhere, and they include false positives 
resulting from direct irradiation of ligand as discussed in the previous section, as well as false negatives 
resulting from incomplete saturation of protein.72 The variables leading to the difference in hit rates 
between the initial STD NMR and the second STD NMR screen have been discussed in detail, which 
included contributions of using a buffer with high ionic strength, as well as using non-deuterated 
solvents. Additionally, the fact that the initial STD NMR was run using cocktails of two fragments is also 
responsible that some hits were missed.176 Efficiency of screening cocktails in NMR will be discussed in 
section 4.5.  
 
Figure 4.19:  Venn diagram showing a comparison of fragment hit rates of water LOGSY NMR in cyan, the initial STD NMR in 






4.3 Fragment Screening Using Surface Plasmon Resonance 
 
In our previous comparative analysis study175, Surface Plasmon Resonance (SPR) as a prominent 
biophysical method in fragment screening was not included. The reason for this was the difficulty to 
immobilize endothiapepsin to the dextran chip. The theoretical pI of endothiapepsin is  4.14 (calculated 
using protparam184). To immobilize a protein successfully, the pH at which this process takes place 
should be at least one order of magnitude below the pI of the protein (so it can adopt an overall 
positive charge) but above a pH of 3.5 as the carboxylates of dextran on the chip surface have to remain 
negatively charged. For successful immobilization this opens a very small pH window - between 3.5 
and 4.1 - to work with and likely the required charged states are impossible to achieve. To overcome 
this challenge, we decided to use a reversed inhibition assay – the inhibition in solution assay (ISA) 
rather than the classic direct binding assay (DBA). Experimental details are discussed in Materials and 
Methods. 
4.3.1 ISA Methodology  
 
In ISA, a target definition compound (TDC) which is a known active-site binder of the target protein is 
immobilized onto the sensor chip instead of immobilizing the target protein as is done in DBA (Figure 
4.20a). In our experiments we used a potent inhibitor of endothiapepsin, the peptide H-142 195 
(sequence: PHPFHLRVIHK, where R depicts the reduced isostere of the scissile peptide bond between 
residue Leu10 and Val11 in human angiotensinogen) (Figure 4.20b).174  The target (endothiapepsin) 
and the fragments are then incubated together in a 96-well plate and the mixture is injected over the 
TDC immobilized surface. The initial binding rate is used to determine the percentage of free protein 
in solution, in other words the unbound endothiapepsin available in the mixture to bind to the 
immobilized H-142 peptide, which will change depending on the concentration of the competing 
fragment. When the fragment is binding to the endothiapepsin in the mixture, it competes with the 
immobilized TDC for the endothiapepsin active site and the recorded ‘free protein’ signal is decreased. 
This is then recorded as a reduction of the percentage of bound endothiapepsin to the H-142 peptide 
and hence a higher percentage of active-site binding of the fragment to endothiapepsin. This allows a 







Figure 4.20: a) Concept of ISA derived from Geschwindner, S. et al. (2013) where a TDC is immobilized onto the surface of a 
sensor chip, and a solution of fragment and protein is passed over the surface so that the fragment and TDC are in 
competition for the binding site of the protein. b) Structure of peptide H-142 potent endothiapepsin inhibitor with reported 









4.3.2 Fragment Hits 
 
The entire 361-fragment library was screened, resulting in a hit rate of 34%. Hits were considered as 
such giving a percentage inhibition above 3%. This value was determined based on the calculated 
standard deviation of the percentage inhibition measured for the buffer control. The overlapping hits 
between crystallography and SPR were 11% (38 fragments), the highest match in comparison with the 




For the SPR fragment hits that gave a percentage inhibition of at least 50%, the IC50 values were 
determined by running a dose-response curve and plotting the logarithmic fragment concentration 
against the percentage of inhibition (Figure 4.22). The strongest fragment is F177 which was previously 
reported to also be the most potent fragment in other five out of six assays.197 The reason behind this 
has been described in detail in literature197 where it was proven that the reactive nature of this 
fragment causes its oxidization and oligomerization into another compound, making it essentially a 
false positive binder. The Table 4.6 below lists the IC50 values and the previously calculated Kd values 
from ITC175 and IC50 from the reporter displacement assay (RDA)70 where available.  To rule out non-
specific binding of these fragment hits to the TDC, they were injected over the H-142 immobilized 
surface without addition of endothiapepsin and the resulting percentage binding analyzed. The values 
were comparable to those from the buffer controls, so we could confirm that the percentage inhibition 
calculated in the presence of endothiapepsin is due to specific binding to the protein. 
Table 4.6: Overview of the most potent fragment hits by SPR and their calculated IC50s from SPR, as well as previously 
calculated Kd from ITC, and IC50s from the RDA. 
Fragment IC50 µM SPR Kd µM IC50 µM RDA 
177 135  3 
248 526   
306 597 100 40 
79 628   
284 781  260 
290 834 100 40 
255 846 200 1,160 
236 915 600  
149 974  150 
167 1136   
X-Ray Crystallography 
SPR 
38 85 33 
Figure 4.21: Venn Diagram depicting the number of fragment hits overlapping between the SPR and X-ray crystallography screens, 
as well as the additional fragment hits of each screen independently. In the SPR screen in blue, a total of 123 fragments were 
detected, 38 of which were also detected in X-ray crystallography in green. An additional 33 fragments were detected as hits by X-






218 1250 100  
47 1304   
64 1581   
337 1551   
162 1614   
178 1672  230 
148 2088  > 1,300 
159 2294   
65 2544   
334 2958   












Figure 4.22: Plot of log concentration of fragments against their % inhibition. The resulting IC50s were calculated for fragments 










SPR was the method that showed the highest overlapping hit rate with crystallography of 11%, even 
higher than the RDA from our previous study that had a correlation of 8% with the crystallographic 
hits.175 SPR detected 84 additional fragments as hits that were not detected by X-ray crystallography, 
giving SPR a total hit rate of 34% which is quite high. This hit rate, however, does not account for 
unspecific binding that may have occurred between the TDC on the chip surface and the fragments 
themselves, which would also change the recorded signal. Also, a more stringent cut off set to a higher 
threshold than 3% inhibition would reduce the number of hits. For example, setting the threshold to 
10% inhibition would lead to 61 hits, cutting the number of hits by half. The 21 most potent hits, 
however, were tested for unspecific binding, but their specific binding could be confirmed.   
If we analyze the 33 crystallographic fragment hits that were not detected as hits by SPR, we find that 
they all share low binding affinities in common (Table 4.7). There are two fragments that had 
measurable binding affinities below 1.5 mM but were still not detected as hits in SPR. In fact, one of 
them, F051 with binding affinity of 1mM, was not detected by any of the STD NMR screens either due 
to reasons discussed previously in section 4.2.    
 
Table 4.7: Chemical structures of crystallographic fragment hits that were not detected as hits in SPR.a  
Fragment Chemical Structure 
Binding 
Affinity  
(Kd in mM) 
Fragment Chemical Structure 
Binding 
Affinity 











































































a) Their binding affinities determined by ITC are all above 1.5 mM. 
There are 16 fragments in total that were measured and detected as hits in crystallography, the first 
NMR screen, and SPR. Their chemical structures, binding affinities, and binding positions which deviate 
are shown below (Figure 4.23). They are color-coded based on their binding positions. The diverse 
nature of these fragments suggests that there are no cardinal rules that we can use to claim a certain 
moiety or property as transferable across different biophysical methods. We can, however, keep in 







































Highest Overlapping Methods 
As mentioned earlier, the overlap between SPR and X-ray hits was the highest reported, at 11%. The 
second highest overlap between the methods was seen between SPR and RDA hits, at 9%, followed by 
an 8% overlap between RDA and X-ray hits. These three methods are also from the ones that detected 
the highest number of hits, where SPR detected 123 fragments, X-ray detected 71, and RDA detected 
50. The first STD NMR detected 58 hits, which brings the overlap of the first STD NMR and SPR at 7%. 





 Figure 4.23: Chemical structures, binding affinities, and color-coded binding positions of all 16 fragments that were 
detected as hits in crystallography, the first STD NMR, and SPR. The diverse nature of the fragments makes it difficult to 





4.5 Comparison of Cocktail Screening in X-Ray Crystallography vs NMR  
 
4.5.1 Definition of Cocktail Screening 
 
Cocktail screening, whether in the realm of crystallography or NMR, was designed as a technique to 
allow accelerated examination of larger libraries in a reduced time and to enable rapid hit 
identification.198 There are several aspects that must be considered in designing a cocktail experiment 
in crystallography, among these is the structural shape diversity of fragments and the number of 
fragments in every cocktail set.  However, it has been proven in previous fragment screening studies 
that cocktail soaking can miss a great deal of hits due to blurred and fuzzy electron density in the final 
structure, as well as competitive behaviors between the fragments; both which could be avoided by 
single soak experiments.175  
While previous studies have analyzed differences in experimental results between cocktail soaking and 
single soaking crystallography, there is still a need to study differences between fragment detection 
and cocktailing in crystallography in comparison to fragment cocktailing in NMR.  
 
4.5.2 Results & Discussion  
 
In this study, we performed a retrospective STD NMR screen using the same sets of fragment cocktails 
that were used before in a cocktail fragment screening in crystallography to determine whether STD 
NMR could pick up hits in the fragment cocktails with comparable or improved efficiency to 
crystallography.  
All the cocktails tested are composed of fragments previously detected as hits in crystallography with 
the exception of F308, F040, and F142. Additionally, all fragments were detected as hits when screened 
separately by the second STD NMR, with the exception of, F236, F103, F058, F207, F227, F274, F051, 
F236. Additionally, F040 and F142 were excluded from the single fragment screens in the second STD 
NMR but were not found to bind in the first STD NMR either.    
In the figures below, the 1H 1D NMR spectra of the cocktails were compared to the 1H 1D NMR spectra 
of the single fragments, to ensure that the peaks in the cocktail set correspond to the single fragments. 
The STD NMR spectra of the endothiapepsin protein with the cocktail sets were then compared to the 
1H 1D NMR spectra of the cocktail set alone and the 1H 1D NMR spectra of the single fragments thus 
identifying the bound fragments in the STD NMR. An overview of the results is listed in Table 4.8, in 
addition to the chemical formulas of the fragments. For the electron densities of the crystal structures 
in the figures below, the 2m|Fo|-|Fc| density contoured at a σ level of 1 is colored in blue while the 
m |Fo|-|Fc| density contoured at a σ level of 3 is colored in green. For all of the cocktail sets processing 
with the Gaussian multiplication (Gaussian transformation)199, which is done to improve resolution at 
the expense of the signal-to-noise ratio, lead to a spectrum with a noisy baseline and the binding 
signals could not be clearly seen. Therefore, the spectra is displayed only after FT processing. The only 
exception to this is cocktail set D. Additional information regarding fragment binding occupancies in 









Cocktail A – F063, F267, F291  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows binding for F063 (green), 
F267 (violet), and F291 (yellow). In the crystal structure (PDB: 5MB0) all three fragments could be 
clearly assigned to the electron densities. In the individually soaked crystal structures, F063 (PDB 4Y57) 
binds in a different position than that where it binds as part of the cocktail set (Figure 4.38). F291 binds 
as two copies when soaked individually (PDB 4Y45) but when part of a cocktail set, one of these copies 
binds with an RMSD of 0.057 to its original binding position and the second copy binds stacked to F267, 
partially assigned with benzodioxanyl in the S1 pocket instead of pyridine . In the cocktail set, the new 
binding position of F063 would clash with the binding position of the second copy of F291, thus they 
seem to be in competition and F063 binds instead.  F267 binds in the same position when individually 
soaked and when part of a cocktail set.   
 
 
Cocktail B – F224 and F236  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows binding for both F224 (green) 
and F236 (violet). In the crystal structure (PDB: 5MB7), only F236 could be assigned to the electron 




Figure 4.24: a) STD NMR spectra of endothiapepsin and cocktail set shows binding signals for all three fragments in the cocktail 
set. b) The crystal structure shows clear electron densities that can be assigned to F063, F267, and F291.  
Figure 4.25: a) STD NMR spectra of endothiapepsin and cocktail set shows binding signals for both fragments in the cocktail 


























Cocktail C – F103 and F171  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows no binding for any of the 
fragments. It is worth mentioning that F103 also did not show binding in the STD NMR when tested 
individually with endothiapepsin. In the crystal structure (PDB: 5MB5) only F171 could be assigned to 
the electron density where it binds similarly to its original binding position in the individual fragment 
soaking (PDB 4Y3X). 
 
 
Cocktail D – F308 and F333  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows binding for only F333 (violet). 
F308 was also not a crystallographic hit. In the crystal structure (PDB: 5MB6) F333 could not be 
assigned to the electron density.  
Figure 4.26: a) STD NMR spectra of endothiapepsin and cocktail set shows no clear binding for any of the fragments. b) The 
crystal structure shows electron density only for F171, and no visible electron density for F103. 
Figure 4.27: a) STD NMR spectra of endothiapepsin and cocktail set shows binding only for F333. b) The crystal structure 






















Cocktail E – F052, F058, and F063  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show binding for both F063 (yellow) 
and F052 (green). However, there is no clear binding for F058 (violet). F058 did not show binding in 
the STD NMR when tested individually with endothiapepsin. In the crystal structure only F063 could 
be clearly assigned to the electron density, as it seems to win the competition with F052 and F058 for 
the same binding position. 
 
 
Cocktail F – F207 and F261  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show binding for F261 (violet) and 
a signal at 2.5 ppm which may correspond to either F261 or F207 (green).  The spectrum of the cocktail 
set however, does not correspond to the 1H 1D spectra of F207 and may reflect insolubility of F207 in 
the cocktail set, and additional signals around 3 ppm may reflect an impurity in the cocktail set. In the 
crystal structure F207 could be clearly assigned to the electron density, as well as fragments of F261. 
One copy of F261 binds in its original binding position in the Asp81 flap region as seen in the structure 
of the single soaked fragment (PDB: 4Y5B) but the electron density is not sufficient to build the entire 
molecule. F207 and F261 are in competition as F207 binds in the same position as F261 when soaked 












Figure 4.28: a) STD NMR spectra of endothiapepsin and cocktail set shows binding for F063 and F052, but no sign of binding 
for F058. b) The crystal structure shows the electron density for F063 but no clear electron density for F052 and F058 to be 
built in. 
Figure 4.29: a) STD NMR spectra of endothiapepsin and cocktail set shows binding for F261 and a peak that may correspond 














Cocktail G – F216 and F338  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show binding for both F216 (green) 
and F338 (violet). In the crystal structure, F216 could be assigned to the electron density but only a 
fragment of F338, indicating that the F338 may have been in competition with F216 which hinders 
F338 interacting fully with its binding position  
 
 
Cocktail H – F218 and F224  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show binding for only F218 (green), 
albeit only a single peak at 1.5 ppm is clearly from F218. In the crystal structure only F218 could be 
clearly assigned to the electron densities. Several copies bind in different places, one of which pushes 
residues Asp81 to Tyr79 out of their original positions (PDB: 4Y5L).  A total of four copies of F218 could 




Figure 4.30: a) STD NMR spectra of endothiapepsin and cocktail set shows binding for both F216 and F338. b) The crystal 
structure shows a clear electron density for F216 and partial electron density for F338.   
Figure 4.31: a) STD NMR spectra of endothiapepsin and cocktail set shows binding only for F218. b) The crystal structure shows 
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Cocktail I – F227 and F274  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show no binding for either 
fragments. It is worth mentioning that both fragments did not show binding in the STD NMR when 
tested individually with endothiapepsin. In the crystal structure, both F227 and F274 could be clearly 




Cocktail J – F041 and F051  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show only weak binding for F051 
(violet). It is worth mentioning that both fragments did not show binding in the STD NMR when tested 
individually with endothiapepsin. In the crystal structure both fragments could be clearly assigned to 













Figure 4.32: a) STD NMR spectra of endothiapepsin and cocktail set shows no binding for either fragment. b) The x-ray 
structure shows clear electron densities for F227 and c) F274 which bind to a different part of the protein crystal next to the
S1’ S2’ pocket. 
Figure 4.33: a) STD NMR spectra of endothiapepsin and cocktail set shows only binding for F051. b) The crystal structure shows 
clear electron densities for F041 and F051. 
F227 
F274 
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Cocktail K – F162, F236, and F338  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show only binding for F338 (yellow) 
where a signal can be seen at 0.5 ppm (orange spectrum). It is worth mentioning that F236 (violet) did 
not show binding in the STD NMR when tested individually with endothiapepsin. In the crystal structure 
none of the fragments could be clearly assigned to the weak electron density.  
Cocktail L – F063 and F272  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set show only binding for F063 (green). 
As F272 has several peaks that overlap with F063, it could also be that F272 is binding (e.g: peak at 





Figure 4.34: a) STD NMR spectra of endothiapepsin and cocktail set shows binding only for F338.  b) The crystal structure 
shows dispersed electron densities unclear for assigning any of the three fragments. 
Figure 4.35: a) STD NMR spectra of endothiapepsin and cocktail set shows binding for F063 and overlapping peaks of F063 and 
F272 may also indicate binding for F272. b) The crystal structure shows clear electron density for F063 only. 
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Cocktail M – F063 and F268  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows binding for both F063 (green) 
and F268 (violet). In the crystal structure F063 could be clearly assigned to the electron density while 
F268 had a weak and dispersed electron density so could not be built in. 
 
 
Cocktail N – F207 and F240  
The STD NMR spectra (blue) of endothiapepsin and the cocktail set shows no binding for either 
fragment. It is worth mentioning that F207 did not show binding in the STD NMR when tested as 
individual fragments with endothiapepsin. Similar to cocktail N, the spectrum of the cocktail set does 
not correspond to the 1H 1D spectra of F207. This may reflect insolubility of F207 in the cocktail set 
and additional signals at 3 ppm may reflect an impurity in the cocktail set. In the crystal structure both 
fragments could be clearly assigned to the electron density where two copies of F207 bind clearly, one 












Figure 4.36: a) STD NMR spectra of endothiapepsin and cocktail set shows binding for F063. b) The crystal structure shows a 
clear electron density for F063 and a less clear electron density for F268. 
Figure 4.37: a) STD NMR spectra of endothiapepsin and cocktail set shows no binding for either fragment. b) The x-ray 




















STD NMR records the binding properties of a fragment to the protein as a dynamic event and not only 
the final result of the binding event as is the case in crystallography. The temporary binding and 
unbinding of a fragment in NMR make it possible that several fragments can bind consecutively at 
different time points, allowing all of them to experience the magnetization transfer. This eliminates 
drawbacks faced with cocktailing in crystallography as competitive binding between fragments can 
result in poorly defined electron density, making it difficult to assign it to fragments during structure 
refinement.175 Here fragments penetrate simultaneously the solvent channels in the crystal packing 
and assemble at available binding positions on the protein. The efficiency with which the population 
at a site builds up depends on the affinity, but also on the diffusion rate through the channels. These 
can be different and there is possibly a gradient in the fragment occupancy from the crystal’s rim to 
the center. An example of this is F338, for which the electron density in cocktail soaking was weakened 
due to possible expelling by the competitive F216. Therefore, fragment cocktailing in NMR can allow 
detection of fragments binding, even in the presence of direct competition. On the other hand, 
fragments in NMR may have signals at the same value on the ppm scale (if not assembled in a way to 
avoid this) and therefore overlapping information in the resulting STD NMR spectra make 
interpretation difficult to reliably distinguish which fragments are binding. 
Some fragments were hits in crystallography when soaked as individual fragments but could not be 
assigned to the electron density in the structures of cocktail soaking. These fragments could be easily 
detected in NMR cocktails, for example F224, F333, F052, and F338.   
In contrast, some fragments that could be resolved by crystallography in cocktail soaking could not be 
seen as binding events in STD NMR, for example F240. Fragments that did not bind when tested as 
single fragments in STD NMR such as F207, F227, and F274 also showed no binding when tested in a 
cocktail set, as expected.  
For the tested cocktail sets, STD NMR was just as likely to detect fragment binding of the fragments in 
the cocktail set as crystallography was. We must conclude that despite having cases where NMR 
cocktailing out-performed crystallography in detecting the fragments in cocktails, NMR did not detect 
binding for all of the fragments in the tested cocktail sets. They were, however, detected as hits when 
tested as individual fragments which is definitely a case of a false negative in NMR cocktailing. 
Cocktailing in crystallography can also lead to false negatives due to competitive fragment behavior. 
This fact still holds the advantage of elucidating how the fragments in the cocktail are binding and 
whether they adopt different binding poses compared to single soaks or not. It must be considered, 
however, that in some cases cocktailing in crystallography can reveal a different binding mode for a 
given fragment compared to the adopted geometry found when soaking them individually. An example 
of this can be seen for cocktail set A (fragments 63, 267, and 291). F063 in the cocktail soak binds in a 
remote location to its original binding position in the individual soak (PDB: 4Y57). This can provide 
incorrect information regarding the binding locations of fragments in cocktail soaking (Figure 4.38). 
  




















Table 4.8: Results of fragment hit detection in fragment cocktails screened by STD NMR in comparison to cocktailing in X-ray 
crystallography. 
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yes yes (73%) yes yes 
Figure 4.38: Binding position of F063 (cyan) when soaked as an individual fragment (PDB: 4Y57) binds in the catalytic dyad 
where it forms a water-mediated hydrogen bond (W05) (2.6Å) with its pyridine to the catalytic residues Asp35 (3.3Å) and 
Asp219 (2.9Å), in addition to two hydrogen bonds formed by its terminal nitrogen to the carboxylate of Asp81 (2.8Å) and 
carbonyl of Ser115 (2.9Å).  The binding position of F063 (orange) when soaked as part of a cocktail set however is markedly 
different. It no longer forms a water-mediated interaction to the catalytic dyad but instead binds near the S1 and S3 pockets, 
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a) Value after one round of structural refinement 
 
Overall, it remains dubious whether the presumed speed improvement of screening fragments in 
cocktails is advisable, particularly in crystallography, in light of the huge number of created artifacts, 
e.g. arbitrarily modulated binding modes, or false positively and negatively detected hits. The danger 
exists that false information is followed up or promising fragments are lost in a screen. To recover such 
information would involve complex deconvolution of the cocktails which at the end will be elaborate, 
time consuming, and most likely avoidable with individual soaks. As for NMR, despite the ability to 
detect competitive binding of fragments due to the temporary binding and unbinding events, the 
parallel binding and thus detection of fragments is not always guaranteed. As seen in our experiments, 
20% of the fragments that were detected as hits when screened individually in NMR were not detected 
as hits when screened as cocktails. Additionally, there are two cases were fragments were detected or 
not detected in the cocktail NMR depending on the cocktail set they were a part of. These fragments 
are F224 and F236. When screened as pairs in a cocktail set, both F224 and F236 were detected as hits. 
On the other hand, when F224 was screened as part of a cocktail set with F218 it was not detected, 
and F236 when screened as part of a cocktail set with F162 and F338 was also not detected. 
 
4.6 Materials and Methods 
 
4.6.1 Purification of EP 
 
Endothiapepsin aliquots were obtained from Suparen (provided by DSM Food Specialties) and the 
storage buffer was exchanged with 0.1 M sodium acetate (pH 4.6) using a Vivaspin 20 with a 10 kDa 
molecular weight cutoff. Protein concentration was determined by absorbance at λ = 280 nm, 
assuming an extinction coefficient of 1.15 for 1 mg·mL-1 solutions. For NMR experiments, the buffer 
was further exchanged with 3 mM acetic acid (pH 4.6). 
4.6.2 Crystallization and Structure Refinement of EP 
 
Endothiapepsin crystals were grown at 18°C using the sitting-drop vapor diffusion method. 
2 µL of 5 mg · mL -1 were mixed with 2 µL of reservoir solution (0.1 M sodium acetate pH 4.6, 0.1 M 
ammonium acetate, 28% - 30% (w/v) PEG4000) in the wells of a crystallization plate containing 1 mL 
reservoir solution. Crystals could be obtained within three days.  
The crystallography screening of the 361 fragment library was done by Dr. Nedyalka Radeva and 
experimental details can be found in her dissertation. 200  
Displacer ritonavir was purchased from Sigma Aldrich. For the reporter ligand experiments, initially the 
endothiapepsin crystals were soaked with a solution containing 2 mM of ritonavir (dissolved in 100% 
DMSO), 0.1 M sodium acetate pH 4.6, 0.1 M ammonium acetate, 28% - 30% (w/v) PEG4000, 25% 





(dissolved in 100% DMSO), 0.1 M sodium acetate pH 4.6, 0.1 M ammonium acetate, 28% - 30% (w/v) 
PEG4000, 25% glycerol, for 18 hours. In the second part of the reporter ligand experiments, the 
endothiapepsin crystals were soaked with 2 mM of ritonavir in the same way as described above but 
for 5 hours, after which they were transferred to a well containing both 2 mM of the reporter ligand 
and 100 mM of the fragment solution (same solution described as above) for 24 hours. 
For the cocktail soaking experiments performed by Helene Köster and Johannes Schiebel, apo 
endothiapepsin crystals were soaked into cocktails of fragments each at 90 mM concentration, with 
the exception of cocktails B and D where the fragment concentration was 50 mM, and cocktails L, M, 
and N where the fragment concentration was 100 mM.  
Data collection and refinement statistics can be found in the Appendix (Table 9 – Table 15).  The 
diffraction data were indexed, scaled, and merged using XDS90 and XDSAPP.91 Molecular replacement 
from the program PHASER MR92 from the CCP4 suite93 was used to determine all crystal structures. 
The structure 5DQ4 was used as a search model. In the refinement, a 5% subset of all reflections was 
omitted during refinement to be used for Rfree calculation. Model building was achieved in COOT44 and 
refinement using PHENIX.refine version 1.10.1-2155.94 Cartesian simulated annealing with default 
parameters was used as a first refinement step for all the structures. This was followed by refinement 
of XYZ coordinates and occupancies of protein residues and fragments (with the exception of water 
molecules whose occupancies were fixed). In the case of protein residues that gave additional density, 
they were refined in double confirmation and kept if their refined occupancy was ≥ 20%. When 
appropriate, hydrogen atoms were added to the refined structures in the last refinement step in 
PHENIX.refine. For published structures, details of their refinement can be found in the dissertation of 
Dr. Nedyalka Radeva.200 Chemicalize96 developed by ChemAxon97 was used for name-to-structure 
generation and SMILES code notation. The ligand PDB and restraint files were generated with the 
Grade Web Server.98  
4.6.3 SPR Conditions 
 
SPR screens were performed at 25°C using a BIAcore 3000 instrument. 
Immobilizing H-142 Peptide 
 
The functional groups of a CM7 GE sensor chip surface were first activated by injecting for 10 min at 
10 µL/min with a 1:1 mixture of 0.5 M 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and 0.5 M N-hydroxysuccinimide (NHS), immediately followed by injecting the H-142 target 
compound for 7 min at a flow rate of 10 µL/min to 865RU (where RU is the resonance units). The 
relation between RU and ng of material bound varies depending on the refractive index of the analyte. 
The H-142 was prepared by diluting a 25 mg · mL -1 DMSO stock solution of H-142 to 0.5 mg · mL -1 in a 
100 mM Na-acetate buffer, pH 4. Remaining activated carboxyl groups on the surface were blocked 
with 4x1.5 min pulses of 0.5 M ethanolamine. 
 
Calibration Free Concentration Analysis 
 
A 96-well plate of various endothiapepsin concentrations (0 to 100 mM) was prepared by diluting the 
protein into the running buffer composed of 25 mM Na-acetate pH 4.5, 125 mM NaCl, 0.005% Tween 
20, 1% DMSO. These protein solutions were passed over the immobilized H-142 and the concentration 
was plotted against the corresponding response values (RU) to create a dose-response curve. The 
response in the SPR assay, expressed as the initial binding rate, was linear with the free protein 
concentration in solution, which ensures that the measurements are done under conditions of mass 
transport limitation, as can be seen in Figure 4.39. The endothiapepsin concentration used in 








Inhibition in Solution Assay 
Endothiapepsin was diluted to a concentration of 100 nM in the running buffer. Fragment plates were 
prepared by diluting 100 mM fragment stocks in running buffer to a final concentration of 2 mM. The 
plates were centrifuged to remove any precipitation and the supernatant was used to prepare the 
screening plates containing a final concentration of 50 nM endothiapepsin and 1 mM fragment. The 
fragment and endothiapepsin mixture were injected onto the H-142 immobilized surface at 20 µL/min, 
and the surface was regenerated after each cycle using 15 s pulses of 100 mM Tris at pH 8.5. The initial 
binding rate (dRU/dt) determined within the first 15 s after injection was used as a measure of the free 
protein concentration (using the subtracted sensorgrams). By dividing the free protein concentration 
measured for each fragment by that of the control measurement without fragment, we can get the 
percentage bound to protein, and therefore percentage inhibited by the fragment. Anything above 3% 
inhibition was considered a hit. Fragments that gave an inhibition of at least 50% were then run again 
using varying concentrations from 0 to 1024 µM. Using the nonlinear regression in GraphPad Prism, 
the logarithmic fragment concentration was plotted against the percentage inhibition to give the IC50. 
In GraphPad Prism, all negative percentage inhibition values were changed to zero, the constraint 
parameters used included setting the bottom and top constants to 0 and 100, respectively, and the 
Hill slope to shared value for all data sets. Only the IC50 values with R-squared above 80% were taken 
into consideration. In some cases, the fragments were run in duplicates when possible.  
4.6.4 NMR conditions  
 
STD and Water LOGSY fragment screening experiments were performed at 283K on a Bruker Avance 
600 MHz NMR spectrometer equipped with a cryogenically cooled probe head. Automatic sample 
changing was accomplished with a SampleJet system. Three separate NMR samples with each 
fragment were prepared for screening in a buffer consisting of 3 mM acetate pH 4.6. The first sample 
contained 310 µM fragment, the second contained 310 µM fragment in addition to 9.6 µM of 
endothiapepsin, and the third contained 310 µM fragment in addition to 9.6 µM of endothiapepsin 
Figure 4. 39: Calibration of BIAcore ISA experiments. Concentration series (0 to 100nM) of EP were run in duplicates at 20 
µL/min at 25°C over a CM7 surface (sensor chip CM7 - GE Healthcare) with an amine-coupled peptide as TDC. The running 
buffer was composed of 25 mM sodium acetate, 200 mM NaCl, 0.005% Tween 20, pH 4.5. After each cycle the surface was 
regenerated with a pulse of 100 mM Tris at pH 8.5. The insert depicts the concentration dependency of the initial binding rate 





and 16 µM of ritonavir. A liquid handling Gilson pipetting robot was used to fill 3 mm NMR tubes in a 
SampleJet rack. Final DMSO concentration in solutions with fragments was 0.20%, and 0.36% in 
solutions with fragment and ritonavir. For STD spectra (pulse program kf_zggpw5std) 320 scans were 
collected and the interscan delay was 2.5 s. In WaterLOGSY experiments (pulse program 
s_M.ephogsy.noe_0) 16 scans were taken and the interscan delay was 2 s. Spectra were processed and 
analyzed with TopSpin®. The water suppression used in STD NMR was WATERGATE w5 with gradients. 
162 The water suppression used in WaterLOGSY was excitation sculpting and water flip back.  The same 
methods were applied to the cocktail screening, with the exception of the samples preparation where 
fragments were added in pairs of two or three, at a fragment concentration of 310 µM. Final DMSO 
concentration in solutions with two fragments was 0.41%, and 0.62% in solutions with three fragments. 
1H 1D NMR spectra of the single fragments were generated using the Water Suppression by Excitation 
Sculpting (pulse sequence zggpw5162) where 64 scans were accumulated, with interscan delay of 1 s.
  
 
The STD NMR comparative analysis experiments between fragments in deuterated and non-
deuterated buffers were performed at at 25°C using a Bruker Avance III-HD 800 MHz NMR 
spectrometer equipped with a cryogenically cooled CPTXI probe head. Sample preparation was done 
off-line using a TECAN EVO Robot running Gemini 4.0. Sample changing was done via a Bruker 
SampleRail system and data acquisition was done using ICON NMR.  Water suppression was done using 
excitation sculpting with gradients. For the STD (pulse program: std2.poe) number of scans collected 
was 1024, and the interscan delay was 3 s, with the exception of the data set for fragment 39 which 
had 512 scans. For the 1H 1D spectrum (pulse program: zgesgppr) 32 scans were accumulated with a 
relaxation delay of 2 s. 
NMR samples were prepared in buffers of heavy and light water. For the deuterated heavy water 
buffer the sample was prepared in 20 mM CD3COONa at pH 4.6 with 300 µM fragment in 100% D2O. 
Endothiapepsin was then added at a concentration of 9.6 µM, as well as ritonavir in case of the 
competitive binding experiments at a concentration of 16 µM. For the non-deuterated light buffer the 
sample was prepared in 20 mM NaAc at a of pH 4.6, 10% D2O (added to allow locking using the 
deuterium resonance), 90% H2O, and 300 µM of fragment. Endothiapepsin was then added at a 
concentration of 9.6 µM, as well as ritonavir for the competitive binding experiments at a 
concentration of 16 µM. Final DMSO concentration in solutions with fragments was 0.20%, and 0.36% 
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 Table 1: Data collection and refinement statistics for TGT structures. 
 
PDB Code 6FSO 5SW3 5N6F 
Fragment Jena ID J14 J41 J64 
A) Data Collection and Processing a    
Wavelength 0.9184 1.000 0.9184 
Beamline BESSY BL 14.1 ELETTRA BL 5.2R BESSY BL 14.1 
Detector PILATUS 6M DECTRIS PILATUS 2M PILATUS 6M 
Resolution range (Å) 43.29 - 1.45 (1.54 - 1.45) 44.46 - 1.38 (1.46 - 1.38) 44.28 - 1.12 (1.19 - 1.12) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell parameters (a, b, c Å) 90.9, 64.9, 70.8 89.0, 64.1, 70.5 88.7, 64.9, 70.7 
Unit cell parameters (α, β, γ °) 90.0, 95.7, 90.0 90.0, 92.8, 90.0 90.0, 93.4, 90.0 
Matthews coefficient b Å3/Da) 2.5 2.4 2.5 
Solvent content b (%) 51.1 49.4 50.8 
Total reflections 183142 (27068) 303178 (47561) 537838 (59077) 
Unique reflections 68249 (10718) 81197 (12961) 149008 (20548) 
Multiplicity 2.7 3.7 3.6 
Completeness (%) 94.8 (92.3) 99.7 (98.9) 97.1 (83.2) 
Mean I/sigma(I) 9.8 (2.2) 12.4 (2.5) 10.3 (2.0) 
Wilson B-factor (Å2) 11.5 13.6 10.9 
R-sym c (%) 7.3 (48.6) 6.0 (49.3) 6.1 (48.7) 
R-meas (%) 9.0 (60.8) 6.9 (57.7) 7.1 (59.2) 
CC1/2 99.6 (76.3) 99.8 (79.7) 99.7 (72.0) 
B) Refinement    
Resolution range (Å) 43.29 - 1.45 44.46 - 1.38 44.28- 1.12 
Total reflections used in refinement 68178 81188 148997 
Reflections used for R-work 64769 77129 141547 
Reflections used for R-free 3409 4059 7450 
Final R value for R-work (%) 16.6 13.3 13.6 
Final R value for R-free (%) 18.6 16.2 15.2 
No. of Protein residues 368 371 364 
No. of Water molecules 252 223 280 
No. of Ligand molecules 1 2 1 
No. of Other ligand molecules 8 6 4 
RMSD bond lengths (Å) 0.008 0.007 0.007 
RMSD bond angles (°) 1.0 0.9 1.0 
Ramachandran plot d    
Residues in most favored regions (%) 93.9 95 96.1 
Residues in additionally allowed regions 
(%) 
5.4 4.7 3.6 
Residues in generously allowed regions 
(%) 
0.3 0.3 0.3 
Residues in disallowed regions (%) none none None 
Average B-factor all atoms e (Å2) 16.2 17.9 16.1 
Protein main chain 13.4 15.7 13.7 
Protein side chain 16.6 18.2 16.1 
Protein all atoms 15.1 17.0 15.0 
Ligand 21.6 30.1 12.2 
Water molecules 25.5 26.4 27.4 
Other ligands f 36.3 36.3 33.5 




Table 2: Data collection and refinement statistics for TGT structures. 
 
PDB Code 5UTI 5UTJ 5V3C 
Fragment Jena ID J72 J79 J86 
A) Data Collection and Processing a    
Wavelength 1.000 0.9184 0.9184 
Beamline ELETTRA BL 5.2R BESSY BL 14.1 BESSY BL 14.1 
Detector DECTRIS PILATUS 2M PILATUS 6M PILATUS 6M 
Resolution range (Å) 44.51 - 1.36 (1.44 - 1.36) 44.50 - 1.55 (1.64 - 1.55) 44.33 - 1.42 (1.51 - 1.42) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell parameters (a, b, c Å) 89.2, 64.3, 70.9 89.1, 64.8, 70.5 88.8, 63.7, 70.4 
Unit cell parameters (α, β, γ °) 90.0, 93.1, 90.0 90.0, 93.2, 90.0 90.0, 92.6, 90.0 
Matthews coefficient b (Å3/Da) 2.5 2.5 2.4 
Solvent Content b (%) 50.1 51.0 48.8 
Total reflections 239209 (38188) 219498 (34906) 276359 (43372) 
Unique reflections 81480 (12780) 58079 (9314) 73712 (11753) 
Multiplicity 2.9 3.8 3.8 
Completeness (%) 95.0 (92.5) 99.7 (99.4) 99.4 (98.4) 
Mean I/sigma(I) 11.6 (2.3) 15.4 (2.0) 15.6 (2.0) 
Wilson B-factor (Å2) 15.4 18.0 15.7 
R-sym c (%) 5.0 (44.5) 5.2 (55.6) 4.6 (55.1) 
R-meas (%) 6.1 (54.2) 6.0 (64.7) 5.4 (64.3) 
CC1/2 99.8 (81.6) 99.9 (77.4) 99.9 (74.1) 
B) Refinement    
Resolution range (Å) 44.51 - 1.36 44.50 - 1.55 44.33 - 1.42 
Total reflections used in refinement 81466 58069 73705 
Reflections used for R-work 77393 55166 70020 
Reflections used for R-free 4073 2903 3685 
Final R value for R-work (%) 13.5 14.7 13.4 
Final R value for R-free (%) 15.8 17.7 15.5 
No. of Protein residues 371 364 373 
No. of Water molecules 269 322 359 
No. of Ligand molecules 1 1 1 
No. of Other ligand molecules 4 4 6 
RMSD bond lengths (Å) 0.007 0.008 0.007 
RMSD bond angles (°) 0.9 0.9 0.9 
Ramachandran plot d    
Residues in most favored regions (%) 94.6 94.2 94 
Residues in additionally allowed regions 
(%) 
5 5.5 5.6 
Residues in generously allowed regions 
(%) 
0.3 0.3 0.3 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2) 20.5 24.6 22.1 
Protein main chain 17.9 22.1 19.7 
Protein side chain 20.9 25.9 22.5 
Protein all atoms 19.5 24.1 21.1 
Ligand 27.1 57.5 26.8 
Water molecules 29.8 30.4 31.2 
Other ligands f 44 36.4 46 




 Table 3: Data collection and refinement statistics for TGT structures. 
a) Statistics for the highest-resolution shell are shown in parenthesis, b) Calculated with Matthews_coef program from CCP4 suite version 
7.0.04793, c) Calculated by the equation R(I)sym=[ΣhΣi|Ii(h)-‹I(h)›|/ΣhΣiIi(h)] · 100, where ‹I(h)› is the mean of the I(h) observation of 
reflection h. d) Calculated with PROCHECK201, e) Calculated with MOLEMAN202, f) other ligands include DMSO, PEG, Glycerol, ACT, Zn.  
 
PDB Code Unpublished Unpublished 6RKT 6RKQ 
Ligand J19 J33 4.1 4.2 
A) Data Collection and 
Processing a 
    
Wavelength 0.895 1.033200 0.9184 0.9184 
Beamline BESSY BL 14.3 ESRF BM30A BESSY BL 14.2 BESSY BL 14.2 
Detector Rayonix MX225 CCD ADSC Q315r CCD PILATUS3S 2M PILATUS3S 2M 
Resolution range (Å) 44.63 -1.37 (1.46-1.37) 44.38 -1.25 (1.33-1.25) 44.74 -1.75 (1.85-1.75) 45.19 -1.67 (1.77-1.66) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell parameters (a, b, c Å) 89.7, 64.8, 70.5 90.0, 65.0, 70.0 89.6, 64.6, 71.2 90.5, 64.8, 71.5 
Unit cell parameters (α, β, γ °) 90.0, 95.6, 90.0 90.0, 93.0, 90.0 90.0, 93.3, 90.0 90.0, 93.1, 90.0 
Matthews coefficient b (Å3/Da) 2.5 2.5 2.5 2.6 
Solvent Content b (%) 50.3 50.1 51.4 51.9 
Total reflections 248324 (34930) 361277 (52153) 137815 (19404) 180914 (28178) 
Unique reflections 82394 (12435) 108083 (16922) 40353 (6118) 47621 (7421) 
Multiplicity 3.0 3.3 3.42 3.78 
Completeness (%) 98.1 (91.7) 98.5 (95.8) 97.7 (92.2) 98.3 (95.7) 
Mean I/sigma(I) 13.2 (2.6) 10.1 (2.3) 17.6 (2.0) 14.1 (2.1) 
Wilson B-factor (Å2) 11.0 14.2 29.6 37.2 
R-sym c (%) 6.0 (47.7) 6.4 (49.0) 3.5 (50.4) 4.7 (46.3) 
R-meas (%) 7.2 (57.8) 7.6 (59.3) 4.2 (60.4) 5.5 (53.8) 
CC1/2 99.8 (79.0) 99.5 (75.4) 99.9 (86.7) 99.8 (88.4) 
B) Refinement     
Resolution range (Å) 44.63 – 1.37 44.38 – 1.25 38.90 - 1.75 43.03 - 1.66 
Total reflections used in 
refinement 
82364 108075 40307 47606 
Reflections used for R-work 78246 102671 38292 45226 
Reflections used for R-free 4118 5404 2015 2380 
Final R value for R-work (%) 13.6 14.5 16.9 16.3 
Final R value for R-free (%) 15.5 16.5 20.5 19.4 
No. of Protein residues 371 368 366 369 
No. of Water molecules 280 264 193 186 
No. of Ligand molecules 1 1 1 1 
No. of Other ligand molecules 2 7 3 3 
RMSD bond lengths (Å) 0.007 0.005 0.009 0.009 
RMSD bond angles (°) 1.0 0.8 1 1 
Ramachandran plot d     
Residues in most favored regions 
(%) 
94.6 94.6 95.5 95.2 
Residues in additionally allowed 
regions (%) 
5.0 5.1 4.2 4.5 
Residues in generously allowed 
regions (%) 
0.3 0.3 0.3 0.3 
Residues in disallowed regions 
(%) none none none none 
Average B-factor all atoms e (Å2)   42.3 37.1 
Protein main chain 12.5 19.2 39.6 35.1 
Protein side chain 14.5 21.8 44.6 38.5 
Protein all atoms 13.6 20.5 42.2 36.9 
Ligand 25.8 24.7 37.2 32.6 
Water molecules 24.7 32.1 44.5 41.2 
Other ligands f 26.1 42.1 55.1 53.7 











PDB Code 5J9M 5JT5 5J9N 
Ligand 2.1 2.2 2.5 
A) Data Collection and Processing a    
Wavelength 0.8944 0.91841 0.91841 
Beamline BESSY BL 14.3 BESSY BL 14.1 BESSY BL 14.1 
Resolution range (Å) 45.21 - 1.33(1.41 - 1.33) 43.53 - 1.21 (1.28 - 1.21) 45.12 - 1.64 (1.74 - 1.64) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell parameters (a, b, c Å) 91.0, 64.9, 70.7 90.3, 65.3, 70.6 90.4, 64.5, 71.3 
Unit cell parameters (α, β, γ °) 90.0, 96.3, 90.0 90.0, 96.1, 90.0 90.0, 92.8, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 49.0 48.9 49.1 
Unique reflections 93288 (14902) 122593 (19268) 49307 (7770) 
Multiplicity 2.9 3.7 3.0 
Completeness (%) 99.2 (98.4) 98.7 (96.4) 97.5 (95.2) 
Mean I/sigma(I) 14.3 (2.3) 15.7 (3.3) 9.28 (2.0) 
R-sym c (%) 4.5 (48.9) 4.1 (38.4) 6.3 (34.2) 
B) Refinement    
Resolution range (Å) 45.21 - 1.33 39.80 - 1.21 41.68 - 1.64 
Total reflections used in refinement 93249 122586 49285 
Final R value for R-work (%) 12.9 13.5 21.3 
Final R value for R-free (%) 15.7 15.7 23.7 
No. of Protein atoms 3002 2988 2823 
No. of Water molecules 400 430 208 
No. of Ligand atoms 14 15 15 
RMSD bond lengths (Å) 0.005 0.005 0.006 
RMSD bond angles (°) 0.8 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 94.9 94.9 95.5 
Residues in additionally allowed 
regions (%) 
4.8 4.8 4.2 
Residues in generously allowed 
regions (%) 
0.3 0.3 0.3 
Average B-factor e (Å2)    
Protein atoms 17.2 17.1 30.5 
Water molecules 34.7 33.6 37.6 




Table 5: Data collection and refinement statistics for TGT structures. Copied from the dissertation of Dr. Frederik Ehrmann, 
2016.95 
a) Values in parentheses are statistics for the highest resolution shell. b) Calculated with MATTPROB 203 c) 
R(I)sym=[ΣhΣi|Ii(h)-‹I(h)›|/ΣhΣiIi(h)] · 100, where ‹I(h)› is the mean of the I(h) observation of reflection h. d) Determined 
with PROCHECK 201. e) Calculated with MOLEMAN 202 
 
 
PDB Code 5JT6 5J9O 5JT7 
Ligand 2.6 3.1 3.2 
A) Data Collection and Processing a    
Wavelength 0.91841 0.91841 0.91841 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Resolution range (Å) 45.11 - 1.54 (1.63 - 1.54) 19.45 - 1.41 (1.49 - 1.41) 42.80 - 1.70 (1.80 - 1.70) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell parameters (a, b, c Å) 90.3, 64.2, 71.0 90.1, 63.8, 71.0 90.3, 64.2, 71.2 
Unit cell parameters (α, β, γ °) 90.0, 92.8, 90.0 90.0, 92.9, 90.0 90.0, 93.2, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 48.6 48.1 48.7 
Unique reflections 59224 76131 44054 
Multiplicity 2.9 3.8 2.5 
Completeness (%) 98.4 (97.3) 97.9 (95.6) 98.1 (98.4) 
Mean I/sigma(I) 18.8 (2.1) 16.9 (2.3) 15.8 (2.0) 
R-sym c (%) 2.8 (49.3) 3.5 (49.3) 3.1 (40.6) 
B) Refinement    
Resolution range (Å) 41.11 - 1.54 19.45 - 1.41 42.80 - 1.70 
Total reflections used in refinement 59215 76103 44050 
Final R value for R-work (%) 16.3 14.0 17.2 
Final R value for R-free (%) 18.1 16.9 20.5 
No. of Protein atoms 2889 2978 2853 
No. of Water molecules 207 294 209 
No. of Ligand atoms 15 15 15 
RMSD bond lengths (Å) 0.006 0.006 0.006 
RMSD bond angles (°) 0.8 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 95.9 94.3 95.8 
Residues in additionally allowed 
regions (%) 
3.8 5.4 3.9 
Residues in generously allowed 
regions (%) 
0.3 0.3 0.3 
Average B-factor e (Å2)    
Protein atoms 31.6 26.8 35.9 
Water molecules 37.3 40.3 40.6 




Table 6: Data collection and refinement statistics for E1W PEX14 structures.  
 
PDB Code 6S6R 6S7M Not published 
Ligand F5 F6 Apo - Crystal form 1 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 43.31 - 1.58 (1.68 - 1.58) 39.89 - 1.76 (1.86 –1.76) 43.18 - 1.56 (1.65 - 1.56) 
Space group P4(1)2(1)2 P2(1) P4(1)2(1)2 
Unit cell parameters (a, b, c Å) 43.3, 43.3, 80.9 79.8, 39.7, 81.1 43.18, 43.18, 80.96 
Unit cell parameters (α, β, γ °) 90.0, 90.0, 90.0 90.0, 90.1, 90.0 90.0, 90.0, 90.0 
Matthews coefficient b Å3/Da) 2.4 2.1 2.4 
Solvent Content b (%) 49.2 42.5 48.9 
Total reflections 90149 (14571) 185815 (30160) 95671 (15433) 
Unique reflections 10965 (1705) 49925 (7928) 11386 (1761) 
Multiplicity 8.2 3.7 8.4 
Completeness (%) 98.4 (97.4) 97.6 (96.7) 98.9 (97.9) 
Mean I/sigma(I) 16.9 (4.2) 14.7 (2.5) 25.9 (3.9) 
Wilson B-factor (Å2) 18.9 23.1 20.6 
R-sym c (%) 6.9 (49.7) 5.2 (50.2) 4.3 (55.4) 
R-meas (%) 7.4 (52.9) 6.1 (58.4) 4.6 (58.8) 
CC1/2 99.8 (93.9) 99.9 (88.0) 100 (96.8) 
B) Refinement    
Resolution range (Å) 38.18 – 1.58 39.89 – 1.76 38.10 – 1.56 
Total reflections used in refinement 10960 49847 11365 
Reflections used for R-work 10412 47355 10797 
Reflections used for R-free 548 2492 568 
Final R value for R-work (%) 18.7 23.1 20.5 
Final R value for R-free (%) 23.5 26.7 26.5 
No. of Protein residues  





No. of Water molecules 42 151 42 
No. of Ligand molecules 1 6 none 
No. of Other ligand molecules 5 2 2 
RMSD bond lengths (Å) 0.006 0.007 0.009 
RMSD bond angles (°) 0.8 0.7 0.9 
Ramachandran plot d   
(Protein molecules A/B/C/D/E/F/G/H) 
   










Residues in generously allowed regions 
(%) 
none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2) 
(Protein molecules A/B/C/D/E/F/G/H) 
   












Ligand 26.1 21.3 N/A 
Water molecules 31.0 28.3 33.2 
Other ligands f 42.4 39.8 36.8 




Table 7: Data collection and refinement statistics for E1W PEX14 structures. 
 
PDB Code Not published g Not published g Not published g 
Ligand Apo – Crystal form 3 Apo – Crystal form 4 Apo - Crystal form 5 
A) Data Collection and Processing a    
Wavelength 1.541790 0.9184 0.873127 
Beamline Inhouse X-ray Source BESSY BL 14.1 ESRF ID23-2 
Detector MAR345 PILATUS 6M DECTRIS PILATUS3 X 2M 
Resolution range (Å) 42.61 -2.59 (2.75-2.60) 40.96 - 2.30 (2.43–2.29) 41.66 - 1.60 (1.70 - 1.60) 
Space group P4(3)2(1)2 P2(1) P4(1)2(1)2 
Unit cell parameters (a, b, c Å) 42.6, 42.6, 81.1 39.0, 82.1, 39.4 41.7, 41.7, 81.6 
Unit cell parameters (α, β, γ °) 90.0, 90.0, 90.0 90.0, 92.9, 90.0 90.0, 90.0, 90.0 
Matthews coefficient b Å3/Da) 2.4 2.0 2.3 
Solvent Content b (%) 47.6 38.2 45.6 
Total reflections 22462 (3529) 37760 (6091) 121577 (19346) 
Unique reflections 2575 (399) 10961 (1755) 10054 (1573) 
Multiplicity 8.7 3.4 12.1 
Completeness (%) 99.7 (99.8) 98.6 (98.2) 99.9 (99.9) 
Mean I/sigma(I) 13.7 (3.5) 7.9 (2.5) 25.1 (4.9) 
Wilson B-factor (Å2) 41.2 25.5 23.1 
R-sym c (%) 11.8 (66.2) 12.3 (50.9) 4.9 (44.0) 
R-meas (%) 12.6 (70.3) 14.6 (60.2) 5.2 (45.9) 
CC1/2 99.8 (99.0) 99.5 (82.2) 100 (98.9) 
B) Refinement    
Resolution range (Å) 37.72 – 2.60 39.35 – 2.23 37.11 – 1.60 
Total reflections used in refinement 2551 11989 10022 
Reflections used for R-work 2423 599 501 
Reflections used for R-free 128 11390 9521 
Final R value for R-work (%) 24.2 21.6 27.0 
Final R value for R-free (%) 34.1 29.7 30.8 
No. of Protein residues  
(Protein molecules A/B/C/D) 
69 69/69/69/69 69 
No. of Water molecules none added none added none added 
No. of Ligand molecules none none none 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.010 0.008 0.006 
RMSD bond angles (°) 1.2 1.0 0.9 
Ramachandran plot d  
(Protein molecules A/B/C/D) 
   
Residues in most favored regions (%) 90.5 90.5/92.1/90.5/93.7 96.8 
Residues in additionally allowed regions (%) 9.5 7.9/4.8/7.9/6.3 3.2 
Residues in generously allowed regions (%) none none/3.2/1.6/0 none 
Residues in disallowed regions (%) none 1.6/0/0/0 none 
Average B-factor all atoms e (Å2) 
(Protein molecules A/B/C/D) 
   
Protein main chain 54.1 34.3/37.3/31.5/37.7 30.2 
Protein side chain 56.1 38.1/41.8/36.0/41.9 35.8 
Protein all atoms 55.1 36.2/39.5/33.7/39.7 32.9 
Ligand N/A N/A N/A 
Water molecules N/A N/A N/A 
Other ligands f N/A N/A N/A 




Table 8: Data collection and refinement statistics for wild-type PEX14 structures. 
a) Statistics for the highest-resolution shell are shown in parenthesis, b) calculated with Matthews_coef program from CCP4 suite version 
7.0.04793, c) calculated by the equation: R(I)sym=[ΣhΣi|Ii(h)-‹I(h)›|/ΣhΣiIi(h)] · 100, where ‹I(h)› is the mean of the I(h) observation of 
reflection h. d) calculated with PROCHECK201, e) calculated with MOLEMAN202, f) other ligands include DMSO, PEG, Glycerol, SO4, g) 
statistics after one cycle of TLS refinement as part of an auto-refinement pipeline. No waters or ligand molecules have been added. h) 
calculated by Xtriage from the Protein Data Bank 88 
PDB Code 6S9Y Not published Not published 
Ligand Apo – Crystal form 7 Apo – Crystal form 8 Compound 1 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 40.63 - 1.64 (1.74 - 1.64) 39.20 - 1.93 (2.04 -1.93) 40.43 - 1.83 (1.94 – 1.83) 
Space group P2(1) C222(1) C222(1) 
Unit cell parameters (a, b, c Å) 38.9, 81.3, 39.3 54.1, 56.8, 81.0 53.9, 56.7, 80.9 
Unit cell parameters (α, β, γ °) 90.0, 92.8, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Matthews coefficient b (Å3/Da) 2.2 2.3 2.2 
Solvent Content b (%) 43.8 45.8 44.1 
Total reflections 95230 (10495) 58085 (9425) 50057 (7949) 
Unique reflections 28782 (3967) 9461 (1463) 11110 (1753) 
Multiplicity 3.3 6.1 4.5 
Completeness (%) 96.2 (82.6) 96.7 (93.6) 98.9 (97.8) 
Mean I/sigma(I) 12.4 (2.3) 19.0 (4.5) 9.2 (2.4) 
Wilson B-factor (Å2) 16.6h 23.7 21.4 
R-sym c (%) 6.1 (37.4) 6.5 (34.1) 10.8 (49.6) 
R-meas (%) 7.3 (46.8) 7.1 (37.1) 12.2 (56.0) 
CC1/2 99.8 (86.2) 99.9 (95.3) 99.6 (84.5) 
B) Refinement    
Resolution range (Å) 39.24 -1.64 39.20 – 1.93 40.43 – 1.83 
Total reflections used in refinement 28758 9445 11103 
Reflections used for R-work 27320 8982 10548 
Reflections used for R-free 1438 463 555 
Final R value for R-work (%) 19.7 25.8 27.9 
Final R value for R-free (%) 22.9 31.0 33.0 
No. of Protein residues  
(Protein molecules A/B/C/D) 
62/63/62/63 62/62 62/62 
No. of Water molecules 88 15 17 
No. of Ligand molecules none none 2 
No. of Other ligand molecules 2 none none 
RMSD bond lengths (Å) 0.005 0.007 0.007 
RMSD bond angles (°) 0.7 0.8 0.8 
Ramachandran plot d 
(Protein molecules A/B/C/D) 
   
Residues in most favored regions (%) 98.2 98.2/98.0 98.2 
Residues in additionally allowed regions (%) 1.8 1.8/2.0 1.8 
Residues in generously allowed regions (%) none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2) 
(Protein molecules A/B/C/D) 
   
Protein main chain 16.5/17.1/21.5 /26.0 23.8/39.9 20.9/38.2 
Protein side chain 20.0/19.3/24.1/27.9 25.6/39.6 21.7/37.1 
Protein all atoms 18.2/18.1/22.7/26.9 24.6/39.8 21.3/37.7 
Ligand N/A N/A 23.2 
Water molecules 31.1 35.1 29.2 
Other ligands f 43.7 N/A N/A 




Table 9: Data collection and refinement statistics for EP structures. 
 
PDB Code Not published g Not published g Not published g 
Ligand F268 and ritonavir F109 and ritonavir F236 and ritonavir 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 42.87 - 1.15 (1.22– 1.15) 42.87 - 1.15 (1.22 – 1.15) 49.75 - 1.38 (1.46 – 1.38) 
Space group P21 P21 P21 
Unit cell parameters (a, b, c Å) 45.3, 72.9, 52.4 45.4, 73.0, 52.5 45.4, 73.0, 52.7 
Unit cell parameters (α, β, γ °) 90.0, 108.9, 90.0 90.0, 109.1, 90.0 90.0, 109.3, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 49.4 49.6 49.7 
Total reflections 419839 (64346) 420086 (64230) 235137 (34332) 
Unique reflections 110654 (17454) 111322 (17547) 64037 (9764) 
Multiplicity 3.8 3.8 3.7 
Completeness (%) 96.8 (94.6) 97.1 (94.9) 95.1 (89.9) 
Mean I/sigma(I) 17.8 (4.2) 12.0 (2.1) 14.0 (2.6) 
Wilson B-factor (Å2) 10.2 10.7 11.9 
R-sym c (%) 3.8 (27.4) 6.0 (53.5) 9.5 (53.5) 
R-meas (%) 4.4 (32.0) 6.9 (62.6) 11.1 (63.1) 
CC1/2 99.9 (93.2) 99.9 (84.1) 99.6 (85.9) 
B) Refinement    
Resolution range (Å) 42.87 – 1.15 42.87 – 1.15 49.75 – 1.38 
Total reflections used in refinement 110651 111298 64016 
Reflections used for R-work 105118 105733 60815 
Reflections used for R-free 5533 5565 3201 
Final R value for R-work (%) 14.5 15.1 19.1 
Final R value for R-free (%) 16.1 16.6 21.4 
No. of Protein residues 330 330 330 
No. of Water molecules 233 232 173 
No. of Ligand molecules none added none added none added 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.006 0.007 0.008 
RMSD bond angles (°) 1.2 1.2 1.2 
Ramachandran plot d    
Residues in most favored regions (%) 93.5 94.2 94.2 
Residues in additionally allowed regions 
(%) 
6.5 5.8 5.8 
Residues in generously allowed regions 
(%) 
none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2)    
Protein main chain 10.6 11.7 14.3 
Protein side chain 12.5 13.6 16.0 
Protein all atoms 11.6 12.7 15.2 
Ligand N/A N/A N/A 
Water molecules 23.5 24.2 22.4 
Other ligands f N/A N/A N/A 




Table 10: Data Collection and Refinement Statistics for EP Structures. 
 
PDB Code Not published g Not published h Not published h 
Ligand F267 and ritonavir F216 and ritonavir F218 and ritonavir 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 42.86 -1.08 (1.14-1.08) 42.78 - 1.05 (1.11 – 1.05) 42.92 - 1.38 (1.46 – 1.38) 
Space group P21 P21 P21 
Unit cell parameters (a, b, c Å) 45.4, 73.0, 52.7 45.3, 72.9, 52.6 45.3, 73.1, 52.6 
Unit cell parameters (α, β, γ °) 90.0, 109.2, 90.0 90.0, 109.2, 90.0 90.0, 108.7, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 49.7 49.4 49.7 
Total reflections 451438 (71810) 548960 (82883) 248840 (39066) 
Unique reflections 133364 (21059) 146027 (22766) 65817 (10466) 
Multiplicity 3.4 3.8 3.8 
Completeness (%) 96.0 (94.0) 96.9 (93.7) 98.3 (97.0) 
Mean I/sigma(I) 17.0 (2.3) 14.6 (2.8) 10.9 (2.2) 
Wilson B-factor (Å2) 10.6 10.2 12.2 
R-sym c (%) 3.5 (49.2) 4.5 (43.1) 7.3 (52.4) 
R-meas (%) 4.2 (58.2) 5.2 (50.3) 8.5 (61.1) 
CC1/2 100.0 (84.7) 99.9 (87.3) 99.7 (80.2) 
B) Refinement    
Resolution range (Å) 41.13 – 1.08 41.03 – 1.05 42.92 – 1.38 
Total reflections used in refinement 133483 146015 65809 
Reflections used for R-work 126809 138714 62519 
Reflections used for R-free 6674 7301 3290 
Final R value for R-work (%) 15.2 21.5 22.0 
Final R value for R-free (%) 16.9 21.8 24.6 
No. of Protein residues 330 330 330 
No. of Water molecules 244 none added none added 
No. of Ligand molecules none added 2 2 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.006 0.003 0.005 
RMSD bond angles (°) 1.2 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 93.5 93.5 93.9 
Residues in additionally allowed regions 
(%) 
6.5 6.5 6.1 
Residues in generously allowed regions 
(%) 
none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2)    
Protein main chain 11.4 11.1 13.1 
Protein side chain 13.2 12.7 14.6 
Protein all atoms 12.3 11.8 13.8 
Ligand N/A 15.7 19.1 
Water molecules 23.9 N/A N/A 
Other ligands f N/A N/A N/A 




Table 11: Data Collection and Refinement Statistics for EP Structures. 
a) Statistics for the highest-resolution shell are shown in parenthesis, b) calculated with Matthews_coef program from CCP4 suite version 7.0.04793, 
c) calculated by the equation: (SUM(ABS(I(h,i)-I(h))))/(SUM(I(h,i))) d) calculated with PROCHECK201, e) calculated with MOLEMAN202, f) other ligands 
include DMSO, PEG, Glycerol, SO4, ACT. g) statistics after 11 cycles of refinement as part of an auto-refinement pipeline including anisotropic 
refinement of protein and water molecules, and addition of hydrogen. No ligand molecules have been added. h) only the ligand of interest was added 
after TLS refinement. No water molecules or other ligand molecules have been added. 
PDB Code Not published h Not published h Not published h 
Ligand F063 and ritonavir F290 and ritonavir F306 and ritonavir 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 42.72 -1.59 (1.68-1.59) 42.74 - 1.25 (1.32 - 1.25) 42.74 - 1.35 (1.43 – 1.35) 
Space group P21 P21 P21 
Unit cell parameters (a, b, c Å) 45.4, 73.2, 52.7 45.3, 73.2, 52.6 45.4, 73.0, 52.8 
Unit cell parameters (α, β, γ °) 90.0, 109.6, 90.0 90.0, 109.4, 90.0 90.0, 109.5, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 49.6 49.6 49.6 
Total reflections 159269 (24928) 326127 (51548) 265100 (40471) 
Unique reflections 43134 (6881) 88133 (14142) 68512 (10690) 
Multiplicity 3.7 3.7 3.9 
Completeness (%) 98.2 (97.0) 98.1 (97.7) 96.0 (92.8) 
Mean I/sigma(I) 16.3 (2.5) 17.4 (2.5) 13.5 (2.7) 
Wilson B-factor (Å2) - - 12.0 
R-sym c (%) 6.0 (52.1) 4.4 (55.2) 6.0 (45.9) 
R-meas (%) 7.0 (61.1) 5.2 (64.7) 7.0 (53.3) 
CC1/2 99.9 (76.5) 99.9 (76.4) 99.8 (84.3) 
B) Refinement    
Resolution range (Å) 42.72 – 1.59 39.50 – 1.25 42.74 – 1.35 
Total reflections used in refinement 43133 88127 68503 
Reflections used for R-work 40976 83721 65078 
Reflections used for R-free 2157 4406 3425 
Final R value for R-work (%) 22.3 22.0 22.6 
Final R value for R-free (%) 23.7 23.3 23.2 
No. of Protein residues 330 330 330 
No. of Water molecules none added none added none added 
No. of Ligand molecules 1 1 1 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.005 0.004 0.004 
RMSD bond angles (°) 0.8 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 93.5 93.9 93.9 
Residues in additionally allowed regions (%) 6.5 6.1 6.1 
Residues in generously allowed regions (%) none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2)    
Protein main chain 15.5 13.2 13.0 
Protein side chain 16.9 14.9 14.5 
Protein all atoms 16.1 14.0 13.7 
Ligand 27.4 19.8 20.1 
Water molecules N/A N/A N/A 
Other ligands f N/A N/A N/A 








Cocktail A:  
F63, F267, F291 
Cocktail B:  
F224 and F236 
Cocktail C:  
F171 and F103 
Cocktail D:  
F308 and F333 
PDB code 5MB0 5MB7 5MB5 5MB6 
Data collection and 
processing     
  
  
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline BESSY BL14.1  BESSY BL14.2   BESSY BL14.1  BESSY BL14.2 
Detector PILATUS 6M MX-225 CCD PILATUS 6M MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a       
     a, b, c (Å) 45.4, 73.1, 52.5 45.4, 72.9, 52.7 45.4, 72.9, 52.6 45.4, 73.5, 53.2 
     α, β, γ (°) 90.0, 109.6, 90.0 90.0, 109.5, 90.0 90.0, 109.7, 90.0 90.0, 110.5, 90.0 
Resolution range (Å)  42.8-1.15 (1.22-1.15) 30.0-1.30 (1.32-1.30) 42.7-0.98 (1.04-0.98) 30.0-1.20 (1.22-1.20) 
Wilson B factor (Å2)   9.5 10.9 8.4 8.3 
No. of unique reflections  113549 (17691) 78870 (3975) 179855 (27996) 95743 (3095) 
Multiplicity  3.6 (3.2) 3.2 (3.1) 3.8 (3.5) 2.8 (1.8) 
Rsym (%)  7.4 (46.6) 5.2 (52.0) 6.6 (45.0) 5.4 (23.8) 
Completeness (%)  98.8 (95.2) 99.9 (99.3) 97.4 (94.0) 94.2 (61.2) 
<I/σ(I)>  9.5 (2.8) 22.3 (2.0) 10.2 (2.2) 21.7 (3.8) 
Refinement       
Resolution range  42.8 - 1.15 18.9 - 1.30 36.5 – 0.98 27.9 – 1.20 
No. of reflections used for 
refinement (work (free))  
113540 (5677) 78840 (3850) 179793 (8989) 95693 (4629) 
Rcryst (%) 15.2 13.5 14.7 13.3 
Rfree (%)  17.0 15.8 16.2 14.9 
No. of refined residues  330 330 330 330 
No. of fragment atoms 59 13 13 ‒ 
No. of other ligand atoms 30 6 30 11 
No. of water molecules  387 337 408 464 
RMSD, bond length (Å)  0.006 0.006 0.005 0.006 
RMSD, bond angles (˚)  0.9 0.9 0.9 0.9 
Ramachandran plot (%) b     
     Most favoured  94.2 93.5 93.5 94.2 
     Additionally allowed  5.8 6.5 6.5 5.8 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c     
     All protein atoms  11.2 12.5 9.6 9.6 
     Main chain  10.3 11.5 8.8 8.7 
     Side chain  12.1 13.4 10.3 10.4 
     Fragment atoms 13.4 37.6 10.1 ‒ 
     Other ligand atoms d 21.6 17.5 19.8 12.6 
     Waters  28.7 27.2 27.2 26.9 
a) Statistics for the highest-resolution shell are shown in parenthesis, b) Calculated by PROCHECK201, c) Calculated by 





Table 13: Data Collection and Refinement Statistics for EP Structures. 
 
PDB Code Not published Not published Not published 
Ligand 
Cocktail E 
F063, F052, F058 
Cocktail F 
F207, F261 
Cocktail G  
F216, F338 
A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 41.03 - 1.15 (1.22 – 1.15) 39.64 - 1.23 (1.30 – 1.23) 42.70 - 1.08 (1.14 – 1.08) 
Space group P21 P21 P21 
Unit cell parameters (a, b, c Å) 45.4, 73.2, 52.7 45.5, 72.9, 52.7 45.4, 73.2, 52.7 
Unit cell parameters (α, β, γ °) 90.0, 109.8, 90.0 90.0, 109.5, 90.0 90.0, 109.7, 90.0 
Matthews coefficient b (Å3/Da) 2.4 2.4 2.4 
Solvent Content b (%) 49.6 49.6 49.7 
Total reflections 424924 (66924) 350510 (55884) 511677 (79502) 
Unique reflections 114661 (18351) 93643 (15033) 138339 (22228) 
Multiplicity 3.7 3.7 3.7 
Completeness (%) 99.5 (98.5) 99.6 (99.1) 99.6 (99.2) 
Mean I/sigma(I) 13.9 (2.3) 16.4 (2.5) 10.6 (2.2) 
R-sym c (%) 5.0 (51.5) 4.4 (49.4) 6.4 (50.5) 
R-meas (%) 5.9 (60.4) 5.1 (57.6) 7.4 (59.3) 
CC1/2 99.9 (76.8) 99.9 (79.7) 99.8 (77.5) 
B) Refinement    
Resolution range (Å) 41.03 – 1.15 39.64 – 1.23  
Total reflections used in refinement 114655 93641 138328 
Reflections used for R-work 108922 88959 131412 
Reflections used for R-free 5733 4682 6916 
Final R value for R-work (%) 15.5 15.7 16.1 
Final R value for R-free (%) 17.3 17.8 17.7 
No. of Protein residues 330 330 330 
No. of Water molecules 213 211 243 
No. of Ligand molecules 1 2 2 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.004 0.004 0.004 
RMSD bond angles (°) 0.8 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 93.9 94.6 94.2 
Residues in additionally allowed regions 
(%) 
6.1 5.4 5.8 
Residues in generously allowed regions 
(%) 
none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2)    
Protein main chain 11.7 11.9 10.2 
Protein side chain 13.0 13.1 11.4 
Protein all atoms 12.3 12.4 10.7 
Ligand 18.0 21.0 16.7 
Water molecules 23.0 20.6 22.2 
Other ligands f N/A N/A N/A 




Table 14: Data Collection and Refinement Statistics for EP Structures. 
 








A) Data Collection and Processing a    
Wavelength 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.1 BESSY BL 14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 6M 
Resolution range (Å) 42.97- 1.34 (1.42 - 1.34) 36.87 - 1.27 (1.35 - 1.27) 41.14 – 1.12 (1.19 - 1.12) 
Space group P21 P21 P21 
Unit cell parameters (a, b, c Å) 45.5, 73.2, 52.9 45.3, 73.3, 52.7 73.2, 52.8, 90.0 
Unit cell parameters (α, β, γ °) 45.5, 73.2, 52.9 90.0, 109.7, 90.0 90.0, 109.6, 90.0 
Matthews coefficient b (Å3/Da) 2.5 2.4 2.5 
Solvent Content b (%) 50.2 49.7 49.8 
Total reflections 275538 (40917) 319269 (50025) 450342 (71003) 
Unique reflections 73346 (11686) 85259 (13719) 123825 (19873) 
Multiplicity 3.8 3.7 3.6 
Completeness (%) 99.5 (98.5) 99.7 (99.5) 99.1 (98.7) 
Mean I/sigma(I) 13.1 (2.3) 14.1 (2.4) 12.4 (2.4) 
R-sym c (%) 5.5 (50.4) 6.0 (51.3) 5.9 (49.4) 
R-meas (%) 6.4 (59.5) 7.0 (60.1) 6.9 (58.0) 
CC1/2 99.8 (78.2) 99.9 (79.8) 99.9 (78.0) 
B) Refinement    
Resolution range (Å) 22.38 – 1.34 28.03 – 1.27 24.12 – 1.12 
Total reflections used in refinement 73334 85254 123724 
Reflections used for R-work 69667 80991 117538 
Reflections used for R-free 3667 4263 6186 
Final R value for R-work (%) 17.7 16.1 18.2 
Final R value for R-free (%) 19.2 18.1 19.5 
No. of Protein residues 330 330 330 
No. of Water molecules 166 226 219 
No. of Ligand molecules 4 2 2 
No. of Other ligand molecules none added none added none added 
RMSD bond lengths (Å) 0.004 0.004 0.004 
RMSD bond angles (°) 0.8 0.8 0.8 
Ramachandran plot d    
Residues in most favored regions (%) 94.2 94.2 93.9 
Residues in additionally allowed regions 
(%) 
5.8 5.8 6.1 
Residues in generously allowed regions 
(%) 
none none none 
Residues in disallowed regions (%) none none none 
Average B-factor all atoms e (Å2)    
Protein main chain 15.3 10.5 10.8 
Protein side chain 17.0 11.6 11.8 
Protein all atoms 16.0 11.0 11.3 
Ligand 23.7 15.9 17.5 
Water molecules 22.0 19.7 19.2 
Other ligands f N/A N/A N/A 




Table 15: Data Collection and Refinement Statistics for EP Structures. 
PDB Code Not published Not published Not published Not published 
Ligand 
Cocktail K 
F162, F236, F338 
Cocktail L 
F063, F272 




A) Data Collection and 
Processing a 
    
Wavelength 0.9184 0.9184 0.9184 0.9184 
Beamline BESSY BL 14.1 BESSY BL 14.2 BESSY BL 14.2 BESSY BL 14.2 
Detector PILATUS 6M MX-225 CCD MX-225 CCD MX-225 CCD 
Resolution range (Å) 
42.65 - 1.37 (1.45- 
1.37) 
42.68 – 1.18 (1.25-
1.18) 
42.72 -1.06 (1.06 - 
1.12) 
42.77 – 1.28 (1.36 – 
1.28) 
Space group P21 P21 P21 P21 
Unit cell parameters (a, 
b, c Å) 
45.2. 73.2, 52.6 45.3, 73.0, 52.5 45.4, 72.8, 52.4 45.4, 73.0, 52.7 
Unit cell parameters (α, 
β, γ °) 
90.0, 109.4, 90.0 90.0, 109.8, 90.0 90.0, 109.8, 90.0 90.0, 109.8, 90.0 
Matthews coefficient b 
(Å3/Da) 
2.4 2.4 2.4 2.5 
Solvent Content b (%) 49.5 49.4 49.3 49.8 
Total reflections 252016 (37139) 373081 (26284) 548543 (55318) 347394 (54718) 
Unique reflections 68024 (10653) 98039 (10843) 138620 (17410) 83375 (13410) 
Multiplicity 3.7 3.8 4.0 4.2 
Completeness (%) 99.2 (96.9) 92.7 (63.6) 95.5 (74.5) 99.7 (99.4) 
Mean I/sigma(I) 14.3 (2.6) 20.4 (3.0) 19.3 (3.7) 18.7 (3.3) 
R-sym c (%) 5.3 (46.9) 3.8 (33.2) 4.0 (29.8) 5.1 (48.8) 
R-meas (%) 6.2 (55.2) 4.4 (43.2) 4.7 (35.9) 5.9 (56.2) 
CC1/2 99.9 (81.7) 99.9 (83.5) 99.9 (90.9) 99.9 (85.3) 
B) Refinement     
Resolution range (Å) 42.65 – 1.37 25.46 – 1.18 40.90 – 1.06 42.77 – 1.28 
Total reflections used in 
refinement 
68019 98008 138586 83347 
Reflections used for R-
work 
64618 93108 131657 79180 
Reflections used for R-
free 
3401 4900 6929 4167 
Final R value for R-work 
(%) 
17.2 12.5 15.2 17.6 
Final R value for R-free 
(%) 
18.4 14.5 16.6 18.7 
No. of Protein residues 330 330 330 330 
No. of Water molecules 181 332 2593 240 
No. of Ligand molecules none 1 1 2 
No. of Other ligand 
molecules 
none added 6 none added none added 
RMSD bond lengths (Å) 0.006 0.008 0.004 0.005 
RMSD bond angles (°) 1.1 1.3 0.8 0.8 
Ramachandran plot d     
Residues in most 
favored regions (%) 
94.2 94.2 93.5 94.6 
Residues in additionally 
allowed regions (%) 
5.8 5.8 6.5 5.4 
Residues in generously 
allowed regions (%) 
none none none none 
Residues in disallowed 
regions (%) 
none none none none 
Average B-factor all 
atoms e (Å2) 




a) Statistics for the highest-resolution shell are shown in parenthesis, b) calculated with Matthews_coef program from CCP4 
suite version 7.0.04793, c) calculated by the equation: (SUM(ABS(I(h,i)-I(h))))/(SUM(I(h,i))) d) calculated with PROCHECK201, 
e) calculated with MOLEMAN202, f) other ligands include DMSO, PEG, Glycerol, SO4, ACT. 
 
Protein main chain 13.6 10.2 9.3 10.3 
Protein side chain 15.3 12.0 10.4 11.9 
Protein all atoms 14.3 11.1 9.8 11.0 
Ligand N/A 17.3 11.5 14.9 
Water molecules 22.0 24.4 18.8 19.0 
Other ligands f N/A 19.0 N/A N/A 




Table 16: Chemical Structures of the 96 Jena fragments. Marvin was used for displaying chemical structures, Marvin 6.3.1, 





















































































































































































































Table 17: Binding level in RU (response units) of Jena fragments to TGT screened by SPR. a 
Jena Fragment ID RU Jena Fragment ID RU 
J50 45.6 J66 7.6 
J36 21.3 J93 7.5 
J92 21.1 J14 7.4 
J9 17.3 J25 7.4 
J51 16.7 J89 7.4 
J55 15.3 J56 7.3 
J24 14.7 J91 7.3 
J7 14.3 J18 7.2 
J29 13.7 J49 7.2 
J79 13.5 J67 6.8 
J32 11.7 J61 6.7 
J47 11.6 J17 6.6 
J84 11.6 J15 6.5 
J62 10.6 J63 6.3 
J19 10.3 J80 6.3 
J37 10.3 J58 6.2 
J12 9.9 J64 6.2 
J5 9.8 J88 6.2 
J59 9.8 J52 6.1 
J60 9.5 J85 6.1 
J38 9.3 J87 6 
J76 9.3 J30 5.7 
J20 9.2 J69 5.7 
J27 9.2 J96 5.6 
J23 9.1 J71 5.4 
J13 9 J72 5.4 
J45 9 J73 5.2 




J6 8.6 J77 4.9 
J22 8.5 J78 4.9 
J10 8.4 J95 4.8 
J41 8.4 J39 4.5 
J46 8.4 J86 4.3 
J43 8.3 J82 4.2 
J4 8.1 J70 4.1 
J28 7.7 J81 4.1 
J44 7.7 J42 1.8 





Table 18: Structures of fragments not included in SPR binding level screen to TGT. 






































Table 19: Structures of fragments not included in NMR fragment screen of TGT 












































Table 20: Potent inhibitors of TGT used in displacement and competitive binding experiments in NMR and SPR screens. 
Compound No. Chemical Structure Binding Affinity (KD nM) 
Compound 1 
 





Table 21: Synthesized ligands used to study the preQ1 transient sub-pocket of TGT. 










0.058 ± 0.036 76 
 
 













300 ± 37 
 
 













270 ± 50 
 
 














283 ± 40 
 
 













19 ± 2 
 
 



























29 ± 21 (KD) 
 
 

























Table 22: The various crystal forms E1W PEX14 variant was found to crystallize in. 
Crystal 










Unit Cell Dimensions 
a b c α β γ 






Unit Cell Dimensions 
a b c α β γ 






Unit Cell Dimensions 
a b c α β γ 






Unit Cell Dimensions 
a b c α β γ 






Unit Cell Dimensions 
A b c α β γ 
41.7 41.7 81.6 90.0 90.0 90.0 
tetragonal 
P41212 
1 VS influenced 
6 
 
Unit Cell Dimensions 
a b c α β γ 













Table 23: The crystal forms wild-type PEX14 was processed as. 
Crystal  








Unit Cell Dimensions 
a b c α β γ 


















Unit Cell Dimensions 
a b c α β γ 










Unit Cell Dimensions 
a b c α β γ 














Table 24: Fragment hits from the library used to screen T. brucei PEX14 by NMR. 
Fragment Number Chemical Name Chemical Structure 
F1 1-benzothiophene-3-carboxylic acid 
 






F5 1H-indole-7-carboxylic acid 
 
F6 benzo[b]thiophene-7-carboxylic acid 
 
F8 3-benzofuranacetic acid 
 
F9a alpha, alpha-dimethyl-6-methoxy-2-napthalenemethanol 
 
F10 4H-Thieno[3,2-b]pyrrole-5-carboxylic acid 
 
F11 Ethyl 3-indoleacetate 
 





Table 25: Chemical structures of PEX14 compounds and PDB codes of their crystal structures in complex with PEX14. 
















Table 26: Chemical structures of the selected PEX14 binders found through a combination of SBVS and LBVS. 






















































































Table 27: Values of % inhibition of the fragment hits of ISA SPR screen against endothiapepsin. 
Fragment ID % Bindinga % Inhibition Fragment ID % Bindinga % Inhibition 
177 11.4 88.6 54 83.8 16.2 
218 19.3 80.7 338 83.9 16.1 
284 23.0 77.0 356 84.6 15.4 
306 23.9 76.1 242 85.4 14.6 
290 27.9 72.1 150 85.4 14.6 
159 32.1 67.9 76 85.5 14.5 
255 35.3 64.7 318 85.8 14.2 
64 40.6 59.4 16 86.2 13.8 
149 45.4 54.6 243 86.3 13.7 
343 46.2 53.8 319 86.4 13.6 
337 48.1 51.9 85 87.1 12.9 
178 48.9 51.1 128 87.1 12.9 
161 52.4 47.6 37 87.6 12.4 
167 52.7 47.3 291 88.5 11.5 
65 53.7 46.3 109 88.6 11.4 
148 57.5 42.5 323 88.7 11.3 
47 59.7 40.3 181 89.1 10.9 
334 61.3 38.7 8 89.7 10.3 
162 62.5 37.5 252 89.9 10.1 
79 63.3 36.7 57 89.9 10.1 
248 64.7 35.3 251 90.1 9.9 
236 69.4 30.6 208 90.1 9.9 
63 70.5 29.5 234 90.2 9.8 
41 71.7 28.3 5 90.3 9.7 
261 73.5 26.5 44 90.4 9.6 
88 74.1 25.9 133 90.5 9.5 
272 75.7 24.3 114 90.5 9.5 




175 76.3 23.7 209 90.5 9.5 
Fragment ID % Bindinga % Inhibition Fragment ID % Bindinga % Inhibition 
216 76.5 23.5 262 90.9 9.1 
101 77.6 22.4 196 90.9 9.1 
66 77.9 22.1 267 91.0 9.0 
142 79.3 20.7 62 91.1 8.9 
40 80.3 19.7 137 91.2 8.8 
75 80.7 19.3 332 91.5 8.5 
222 80.7 19.3 357 92.0 8.0 
293 80.8 19.2 18 92.0 8.0 
247 81.4 18.6 158 92.1 7.9 
112 82.0 18.0 320 92.1 7.9 
17 82.3 17.7 304 92.1 7.9 
316 82.7 17.3 333 92.2 7.8 
273 92.3 7.7 122 94.5 5.5 
321 92.6 7.4 307 94.8 5.2 
152 92.6 7.4 173 94.9 5.1 
188 92.7 7.3 144 95.0 5.0 
33 93.1 6.9 264 95.0 5.0 
287 93.2 6.8 260 95.0 5.0 
285 93.4 6.6 263 95.1 4.9 
328 93.6 6.4 299 95.1 4.9 
326 93.7 6.3 254 95.3 4.7 
60 93.8 6.2 361 95.3 4.7 
335 93.8 6.2 39 95.5 4.5 
223 94.0 6.0 126 95.6 4.4 
192 94.0 6.0 191 95.7 4.3 
180 94.0 6.0 244 95.9 4.1 
3 94.0 6.0 258 96.4 3.6 




189 94.2 5.8 226 96.5 3.5 
Fragment ID % Bindinga % Inhibition Fragment ID % Bindinga % Inhibition 
34 94.3 5.7 171 96.6 3.4 
277 94.4 5.6 235 96.6 3.4 
351 94.4 5.6 42 96.7 3.3 
160 94.5 5.5 347 96.7 3.3 
346 94.5 5.5    






Table 28: Buffers used in purification, crystallization, and screening of the various proteins. 
Protein TGT PEX14 EP 
Lysis Buffer 
20 mM TRIS pH 7.8, 10 mM 
EDTA, 1mM DTT and 2 
cOmplete™-Protease 
Inhibitor Cocktail Tablets 
50 mM TRIS pH 8, 20 
mM imidazole, 300 mM 
NaCl, 0.5 mM TCEP and 2 
cOmplete™-Protease 
Inhibitor Cocktail Tablets 
-- 
Purification buffer 
Q-Sepharose anion exchange 
column: 
 
Buffer A:  
10 mM TRIS pH 7.8, 1 mM 
EDTA, 1mM DTT 
 
Elution buffer B:  
10 mM TRIS pH 7.8, 1 mM 





100 mM TRIS pH 7.8, 1M 
NaCl, 1 mM EDTA 
 
Elution buffer E: 
100 mM TRIS pH 7.8, 1 M 







50 mM TRIS pH 8, 20 
mM imidazole, 300 mM 
NaCl, 0.5 mM TCEP 
 
Elution buffer: 
50 mM TRIS pH 8, 250 
mM imidazole, 300 mM 
NaCl, 0.5 mM TCEP 
 
Dialysis buffer: 
50 mM TRIS pH 8, 1 mM 




5 mM TRIS pH 8, 150 
mM NaCl, 0.5 mM TCEP 
-- 
Storage buffer 
10 mM TRIS pH 7.8, 2M NaCl, 
1mM EDTA 
5 mM TRIS pH 8, 150 
mM NaCl, 0.5 mM TCEP 






100 mM MES pH 5.5, 1 mM 
DTT, 13% (w/v) PEG8000, 




0.23 mM protein, 6.6 mM 
ligand 
E1W variant: 
0.2 M Ammonium 
Sulphate, 30 %(w/v) PEG 
8000, 2 mM protein, 4° C 
 
0.1 M Trisodium Citrate 
pH 5.6, 0.1 M Lithium 
Sulphate, 30% PEG 400, 
3.7 mM protein, 18° C  
 
0.05 M Trisodium Citrate 
pH 4.5, 0.07 M Sodium 
Chloride, 22% PEG 400, 
3.7 mM protein, 18° C 
 
Co-crystallization: 
0.17 M ammonium 
acetate, 0.085 M sodium 
citrate pH 5.6, 25.5% 
PEG 4000, 15% glycerol, 
1 mM protein, 20 mM 
ligand, 18° C 
 
Wild-type: 
0.1 M Trisodium Citrate 
pH 5.5, 
40% PEG 600,  





0.1 M sodium acetate 
pH 4.6, 0.1 M 
ammonium acetate, 28% 
- 30% (w/v) PEG4000, 
0.13 mM protein 
 
Soaking 
17.5% PEG3350, 25% 
PEG400, 200 mM NaCl, 100 
mM Fragment 
E1W Variant: 
0.2 M Ammonium 
Sulphate, 30 %(w/v) PEG 
8000, 25% glycerol 
 
 
0.17 M ammonium 
acetate, 0.085 M sodium 
citrate pH 5.6, 25.5% 
PEG 4000, 15% glycerol 
 
100 mM Fragment 
 
Wild-Type: 
0.1 M Trisodium Citrate 
pH 5.5, 
40% PEG 600, 25% 
glycerol, 4° C 
 
100 mM compound  
143 mM compound  
 
 
0.1 M sodium acetate 
pH 4.6, 0.1 M 
ammonium acetate, 28% 
- 30% (w/v) PEG4000, 
25% glycerol.  





10 mM Hepes buffer pH 7.4, 
0.05% Tween 20, 150 mM 
NaCl, 1 mM TCEP, 1% DMSO, 





25 mM Na-acetate pH 
4.5, 125 mM NaCl, 
0.005% Tween 20, 1% 
DMSO, 50 nM protein, 
1 mM fragment 
NMR screening 
20 mM deuterated TRIS at 
pH 7.4, 1 mM EDTA, 150 mM 
NaCl, 10% (vol/vol) D2O, 3 
mM TCEP and 10 µM TMSP-
d11, 3 µM protein, 
200 µM fragment 
 
20mM sodium 
phosphate pH 6.5 and 50 
mM NaCl, 10% D2O, 100 
µM of protein, 1 mM 
ligand 
3 mM acetic acid pH 4.6, 
356 µM H-142 peptide, 
9.6 µM protein, 
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